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Dementia is a clinical syndrome characterized by progressive deterioration of 
cognitive functions, which interferes with daily living, and eventually results in 
reliance on others for care [1]. The clinical presentation of dementia varies greatly 
among individuals, and depends on the underlying neurodegenerative disease that 
causes dementia. Alzheimer’s Disease (AD) is the predominant cause of dementia 
affecting around 70% of all dementia cases. Other major neurodegenerative 
diseases which could cause dementia include frontotemporal dementia (FTD), 
and dementia with Lewy bodies (DLB).
Currently, dementia affects around 50 million individuals in 2019 globally [2]. 
However, as a result of the growing and ageing population, and a current lack of 
preventive or curative treatment, it is expected that the number of individuals 
with dementia will exceed 152 million by 2050 [2]. From an economic perspective, 
the current global burden is estimated at US $1 trillion with a projected rise to $2 
trillion in 2030 [2]. The significant physical, emotional and financial burden placed 
on patients, their caregivers and society by dementia has led to the World Health 
Organization to recognize dementia as a global public health priority [3]. Currently, 
there are no approved drugs that can cure, revert or arrest the progression of 
dementia.
Neuropathological characteristics of dementia
The neurodegenerative diseases underlying dementia are each characterized by 
core neuropathologies seen at autopsy. For instance, AD is neuropathologically 
characterized by the accumulation of amyloid-β (Aβ) aggregates in amyloid 
plaques and hyperphosphorylated Tau in neurofibrillary tangles (NFT) [4]. For 
FTD, currently two major pathogenic proteins have been implicated in autopsy 
studies, namely, the presence of predominantly microtubuli associated protein Tau 
[5,6] or Tar-DNA Binding 43 (TDP43) protein [7]. Further, DLB is characterized by 
the aggregation of the synaptic α-synuclein protein as ‘Lewy bodies’ in neurons 
associated with brain atrophy. While often one neurodegenerative disease 
is pathologically defined, it is not uncommon for patients to have additional 
neurodegenerative co-pathologies, such as AD mixed with TDP43 pathology 
[8]. For a long time, dementia diagnosis could not be set until the patient had 
reached the advanced stage of clinically overt dementia, based on clinical signs 
and symptoms, and the diagnosis was confirmed at autopsy [9].
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Biofluid biomarkers in dementia
With the discovery of biofluid biomarkers reflecting core pathologies, clinical 
diagnosis of diseases causing dementia changed. To date, the best established 
biofluid biomarkers are those for AD pathology. Lower cerebrospinal fluid (CSF) 
concentrations of the 42 amino acid form of amyloid-β (Aβ42) indicate the presence 
of amyloid plaques, and higher CSF levels of total tau (Tau) and tau phosphorylated 
at threonine 181 (pTau) reflect neuronal degeneration and neurofibrillary 
tangles [4]. According to the newest research criteria decreased CSF Aβ42 levels, 
together with increased Tau and pTau, constitutes an AD biomarker profile and 
as such define AD [4]. These biomarkers are known to closely reflect underlying 
AD neuropathology in-vivo [4], and could therefore, deepen our understanding 
of underlying disease mechanisms. However, several questions regarding these 
biofluid biomarkers still remain. First, it is unclear whether these biomarkers 
behave differently between patient subgroups (e.g. between women and men). 
Second, the accurate implementation of these biomarkers in clinical practice is 
not yet specified in diagnostic criteria, and third, despite the fact we have come a 
long way for AD biomarkers, there is still a need for biomarkers to reflect the full 
complexity of AD as well as diagnostic biomarkers for other major dementia types.
Sex differences in dementia
There is increasing evidence that a disease can manifest itself differently in men 
and women. For example, there is a higher prevalence of auto-immune diseases in 
women [10], and ischemic heart disease is often not recognized in women due to 
different symptomology between sexes [11]. Recent literature has shown that sex 
differences also play a role in dementia. For instance, AD has a higher prevalence 
in women [12,13], while there is a higher prevalence of DLB in men [14–17]. In 
addition, accumulating evidence points towards differences in AD neuropathology 
between women and men, with women having a higher NFT burden, whereas 
differences in Aβ are less apparent [18–21]. For DLB, post-mortem examinations 
showed that men were more likely to have ‘pure’ DLB pathology, whereas women 
were more likely to have mixed DLB and AD pathology [22,23]. Although post-
mortem studies are highly important, a large disadvantage is that they reflect 
end-stage disease, whereas biofluid biomarkers enable in-vivo studies on ongoing 
pathological processes. However, knowledge regarding sex differences in biofluid 
biomarkers, and the effect that disease stage or genetic risk factors, such as 





Implementation of current biomarkers
The discovery of biomarkers for AD has led to a better diagnostic accuracy, than 
using AD clinical criteria alone [24], resulting in sensitivity and specificity levels 
of 80%- 90% to discriminate AD patients from controls [25]. Therefore, these 
CSF biomarkers have been included in research criteria for AD [4,26]. Despite 
the high diagnostic value, there are both patient and physician related factors 
that hamper the implementation of these biomarkers in daily clinical practice. 
One of these factors is the attitude of both patients and clinicians towards the 
lumbar puncture (LP) procedure, which is used to collect cerebrospinal fluid 
(CSF). An additional factor is the proper interpretation of CSF biomarker results 
by clinicians, especially when biomarker results are conflicting. Therefore, there 
is a need to specify the use and to generate tools to sustain interpretation of these 
biomarkers in clinical routine.
Patient-related factors
Day to day practice has shown that patients are often fearful to undergo a LP, due to 
a lack of knowledge regarding the procedure and/or unrealistic ideas concerning 
post-LP complications. Noteworthy, the fear of complications was shown to be a 
risk factor for actually experiencing post-LP complaints. Increased risk of non-
specific headache and local backpain was detected in patients that were very 
worried or even slightly worried [27]. Hence, there seems to be a psychological 
effect of anxiety associated to more complaints, which we hypothesize to be at 
least partly explained by insufficient information beforehand [28]. Simple, easy 
to digest information on the procedure and the use of CSF biomarkers adapted to 
patients’ needs and preferences could help patients prepare for the LP, increase 
their satisfaction with the procedure and could potentially reduce the post-
puncture complaint frequency, but such information is not available.
Clinician-related factors
Beside patient-related factors, the attitude of clinicians towards LP varies greatly. 
Many clinicians are reluctant to perform an LP in clinical practice, as it is generally 
regarded as an invasive procedure. However, the procedure is in fact easy to 
perform and the overall complication risk is low [27]. The most common post-
LP complication is the typical post-lumbar puncture headache (PLHP), of which 
the reported incidence among 3868 patients from a multi-center study was 9%. 
The risk of severe complications needing medical intervention such as a blood 
patch or hospitalization were rare with a reported incidence of 1% [27]. Reasons 
for refraining from performing an LP could be that clinicians feel that their 
knowledge is obsolete or that they experience a lack of training. Tools developed 
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for informing and training clinicians to perform an LP would greatly contribute 
to implementation of CSF biomarkers in clinical practice.
Finally, even when a lumbar puncture has been performed and CSF biomarkers 
are obtained, their interpretation is not straightforward. Not every AD dementia 
patient has a typical AD biomarker profile in clinical practice. As previously shown, 
8% of clinically diagnosed AD patients can have abnormal CSF Aβ42 alone without 
tau pathology [29]. Similarly, another study reported five AD subgroups with 
different CSF biomarker profiles [30]. The diversity of possible CSF biomarker 
profiles within AD can be confusing for clinicians. Therefore, tools need to be 
developed to aid clinicians in adequately interpreting CSF biomarkers.
Development of novel biomarkers
Although current CSF AD biomarkers (i.e. Aβ42, Tau and pTau) work well in 
discriminating between AD and controls, some challenges still remain. First, 
disease modifying therapies were often unsuccessful in the past because clinical 
trial recruitment was based on non-specific clinical assessments, and many 
participants (>25%) were included in clinical trials with anti-amyloid intervention, 
who did not have amyloid pathology [31]. Therefore, biomarkers are needed for 
clinical trials to establish underlying pathology. However, for large scale patient 
screening in clinical trial situations and repeated examinations to evaluate 
drug target engagement, a more accessible body fluid than CSF is preferred. 
Blood biomarker development is, therefore, considered the future in dementia 
research. Second, the development of blood biomarkers could improve patient care 
and potentially accelerate therapeutic discovery for non-AD neurodegenerative 
diseases as well. Yet, not many biomarkers have translated into clinical use for 
non-AD neurodegenerative diseases, such as FTD.
Development of an assay for blood-based AD biomarkers
Considerable progress has been made in the field of AD blood-biomarker discovery. 
A few years ago, reliable immunoprecipitation mass spectrometry (IP-MS)-based 
assays for Aβ40 and Aβ42 were described showing a decrease in the plasma Aβ42/
Aβ40 ratio with around 90% diagnostic accuracy [32,33]. However, despite these 
optimistic results, this technique is often labor-intensive and time-consuming, 
which prevents the high-throughput analysis required for screening purposes. In 
2011, ultrasensitive techniques, such as the Single molecule array (Simoa) assay, 
were developed which were able to show a correlation of plasma with CSF Aβ42 
and a reduced ratio of Aβ42 to Aβ40 in plasma of amyloid PET-positive individuals 




important step forward, this technique presumably measures monomeric forms 
of Aβ40 and Aβ42 [36], whereas accumulating evidence shows that small soluble 
Aβ oligomers (AβOs) are the most toxic and pathogenic form of Aβ species [37,38]. 
Additionally, AβOs have shown a good correlation with the presence and degree of 
cognitive symptoms [39]. This possibly suggest that plasma AβOs could potentially 
reflect clinical disease severity as well. However, literature on how plasma AβOs 
can reflect amyloid status is limited.
Identification of novel blood-based biomarkers for specific diagnosis of FTD
Blood-based biomarkers for FTD such as Neurofilament light (NfL) or progranulin 
(GRN), initially showed promise in discriminating FTD patients from controls 
[40,41]. However, later these markers appeared to be unspecific for in-vivo 
diagnosis of FTD as they were also altered in other types of dementias [41,42], 
or were only specific for genetic variants of FTD, but not sporadic cases [41]. 
More importantly, for the most common FTD pathological subtypes (i.e. FTD-Tau 
and FTD-TDP43), there are also no biomarkers with adequate diagnostic power 
[41,43]. This is relevant as these pathological subtypes will likely require different 
therapeutic approaches. Therefore, there is a strong need for novel biomarker 
candidates for FTD and its pathological subtypes. Studying the proteome in blood 
plasma might lead to the identification of a protein or a combination of proteins 
which could potentially be used as novel biomarker candidates for FTD.
General aim
This thesis focusses on the utility of biofluid biomarkers in specific dementia types 
and was divided into three major aims:
1. To understand the influence of sex on AD CSF biomarkers in different dementia 
types.
2. To facilitate the implementation of current CSF biomarkers in daily clinical 
practice.
3. Identification and development of novel blood-based biomarker assays for the 
diagnosis of FTD and AD
Thesis outline
In part one of this thesis, we employed current biomarkers to deepen our 
understanding of sex differences in ongoing pathological processes of AD and 
DLB. In chapter 2 we studied how CSF biomarkers are influenced by sex at 
different clinical disease stages of AD. Since sex differences might be influenced 
by APOEε4, we also investigated the interaction between and sex and APOE in CSF 
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AD biomarker concentrations. In chapter 3, we employed biofluid biomarkers to 
deepen our understanding of sex differences in CSF biomarkers in DLB. Finally, in a 
response to a study that has identified key differences between women and men in 
post-mortem AD patients, we discussed the nature and burden of AD pathology in 
a broader context in chapter 4. In addition to highlighting possible sex differences 
in AD pathophysiology, we also discussed how sex differences may impact the 
diagnosis and management of this condition.
In the second part of this thesis, we aimed to facilitate the implementation of 
current AD CSF biomarkers in clinical practice by providing easy to digest 
information on the procedure for both patients and physicians (chapter 5 and 
6). In addition, we investigated whether patient’s psychological and physiological 
burden could be altered with the use of informational tools (chapter 7). Next, we 
have developed a tool which can aid clinicians with the interpretation and use of 
CSF AD biomarker results (chapter 8).
The last part of this thesis, focusses on the development and identification of 
novel blood-based biomarkers in AD and FTD. We studied the use of novel -omics 
arrays for the identification of novel biomarkers, hereby focusing on FTD, for 
which no biomarkers are available yet (chapter 9). In addition, we have focused on 
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Sex differences in CSF biomarkers vary 
by Alzheimer’s disease stage 
and APOE ε4 genotype
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Objective: To evaluate sex-differences in cerebrospinal fluid (CSF) biomarkers, 
taking the potential modifying role of clinical disease stage and APOE-e4 genotype 
into account.
Method: We included participants (n=1801) with probable AD dementia (n=937), 
Mild Cognitive Impairment (MCI; n=437) and Subjective Cognitive Decline (SCD; 
n=427). Main outcomes were CSF amyloid β1-42 (Aβ42), total tau (t-Tau) and 
tau phosphorylated at threonine 181 (p-Tau) levels. Age corrected three-way 
interactions between sex, disease stage (i.e. syndrome diagnosis at baseline) and 
APOE-e4 were tested with linear regression analyses for each outcome measure. 
In case of significant interactions (p<0.05), sex-differences were further evaluated 
by stratifying analyses for clinical disease stage and APOE-e4 genotype including 
age as a covariate.
Results: Three-way interactions were significant for t-Tau (p<0.001) and p-Tau 
(p<0.01), but not Aβ42. In APOE-e4 carriers, women showed higher (p)Tau 
concentrations than men in SCD (Cohens d (95%CI): t-Tau= 0.52 (0.19-0.84), p<.001; 
p-Tau= 0.44 (0.11-0.77), p=.004) and MCI (Cohens d (95%CI): t-Tau= 0.54 (0.28-
0.80), p<.001; p-Tau= 0.52 (0.26-0.77), p<.001), but not in AD dementia. In APOE-
e4 non-carriers, women showed higher (p)Tau concentrations in MCI (Cohens d 
(95%CI): t-Tau= 0.49 (0.17-0.80), p=.002; p-Tau= 0.47 (0.16-0.78), p=.003) and AD 
dementia (Cohens d (95%CI): t-Tau= 0.42 (0.19-0.65), p<.001; p-Tau= 0.38 (0.15-
0.61), p=.002), but not in SCD.
Conclusions: Within APOE-e4 carriers, sex-differences in CSF (p)Tau are more 
evident in early disease stages, whereas for APOE-e4 non carriers sex-differences 
are more evident in advanced disease stages. These findings suggest that the effect 
of APOE-e4 on sex-differences in CSF biomarkers depends on disease stage in AD.
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INTRODUCTION
Alzheimer’s Disease (AD) is a global health care challenge due to the rapidly 
growing disease prevalence and the lack of preventive or curative treatment [1]. 
Therefore, knowledge regarding the underlying pathophysiological process of AD 
that could potentially contribute to the development of treatments is needed [2]. 
Current knowledge indicates that AD is characterized by initial brain depositions 
of amyloid-β (Aβ), followed by accumulation of neurofibrillary tangles (NFT) 
[3-5]. A growing body of literature is pointing towards sex differences in AD 
neuropathology, with women showing a higher NFT burden, while differences in Aβ 
are less apparent [6-10]. Additionally, there are indications that sex-differences in 
AD biomarkers are modified by the presence of the Apolipoprotein (APOE) e4 allele, 
the major genetic risk factor for sporadic AD [6,9]. In-vivo studies have shown that 
female APOEe4 allele carriers have higher cerebrospinal fluid (CSF) total Tau and 
phosphorylated Tau (pTau) concentrations than male APOE-e4 carriers [6,9,10]. 
However, post-mortem studies do not show this sex-specific association [6,7]. A 
possible explanation for these seemingly discrepant results is that in-vivo studies 
mostly included pre-dementia subjects (i.e. normal cognition or Mild Cognitive 
Impairment (MCI)), whereas post-mortem studies largely included end-stage 
dementia patients. It could be hypothesized that the association between APOE-
e4 genotype and sex differences in AD neuropathology may be present in initial 
phases of the disease, but diminishes as the disease progresses, and is no longer 
seen in end-stage AD dementia during post-mortem examinations. Therefore, in 
the present study, we investigated whether sex differences in CSF Aβ42, t-Tau and 
p-Tau are modified by APOE-e4 genotype and clinical disease stage.
METHODS
Subjects
We selected 1801 subjects who visited our outpatient clinic between October 2000 
and July 2015. Selection from the Amsterdam Dementia Cohort was based on a 
clinical diagnosis of probable AD dementia (n=937), MCI (n=437) or Subjective 
Cognitive Decline (SCD; n=427, and the availability of CSF biomarker results 
and APOE genotype [11,12]. There were no exclusion criteria. All participants 
underwent a standardized dementia screening at baseline that included physical 
and neurological examination, a neuropsychological test battery including a 
Mini Mental State Examination (MMSE), Electroencephalogram (EEG), Magnetic 
Resonance Imaging (MRI), and laboratory tests. Clinical diagnosis was given by 




clinical criteria. Subjects were labeled as having SCD when results of clinical 
examinations and test results were normal (i.e. criteria for MCI or dementia were 
not fulfilled, and no psychiatric diagnosis was given). MCI subjects were labeled 
according to the criteria by Petersen et al. and the National Institute on Aging and 
Alzheimer’s Association (NIA-AA) clinical criteria [13,14]. The core clinical NIA-AA 
criteria were met for all probable AD patients [15,16]. Clinical diagnosis at time of 
lumbar puncture, that is at baseline visit, was used to reflect clinical AD disease 
stage (i.e. syndrome diagnosis). Sex was self-reported and defined as a biological 
characteristic that discriminate women from men [17]. Educational levels were 
reported according to the Verhage scoring system [18].
Protocol Approvals, Registrations, and Patient Consents
All subjects gave written informed consent and the study was approved by the 
local ethical review board [11,12].
In-vivo markers of AD pathology
CSF Aβ42, t-Tau and p-Tau concentrations were used as in-vivo markers for the 
presence of AD pathology. CSF samples were collected and processed according to 
international consensus protocols as previously described [19,20]. Commercially 
available ELISAs were employed to measure baseline Aβ42, t-Tau and p-Tau 
(Innotest β-amyloid(1-42), Innotest hTAU-Ag and Innotest Phosphotau(181P); 
Fujirebio, Ghent, Belgium) concentrations. Intraand inter-assay variations for all 
analyses were below 3.2% and 10.9% respectively [21]. The team performing the 
CSF analyses was not aware of the clinical diagnosis. To correct for the drift in 
CSF Aβ42 concentrations throughout the analysis-years we used adjusted Aβ42 
concentrations. 22,23 Cut-offs to determine abnormality were 375 pg/ml for t-tau 
[24].
MRI measurements
MRI measurements were acquired on 3T whole-body MR system (Discovery; GE 
Medical Systems Milwaukee, WI, USA), using an eight-channel head coil at the 
Amsterdam UMC, location VUmc. Medial temporal lobe atrophy (MTA) scores 
ranged from 0-4, and were rated on coronal reconstructions of T1-weighted 
images [25]. Posterior cortical atrophy (PCA) and global cortical atrophy (GCA) 
scores ranged from 0-3, and were rated on the combination of T1-weighted and 
FLAIR sequences (PCA), or FLAIR sequences alone (GCA) [26]. White matter 
hyperintensities (WMH) were rated on FLAIR images using the Fazekas scale, 
with scores ranging from 0-3 [27]. The imaging took about 40 minutes in total. 
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There was no intravenous contrast administration. All scans were evaluated by 
an experienced neuroradiologist.
Apolipoprotein E genotyping
DNA was isolated from 10 ml vacutainer tubes containing EDTA using the 
QIAamp DNA blood isolation kit from Qiagen (Venlo, The Netherlands). Followed 
by genotype determination using the LightCycler ApoE mutation Detection Kit 
(Roche Diagnostics, GmbH, Mannheim, Germany). Subjects with at least one APOE-
e4 allele were defined as APOE-e4 carriers, whereas no e4 allele defined subjects 
as non-carriers.
Statistical analysis
Statistical analyses were completed using R studio (version: 3.3.2; “sincere 
Pumpkin Patch”). Prior to performing statistical analyses, t-Tau and p-Tau 
were log transformed as they were not normally distributed. Demographical 
and clinical data were compared between groups using independent t-tests, 
chi-square tests and Mann-Whitney U tests as appropriate. To assess how sex-
differences in biomarkers depend on APOE-e4 genotype and clinical disease stage, 
we used General Linear Models (GLM) with factors sex, APOE-e4 genotype and 
clinical disease stage, their 2-way interactions and 3-way interactions, and age 
was included as a covariate (see table 3 for full models). In case of a significant 
interaction between sex, APOE-e4 genotype and clinical disease stage, we 
performed GLM in CSF biomarker concentrations stratified for APOE genotype and 
clinical disease stage as shown in figure 1. These analyses included sex as a factor 
and age as covariate. We repeated analyses restricted to subjects with abnormal 
CSF Aβ42 concentrations (<813 pg/ml) to study the specificity of the findings for 
the AD spectrum. Reported Effect Sizes were calculated as the difference of the 
means of two groups divided by the weighted pooled standard deviations of these 
groups according to Cohen’s d statistics. In an additional set of sensitivity analyses, 
three-way interactions were repeated in the total sample stratified by age (cut-
off: median 67 years) to assess the effects of age. Three-way interactions included 
factors sex, clinical disease stage and APOE-e4 genotype, their 2-way interactions, 
and main factors. Separate models were run for CSF t-Tau and p-Tau. Finally, we 
performed two additional analyses to test APOE genotype dose effects: 1) we 
repeated analyses after excluding APOE e2e4 carriers (n=43), as the conveyed 
risk of APOE e2e4 carriers for AD is not fully known; 2) We evaluated the effect 
of e2 (i.e. e2e2 = 4; e2e3= 111) and e4 allele carriers (i.e. e3e4 =690; e4e4 = 298) 
against the e3 allele for sex effects on CSF biomarkers. p<0.05 was considered 





The dataset generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request.
RESULTS
Within SCD, the majority was male (61%), and females and males showed a similar 
frequency of APOE-e4 (F: 38% vs M: 37%, p >0.05). Within MCI, the majority was 
male (62%), females showed a higher frequency of APOE-e4 than males (F: 65% 
vs M: 50%, p=0.002), and females had less atrophy than males (table 1). Within AD 
dementia the percentage of females and males was similar (52% vs 48%), as was 
the frequency of APOEe4 carriers between females and males (F: 67% vs. M: 68%, 
p>0.05). Females had less medial temporal atrophy than males (F:1.32 vs M:1.52, 
p>0.01). Females and males did not differ in age within clinical disease stages. In 
MCI and AD dementia, males had higher educational levels and higher MMSE scores 
compared to females. Subject characteristics of the CSF amyloid positive cohort 
were largely comparable to the total cohort (table 2). 
For CSF Aβ42, age adjusted general linear models including sex, APOE-e4 genotype, 
diagnosis and all interactions showed main effects for diagnosis and APOE-e4 
genotype, but not for sex. There were no significant interactions. For CSF t-Tau 
and p-Tau there was a three-way interaction between sex, APOE-e4 genotype, and 
clinical diagnosis (full models shown in table 3). Therefore, we further stratified 
these analyses for APOE-e4 and clinical diagnosis as shown in figure 1.
Within APOE-e4 carriers, females showed higher t-Tau and p-Tau concentrations 
than males in SCD (Cohens d (95%CI): t-Tau= 0.52 (0.19-0.84), p<001; p-Tau=0.44 
(0.11-0.77) p=.004 ) and MCI (Cohens d (95%CI): t-Tau= 0.54 (0.28-0.80), p<.001; 
p-Tau=0.52 (0.26-0.77) p<.0011), but not in AD dementia (figure 1). Within APOE-
e4 non-carriers, females showed higher t-Tau and p-Tau concentrations than males 
in MCI (Cohens d (95%CI): t-Tau= 0.49 (0.17-0.80), p=.002; p-Tau=0.47 (0.16-0.78), 
p=.003) and AD dementia (Cohens d (95%CI): t-Tau= 0.42 (0.19-0.65), p<.001; 
p-Tau=0.38 (0.15-0.61) p=.002), but not in SCD (figure 1). When restricting analyses 
to individuals with abnormal CSF Aβ42, results for t-Tau and pTau were largely 
comparable with that of the total cohort, albeit significance was overall somewhat 
attenuated for t-Tau and p-Tau, and was lost for t-Tau in APOE-e4 carriers in the 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In an additional analysis, we stratified for age and found a significant three way 
interaction between sex, APOE genotype and diagnosis for CSF (p)Tau in older 
individuals (median [IQR]: 72.2 [69.5-76.0]), but not in younger individuals (median 
[IQR]: 61.3 [58.4-64.1]) (full models shown in table 5). When we repeated the 
analyses in the sample excluding APOE e2e4 carriers (n=43), results remained 
essentially unchanged (full models shown in table 6). Finally, we studied dose 
effects for APOE genotypes and found that APOEe2 carriers behaved similar to 
APOEe3 carriers for all clinical disease stages (data available from Dryad: Table 
1; https://doi.org/10.5061/dryad.ttdz08ktw).
DISCUSSION
Our findings suggest that APOE differentially affects sex-differences in CSF 
biomarkers throughout the AD spectrum. Within APOE-e4 carriers, females 
show higher t-Tau and pTau concentrations in early disease stages (i.e. SCD and 
MCI) which equalized in the later dementia stage. Within APOE non-carriers, 
we observed an opposite pattern, with females showing higher t-Tau and p-Tau 
concentrations in later disease stages (i.e. AD dementia and MCI ), but not in the 
early disease stage of SCD. We did not find sex-differences in Aβ concentrations 
between females and males for any disease stage or APOE-e4 genotype. Although 
derived from cross-sectional data our findings suggest that within APOE-e4 
carriers sex-differences in t-Tau and p-Tau become less evident in advanced 
disease stages, whereas for APOE-e4 non-carriers sex-differences in t-Tau and 
p-Tau become more evident in advanced disease stages.
Our results seem to be in line with previous studies who reported higher CSF t-Tau 
and pTau concentrations for female APOE-e4 carriers [6,9,10,28,29]. We further 
expand on those studies by showing that the sex-specific interaction of APOE-e4 
on CSF biomarkers depends also on disease stage. Here we observed that female 
APOE-e4 carriers had higher t-Tau and p-Tau concentrations than male APOE-
e4 carriers in the SCD and MCI stage of AD, which is in line with previous work 
in cognitively normal older adults and MCI subjects [9,10,28,30]. Additionally, a 
recent other study showed that within cognitively normal amyloid positive adults, 
especially female APOE-e4 carriers exhibited accelerated rates of longitudinal CSF 
(p)Tau concentrations [31]. We further show that at the AD dementia stage these 
sex-differences within APOE-e4 carriers seem to diminish. This could possibly 





It has been suggested that the sex-difference in APOE-e4 carriers diminishes with 
increasing age, as previous studies only found a sex-specific interaction with APOE-
e4 in younger individuals (67 years). However, closer inspection of the data in fact 
shows that our ‘older’ participants fall within the same age range as the ‘younger’ 
participants in former studies (i.e. 65-75 years) [6,32]. Another explanation for 
these age dependent sex-differences could be that younger and older participants 
might have different underlying AD pathological mechanisms. For instance, 
younger participants with a similar cognitive status as older individuals, may not 
reflect an earlier phase of AD than older participants and vice versa. Therefore, it 
could be possible that younger individuals might have more (unknown) genetic risk 
factors for AD, which in turn influence t-Tau accumulation and sex-differences in 
t-Tau concentrations [33]. Taken together, our results support the idea that the sex 
by APOE-e4 interaction depends on age, and we further show that this interaction 
effect depends also on clinical disease stage as well.
In the latest framework for AD, t-Tau is considered a marker for neuronal injury 
[5]. As such, higher t-Tau and p-Tau concentrations in female APOE-e4 carriers may 
imply an initial steeper pathological disease course, and more neurodegenerative 
change compared to male APOE-e4 carriers. Increased neurodegenerative changes 
in female APOE-e4 carriers was also implied by previous studies who reported 
increased hypometabolism and (hippocampal) atrophy [34], and a decreased 
hippocampal connectivity [35]. However, other studies have shown discordant 
findings. Previous population studies reported lower hippocampal volume in males 
compared to females [29], and more rapid parahippocampal atrophy in amyloid 
positive males compared to amyloid negative females [36]. In the current study, we 
observed more atrophy in males than females in both APOE-e4 carriers and non-
carriers, which seems in contrast to the higher t-Tau levels we found in females. 
This suggests that discrepant findings between CSF t-Tau and atrophy may reflect 
different pathological processes, and should perhaps not be used interchangeably. 
Similar discrepant findings between t-Tau and MRI have been reported previously, 
which may depend on sex as well [37]. Future research combining in-vivo CSF 
biomarker and MRI data with pathology data is needed to examine the relationship 
with each other and neuropathology.
Possible explanatory biological mechanisms for higher levels of t-Tau and p-Tau in 
females might be related to abrupt hormonal changes that have occurred in post-
menopausal women [17]. A drastic drop of estradiol levels in post-menopausal 
women, has shown to lead to an increased activity of enzymes involved in Tau 
phosphorylation (GSK3-β and Protein Kinase A), thus resulting in a higher p-Tau 
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concentrations [38,39]. In addition, post-menopausal women show indications 
of increased oxidative stress and mitochondrial dysfunction, which through cell 
death and apoptosis mechanisms may lead to increases in CSF t-Tau concentrations 
[5,39]. APOE-e4 has also been associated with higher levels of CSF t-Tau and NFT’s 
[2], and it was shown to stimulate Tau phosphorylation as a result of impaired 
cholesterol exchange between neuronal and non-neuronal cells [6,31,41,42]. 
Therefore, it is conceivable that the lack of neuroprotective effects of estrogen 
together with the presence of APOE-e4 might act synergistically, leading to 
increased t-Tau concentrations in female APOE-e4 carriers. Another factor that 
may influence t-Tau levels is cerebrovascular injury [43–45]. Therefore, it could be 
that the sex-difference in CSF t-Tau concentrations is caused by a difference in the 
amount cerebrovascular injury between both sexes. However, we did not observe 
a difference between sexes in Fazekas scores, which are considered a marker of 
cerebrovascular injury [46]. Further (fundamental) research is needed to discover 
the true underlying cause of the sex-differences seen in AD.
Other possible explanations for higher t-Tau and p-Tau concentrations in female 
APOE-e4 carriers in the earlier stages of the disease spectrum, could be a difference 
in survival between females and males. A faster disease progression in males or 
a higher mortality rate of the “very sick” men dying from comorbidities at young 
ages could possibly cause an overrepresentation of “healthier” males with lower 
levels of neuropathology (i.e. CSF t-Tau concentrations), therefore making it seem 
as though women have higher t-Tau concentrations. However, in our cohort this 
seems less likely since men had more atrophy in general.
In our study population, females and males showed similar Aβ42 concentrations 
within both APOE-e4 genotypes throughout clinical stages of AD. Our findings 
align with previous work, which suggest that sex-differences in AD pathology 
mainly occur in t-Tau and p-Tau concentrations, downstream from amyloid 
deposition [6,7,9,10,29–31,47]. Interestingly, within the current NIA-AA criteria 
[5] CSF t-Tau and p-Tau are seen as markers for separate pathological mechanisms, 
where one represents neuronal injury (t-Tau) and the other is a specific marker for 
Alzheimer’s disease pathology (p-Tau). However, in our cohort t-Tau and p-Tau are 
highly correlated (r= 0.93, p<0.001), and sex-differences in both APOE-e4 carriers 
and noncarriers were similar for t-Tau and p-Tau. This suggests that t-Tau and p-Tau 
to some extent reflect similar or overlapping aspects of neuronal injury.
Among the limitations of our study is that to adequately assess the temporal order 




derived from a tertiary memory clinic cohort which consist of a relatively young 
population, and may result in a lack of generalizability of our findings. Among the 
strengths of this study is the use of a large well-defined cohort, and the careful 
clinical work-up that was used to diagnose all participants. Moreover, as our 
findings were largely replicable in an Aβ42 positive subset, we were able to show 
that our findings were specific for the AD spectrum. Our data show that a woman’s 
brain can be more susceptible to t-Tau pathology depending on disease stage and 
APOE-e4 genotype. The effect sizes we found for (p)Tau concentrations between 
women and men were moderate, and therefore not large enough for clinical use, 
for instance by developing sex-specific cut-offs for t-Tau or p-Tau. However, a 
moderate difference in the underlying pathology of AD between women and men 
is large enough to be taken into consideration when developing disease modifying 
therapies.
In conclusion, within APOE-e4 carriers sex-differences in t-Tau and p-Tau become 
less evident in advanced disease stages, whereas in APOE-e4 non-carriers sex-
differences in t-Tau and p-Tau become more evident in advanced disease stages. 
These findings largely remain for the amyloid positive subgroup. Our findings 
imply a difference in neuropathological trajectories for women and men depending 
on APOE-e4 genotype, and add to a growing body of evidence of sex-differences in 
the underlying mechanism of AD.
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Background: Dementia with Lewy bodies (DLB) is more prevalent in men than 
in women. In addition, post-mortem studies found sex differences in underlying 
pathology. It remains unclear whether these differences are also present 
antemortem in in vivo biomarkers, and whether sex differences translate to 
variability in clinical manifestation. The objective of this study was to evaluate 
sex differences in cerebrospinal fluid (CSF) biomarker concentrations (i.e., alpha-
synuclein (α-syn), amyloid β1-42 (Aβ42), total tau (Tau), phosphorylated tau at 
threonine 181 (pTau)) and clinical characteristics in DLB.
Methods: We included 223 DLB patients from the Amsterdam Dementia Cohort, 
of which 39 were women (17%, age 70 ± 6, MMSE 21 ± 6) and 184 men (83%, age 
68 ± 7, MMSE 23 ± 4). Sex differences in CSF biomarker concentrations (i.e., α-syn, 
Aβ42, Tau, and pTau) were evaluated using age-corrected general linear models 
(GLM). In addition, we analyzed sex differences in core clinical features (i.e., visual 
hallucinations, parkinsonism, cognitive fluctuations, and REM sleep behavior 
disorder (RBD) and cognitive test scores using age- and education-adjusted GLM.
Results: Women had lower CSF α-syn levels (F 1429 ± 164 vs M 1831 ± 60, p = 0.02) 
and CSF Aβ42 levels (F 712 ± 39 vs M 821 ± 18, p = 0.01) compared to men. There 
were no sex differences for (p) Tau concentrations (p > 0.05). Clinically, women 
were older, had a shorter duration of complaints (F 2 ± 1 vs M 4 ± 3, p < 0.001), more 
frequent hallucinations (58% vs 38%, p = 0.02), and scored lower on MMSE and a 
fluency task (MMSE, p = 0.02; animal fluency, p = 0.006). Men and women did not 
differ on fluctuations, RBD, parkinsonism, or other cognitive tests.
Conclusions: Women had lower Aβ42 and α-syn levels than men, alongside a 
shorter duration of complaints. Moreover, at the time of diagnosis, women had 
lower cognitive test scores and more frequent hallucinations. Based on our 
findings, one could hypothesize that women have a more aggressive disease course 
in DLB compared to men. Future research should investigate whether women and 
men with DLB might benefit from sex-specific treatment strategies.
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BACKGROUND
Dementia with Lewy bodies (DLB) is clinically characterized by cognitive 
decline, visual hallucinations, parkinsonism, cognitive fluctuations, and rapid 
eye movement (REM) sleep behavior disorder (RBD) [1]. Pathologically, DLB is 
characterized by the presence of cortical Lewy bodies, i.e., neuronal inclusions 
of alpha-synuclein proteins [2], frequently combined with Alzheimer’s disease 
(AD) pathology, i.e., amyloid plaques and neurofibrillary tangles (NFT) [3]. 
Most studies report a higher prevalence of DLB in men than in women [4,5,6,7], 
although a few report the opposite [8, 9]. In addition to the skewed distribution, 
there is evidence of differences in the underlying pathology between women and 
men with DLB. Post-mortem examinations showed that men were more likely 
to die from “pure” DLB pathology than women, and women were more likely to 
have mixed pathology (DLB + AD) [10, 11]. This is clinically relevant, as mixed 
pathology is linked to a more severe disease manifestation, with more cognitive 
disturbances, more frequent hallucinations, and shorter survival [12, 13]. Although 
post-mortem studies are important, a major drawback is that they reflect end-
stage disease. In contrast, cerebrospinal fluid (CSF) biomarkers enable in vivo 
studies in ongoing pathological processes. Previous CSF biomarker studies in AD 
have shown sex differences in CSF (p) Tau concentrations, suggesting a higher 
antemortem neurofibrillary tangle (NFT) load in women with AD [14,15,16]. 
Literature regarding sex differences in CSF biomarkers in DLB, however, is still 
limited. One small study reported lower levels of CSF alpha-synuclein in DLB 
women compared to DLB men, AD, and controls [17]. In addition, apart from one 
study showing that visual hallucinations were more common in women [18], the 
relationship between clinical symptoms and sex in DLB has neither been studied 
extensively either. In order to provide biomarker-guided personalized medicine 
in the future, it is essential to further clarify sex differences in DLB biomarkers 
and symptomatology. Therefore, in the current study, we aimed to examine sex 
differences in CSF biomarkers and clinical symptomatology in a large well-defined 
cohort of DLB patients.
METHODS
Participants
We included 223 DLB patients who visited the Alzheimer Center Amsterdam 
between 1999 and 2019 from the Amsterdam Dementia Cohort based on 
the availability of CSF [19]. All patients received standardized screening at 




neurological, and neuropsychological examinations; magnetic resonance imaging 
(MRI); electroencephalography (EEG) or magnetoencephalography (MEG); and 
laboratory tests. Diagnoses were made in a multidisciplinary consensus meeting 
based on the results obtained from the standardized screening [19]. DLB patients 
were diagnosed clinically according to the current consensus criteria for probable 
DLB [1, 20]. FP-CIT single-photon emission computed tomography (DAT-SPECT) 
was available in 103 patients and was positive for DLB diagnosis in 92 patients. 
DLB was confirmed at autopsy in 3 patients, of which 2 did not have a DAT-SPECT 
scan. Written informed consent was obtained from all study participants for the 
use of clinical data and biomaterial for research purposes.
MEASURES
Clinical and cognitive features
We rated the core clinical features at baseline from preformatted questionnaires 
or retrospectively from patients’ medical charts. Hallucinations were scored 
according to the caregiver-rated neuropsychiatric inventory (NPI) that was 
available in 222 patients [21]. Parkinsonism was assessed with a preformatted 
checklist for extrapyramidal signs during the neurological exam (i.e., tremor, 
bradykinesia, and/or rigidity), data available for 216 patients. The semi-structured 
patient history interview was reviewed for information on fluctuations and 
RBD. Fluctuations were scored as being present when the patient or caregiver 
reported clear changes in attention and cognition during the day or between days. 
Information on fluctuations was available for 173 patients. REM sleep behavior 
disorder (RBD) was rated positive when caregivers reported that patients “act 
out” their dreams during their sleep. Information on RBD was available of 156 
patients. Duration of complaints was systematically assessed during the patient 
history interview and was defined as the moment when the patient first noticed 
their cognitive complaints. Depressive symptoms were assessed using the 15-
item Geriatric Depression Scale, with higher scores indicating more depressive 
symptoms [22]. Mini Mental State Examination (MMSE) was used to assess global 
cognition. Memory was assessed using the immediate and delayed recall of the 
Dutch version of the verbal learning test (RAVLT) [23]. Attention and speed was 
assessed using Trail Making Test (TMT)-A. Executive functioning was assessed 
using the ratio of TMT-B/TMT-A [24]. We calculated inverse scores for time-
dependent tests (i.e., TMT-A and TMT-B), such that lower scores represent worse 
performance. Missing values of the TMT-B were imputed using the group ratio of 
TMT-B/TMT-A. Neuropsychological test scores were available for 205 patients, 
51
and test results were Z-transformed based on cognitively normal subjects (n = 
533, 60 ± 10 years, 54%F, MMSE = 29 ± 1).
Apolipoprotein E genotyping
The QIAamp DNA blood isolation kit from Qiagen (Venlo, The Netherlands) 
was used to isolate DNA from 10-ml vacutainer tubes containing EDTA. This 
was followed by genotype determination using the LightCycler ApoE Mutation 
Detection Kit (Roche Diagnostics, GmbH, Mannheim, Germany). Subjects with at 
least one APOEe4 allele were defined as APOEe4 carriers, whereas no e4 allele 
defined subjects as APOEe4 non-carriers.
CSF analysis
For CSF collection and processing, standardized protocols were followed [25, 
26]. CSF total α-syn concentrations were determined using a sandwich ELISA 
assay (developed by ADx NeuroSciences, Ghent, Belgium and commercialized 
by Euroimmun AG, Lübeck, Germany) [27]. To avoid blood contamination, α-syn 
measures with high hemoglobuline (Hb) concentrations (> 10 ng/ml) or high 
erythrocyte count (> 500 ery/ml) were excluded. CSF total α-syn was available 
for 127 patients. CSF Aβ1-42, Tau, and pTau concentrations were measured using 
a sandwich ELISA (Innotest, Fujirebio, Gent, Belgium), or the Elecsys Aβ42, Tau, 
and pTau (181P) CSF assays run on the cobas e601 analyzer (Roche Diagnostics 
GmbH). Elecsys values of Aβ42, Tau, and pTau were converted to Innotest values 
using previously described formulas [28]. Drift corrected continuous Aβ42 
concentrations were used in the data analyses, and to define amyloid positivity, 
Aβ42 concentrations were dichotomized using a cutoff < 813 pg/ml [29]. CSF Aβ1-
42, Tau, and pTau were available for all patients.
Statistical analysis
Demographic data were compared between women and men using chi-squared 
tests, independent t test, or Mann-Whitney U tests where appropriate. All variables 
were checked for outliers and normality of residuals using Q-Q plots. TMT-data 
and CSF (p) Tau levels were log-transformed to meet assumptions of normality. 
Other outcome variables met the assumption of normally distributed residuals. 
To evaluate sex differences in clinical outcome measures, we used general linear 
models (GLM) with sex as the factor and baseline cognitive data or core clinical 
features as main outcome measures. Analyses were adjusted for age (clinical data) 
or age and education (cognitive data). Next, we performed general linear models 
(GLM) with sex as the factor and CSF biomarkers (i.e., α-syn Aβ1-42, Tau, and pTau) 




Analyses were adjusted for age (model 1) or age and APOEe4 genotype (model 2). 
A p < 0.05 was considered significant. Analyses were conducted using R statistical 
program (version 3.5.2 “eggshell igloo”).
RESULTS
Baseline characteristics are shown in Table 1. The majority of our sample 
consisted of men (f 17% vs m 83%). Women were older than men (f 70 vs m 68; 
p = 0.04), exhibited a shorter duration of complaints before diagnosis (f 2.3 vs 
m 3.5, p < 0.001), and more often reported visual hallucinations (f 58% vs m 
38%, p < 0.02). Additionally, women more frequently carried the APOEe4 allele 
(f 70% vs m 52%, p = 0.08). No sex differences were found in other core clinical 
features, depressive symptoms, or years of education. After correcting for age and 
education, MMSE scores and animal fluency scores were lower in women than men. 
Performance on RAVLT (immediate and delayed recall), VAT, TMT-A, and TMT-B/A 
did not differ between sexes (Table 1).
Next, we evaluated sex differences in CSF biomarker concentrations (Table 2; Fig. 
1). Adjusted for age, women exhibited lower α-syn concentrations compared to 
men. Moreover, women had lower Aβ42 concentrations than men and exhibited 
more often abnormal CSF amyloid concentrations (f 77% vs m 56%, Table 1). No 
sex differences were found for CSF Tau or pTau concentrations. After adjusting 
for age and APOEe4 genotype, results for all CSF biomarkers remained largely 
similar (Table 2). When repeating the analyses in the subgroup with positive DAT-
SPECT scans (n = 92; f 15 (16%), m 79 (84%)), we found similar effect sizes for all 
CSF biomarkers, although significance for α-syn was lost due to the loss of power 
(eTable 1).
Sex differences in cerebrospinal fluid biomarker concentrations. Mean differences 
in CSF biomarker concentrations in picograms/milliliter between women and men. 
*p < 0.05. Abbreviations: CSF, cerebrospinal fluid; α-syn; alpha-synuclein; Aβ42; 
amyloid-β42; Tau, total tau; (p) Tau, tau phosphorylated at threonine 181. Dashed 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Sex differences in cerebral spinal fluid biomarker concentrations. Mean dif-
ferences in CSF biomarker concentrations in picograms/milliliter between women and 
men. *p<0.05. Abbreviations: CSF, cerebrospinal fluid; α-syn, alpha-synuclein; Aβ42, am-
yloid-β42; Tau, total tau; pTau, tau phosphorylated at threonine 181. Dashed line reflects 
cutoffs for Aβ42 (813 pg/ml), Tau (375pg/ml), and pTau (52 pg/ml).
DISCUSSION
In the present study, where DLB was more prevalent in men than in women, women 
had lower CSF Aβ42 and α-syn concentrations. In addition, women had more 
frequent hallucinations, had shorter duration of complaints before diagnosis, were 
older, and had lower scores on MMSE and fluency-tasks. Based on our findings, one 
could hypothesize that women have a more aggressive disease course compared 
to men.
When using predefined cutoffs for CSF Aβ42, 77% of women had amyloid pathology, 
in contrast to 56% of men. This suggests that women more often had concomitant 
AD pathology, whereas men more often had pure DLB pathology. These in vivo 
findings are in line with previous autopsy studies that observed that men were 
more likely to die with pure DLB pathology and women more often died with 
DLB + AD pathology [11, 30]. However, AD pathology is not only characterized by 




higher (p) Tau levels in CSF. As women in our study showed isolated lowered CSF 
Aβ42 levels, an alternative explanation could be that the lower levels of Aβ42 are 
directly related to the DLB disease process, rather than reflecting concomitant AD 
pathology. Previous studies have shown that Aβ42 induces the formation of high-
molecular-weight α -syn, and vice versa [31]. Therefore, this synergistic interaction 
between Aβ42 and α -syn could lead to increased aggregation and accumulation 
of both α-syn and amyloid pathology in the women in our study compared to men 
[31,32,33].
Concomitant amyloid pathology in DLB has previously been related to a more 
severe clinical disease burden [12]. In line with these former findings, women in our 
cohort had lower MMSE and fluency test scores, and more frequent hallucinations, 
but a shorter duration of symptoms before diagnosis, suggesting a more aggressive 
disease course upon diagnosis in women with DLB. This could well be related 
to the amyloid-pathology that is more often encountered in DLB women. In our 
study, duration of complaints was estimated retrospectively; therefore, we cannot 
completely rule out that women with DLB were already in a later disease stage 
at the moment of diagnosis. Consistent with our hypothesis of a more aggressive 
disease course in women, one other study found that women with DLB have shorter 
survival after onset of dementia [34]. Prospective studies with longitudinal data 
are needed to further investigate sex differences in disease course over time.
Our data are in line with former observations of a strong male-predominance 
in DLB, as 83% of patients in our cohort were men [4,5,6,7]. The strong male-
predominance in DLB could be explained by hormonal differences between 
sexes. Several previous studies have shown that 17β-estradiol (E2) conveys 
neuroprotective effects in women [35]. In fact, a previous in vitro study has 
shown that estradiol exhibits dose-dependent inhibition of α-syn aggregation 
and destabilization of preformed α-syn, which is thought to be driven by the 
antioxidant properties of estrogens [36,37,38,39]. This suggests that until 
menopause occurs in women, at the average age of 55 years, they are protected 
against the development of diseases such as DLB and Parkinson’s disease. During 
the second half of menopause, however, women show a sudden drop of estradiol 
levels [40], thus triggering the aggregation of α-syn and impeding the breakdown 
of preformed α-syn. If this is the case, sex differences in prevalence are expected 
to be more balanced with increasing age. In line with this hypothesis, a recent 
study reported a higher DLB prevalence of men than women under the age of 
75 years, which equalized between the ages of 75 and 80 years. Above the age 
of 80 years, however, DLB was more common in women [8]. Future studies will 
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have to demonstrate whether this shift in prevalence is mediated by hormonal 
differences.
Another explanation for the higher prevalence of DLB in men could be that 
concomitant AD pathology seen in DLB women potentially introduces a bias towards 
diagnosing these women with AD rather than DLB, therefore underdiagnosing 
the true proportion of women with DLB. In line with this reasoning, one study 
found that concomitant AD pathology decreased diagnostic accuracy, as typical 
AD symptoms were more pronounced, in contrast to DLB symptoms [41]. Our 
results imply that clinicians should be conscious of the risk of underdiagnosing 
women with DLB.
Our study has several strengths, including our well-defined, large sample of DLB 
patients. The clinical diagnosis of DLB was largely supported by DAT-SPECT 
imaging. In addition, we had CSF α-syn available in a considerable part of patients 
and CSF AD biomarkers in all patients. Furthermore, CSF collection follows a highly 
standardized protocol, assuring that the possibility of pre-analytical confounders 
is minimized [19].
Among the limitations is the retrospective design of our study. Information on RBD 
and fluctuations was rated retrospectively based on patients’ medical charts. In 
some cases, these features were not reported, which could either mean that they 
were not present or that it was not asked by the medical doctor. Therefore, there 
was a relatively large number of missing values for these features and there is a risk 
of underreporting. Future prospective studies should use standardized methods 
to assess these symptoms. A second limitation is that CSF total α-syn is not yet 
validated as a clinically useful marker in DLB, and there might be differences in 
sensitivity between different α-syn species. For example, soluble α-syn oligomers 
could be more useful in DLB, because oligomeric forms of α-syn seem to play a 
more essential role in the pathogenesis of α-synucleinopathies than t-α-syn [42]. 
Another α-syn species of interest is α-syn phosphorylated at serine 129 (pSer129-
α-syn), as approximately 90% of accumulated α-syn in Lewy bodies consists of 
pSer129-α-syn [43]. However, these species cannot yet be measured robustly with 
commercial assays as these have not yet been validated. A last limitation was that 
a small part of our patients had a normal DAT-SPECT scan, not supportive of DLB 
diagnosis. However, clinical diagnosis was made carefully in a tertiary memory 
clinic setting and false-negative DAT-SPECT scans in early disease stages have 





To conclude, our results indicate sex differences in DLB, wherein concomitant 
AD pathology was more frequent in women and CSF alpha-synuclein levels were 
lower in women compared to men. Concomitant pathology, combined with lower 
cognitive test scores and a shorter duration of complaints before diagnosis, could 
suggest a higher disease severity in women. Our results raise awareness among 
clinicians of the possibility that women are underdiagnosed and have the potential 
to aid in defining sex-specific personalized medicine strategies within DLB.
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difference β coefficient 
(95%CI)a
p-value
α-syn b 1457±471 1767 ±595 -349.5 (-898.4: 199.4) 0.21
Aβ42 684 ±282 825 ±244 -137.1 (-277.7: 2.6) 0.05
Tau c 5.9 ±0.8 5.8 ±0.5 0.1 (-0.2: 0.4) 0.47
pTau c 3.8 ±0.5 3.9 ±0.4 -0.1 (-0.4: 0.2) 0.72
Data presented as mean ± SD.
a. Adjusted for age
b. α-syn analysis was performed in a subset of patients n=45 (f=5 ; m=40 )






Nature and implications of sex 
differences in AD pathology
R Babapour Mofrad and W M van der Flier




A new study has identified key differences between women and men with regard to 
the nature and burden of Alzheimer disease (AD) pathology in the brain. In addition 
to highlighting possible sex differences in AD pathophysiology, the findings could 
have important implications for the diagnosis and management of this condition. 
Refers to Oveisgharan, S. et al. Sex differences in Alzheimer disease and common 
neuropathologies of ageing. Acta Neuropathol. (2018).
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Dementia is characterized by progressive cognitive decline to a point where a 
person is no longer able to live independently and institutionalization may be 
necessary. The prevalence of dementia is increasing rapidly and, in the current 
absence of curative treatment, this condition represents one of the great health-
care challenges of the 21st century [1] .
Alzheimer disease (AD) is the primary cause of dementia, accounting for 60–80% 
of all cases [1]. Almost two-thirds of patients with AD are female [2], and the 
higher observed prevalence of this disease in women has been partly attributed 
to longer life expectancy in comparison with men. However, a growing body of 
literature suggests that sex differences in the underlying pathology also exist. 
Neuropathologically, AD is characterized by accumulation of amyloid-β (Aβ) 
plaques and neurofibrillary tangles (NFTs) consisting of hyperphosphorylated 
tau protein in the brain. Autopsy studies have shown a greater global AD pathology 
burden in women than in men, largely owing to a higher load of NFTs [3,4]. Pure 
AD is rare, however, and the disease almost invariably co-occurs with other types 
of pathology.
A study by Shahram Oveisgharan and colleagues that was recently published in 
Acta Neuropathologica explored sex differences in global AD pathology and other 
common neuropathologies in dementia [5]. Post-mortem examinations were 
performed in a large cohort of 1,453 participants aged 66–108 years, including 
971 women (mean age 90 years) and 482 men (mean age 87 years), from the 
community-based Religious Orders Study and the Rush Memory and Aging Project. 
The examinations included quantification of neocortical Lewy bodies, TAR DNA-
binding protein 43, hippocampal sclerosis, gross infarcts and microinfarcts, 
atherosclerosis, arteriolosclerosis and cerebral amyloid angiopathy. Consistent 
with previous studies, the researchers observed more global AD pathology in 
women than in men, largely driven by NFTs. In addition, the women had slightly 
more arteriolosclerosis. No sex-related differences were observed for the other 
types of neuropathology.
Post-mortem studies are of great value to obtain insight into the pathology of 
disease, but they also have drawbacks, as by definition they are cross-sectional 
in nature and they generally capture only end-stage disease. As such, they are 
unsuitable for studying the early stages and longitudinal development of a disease. 
Cerebrospinal fluid (CSF) and PET biomarkers allow in vivo measurement of AD 
neuropathology at any stage of the disease [1]. A recent study using amyloid 




cognitive decline than men [6]. Several studies using CSF biomarkers have found 
higher concentrations of total tau and phosphorylated tau (indicative of NFTs) 
in women than in men, with particularly pronounced sex differences being 
detected in individuals carrying the apolipoprotein E ε4 risk allele [4,7,8]. These 
observations are in line with the findings of Oveisgharan et al. [5], who observed 
more prominent sex differences in tau pathology than in amyloid pathology.
The disease process in AD probably takes 20–30 years to unfold, and amyloid 
deposition begins decades before the onset of clinical signs and symptoms. 
Neuronal injury subsequently occurs, as reflected by NFTs and neurodegeneration, 
and ultimately, cognitive and functional decline culminate in the clinical syndrome 
of dementia. It is conceivable that the disease trajectory in women differs from that 
in men, as hypothetically illustrated in Fig. 1. Sex differences in AD neuropathology 
seem to be particularly evident in the more downstream disease processes. After 
initial Aβ deposition, which only subtly differs between the sexes, neuronal injury 
and cognitive decline become more severe in women than in men.
The fact that NFTs are more tightly coupled with disease progression than 
are amyloid plaques could explain why, in the presence of a similar Aβ burden, 
women show faster cognitive decline than men. Of note, in the Oveisgharan et 
al. study [5], the difference in the prevalence of clinical AD dementia between 
women and men (45% versus 40%) was seemingly smaller than the difference 
in pathological AD diagnosis (68% versus 58%). Potential explanations for this 
rather counterintuitive finding include a higher cognitive reserve and/or a greater 











Fig. 1: Sex differences in Alzheimer disease. 
This hypothetical model, based loosely on a model by Jack et al.10, 
illustrates how subtle upstream differences between women and men, 
such as a small difference in amyloid-β burden, could become amplified in 
downstream processes, such as tau accumulation. Differences in clinical 
manifestations and cognitive decline might be even more marked, as these 
aspects are related not only to pathological processes but also to other 
factors such as cognitive and behavioural strategies. Women might have 
more cognitive reserve than men, leading to later onset of cognitive 
decline but a steeper rate of decline subsequently. This model could 
explain why the Oveisgharan et al. study [5] found smaller sex difference in 
clinical dementia than in pathology. Adapted from ref. [10], Elsevier. 
Figure 1: Sex differences in Alzheimer disease.
This hypothetical model, based loosely on a model by Jack et al.10, illustrates how subtle 
upstream differences between women and men, such as a small difference in amyloid-β 
burden, could become amplified in downstream processes, such as tau accumulation. 
Differences in clinical manifestations and cognitive decline might be even more marked, 
as these aspects are related not only to pathological processes but also to other factors such 
as cognitive and behavioural strategies. Women might have more cognitive reserve than 
men, leading to later onset of cognitive decline but a steeper rate of decline subsequently. 
This model could explain why the Oveisgharan et al. study [5] found smaller sex difference 
in clinical dementia than in pathology. Adapted from ref. [10], Elsevier.
The causes and underlying mechanisms of the observed sex differences in AD 
are not yet known. Sex differences emerge during fetal development when 
chromosomal and ormonal influ nces result in divergenc  of neuronal circuitry 
between femal  and male brains, which migh  in luenc  the brain’s ability to cope 
with damage in later life. Throughout childhood and adolescence, the maturing 
brain is influenced by environmental factors such as education that might vary 
between boys and girls, and the experiences of women and men continue to differ 
throughout life. Differences in life course, risk factor exposure and daily activities 
could have an impact on the risk of and resilience to disease and, hence, on disease 
pathways [2].
The sudden drop in levels of the sex hormones oestrogen and progesterone that 
occurs in women after menopause could also be an important factor. Oestrogens 
have neuroprotective properties, including improvement of cerebral blood 
flow, prevention of neurotoxicity and maintenance of hippocampal function [2]. 




either natural or surgically induced menopause, although the effect sizes were 
largest in women who experienced surgical menopause at a younger age [5]. This 
latter subgroup also showed a somewhat higher amyloid burden than men.
Studies that contribute to our knowledge of sex differences in the pathology 
and clinical manifestations of AD are of the utmost importance to improve the 
management of this debilitating disease. As cognitive and behavioral strategies 
tend to differ between men and women, they might make different choices 
regarding diagnosis and disease management. Sex and gender should, therefore, be 
taken into consideration when exploring the preferences and wishes of the patient 
in a shared decision-making process. The gender of the caregiver can also influence 
the clinical manifestations of the disease. Men might be less likely than women to 
recognize the disease in a partner or family member at an early stage. In addition, 
evidence indicates that women tend to spend more time than men undertaking 
caregiving tasks and providing assistance with daily activities, thereby delaying 
the need for institutionalization [9]. Finally, sex differences in the pathological 
pathways of AD imply that men and women could benefit from different disease-
modifying therapies, and personalized medicine strategies should take both sex 
and gender into account.
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Chapter 5
Lumbar puncture in patients with 
neurologic conditions
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A lumbar puncture (LP) is performed to obtain cerebrospinal fluid. It is 
implemented in the clinic on a routine basis to aid the diagnosis of neurologic 
diseases. This paper accompanies an informative lumbar puncture video that 
shows the lumbar puncture procedure as routinely performed in the VUmc 
Alzheimer center based on the consensus guidelines by Engelborghs et al
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INTRODUCTION
This article accompanies an informative lumbar puncture (LP) Video in which 
we illustrate how to perform an LP in neurologic diseases. Our aim is to provide 
a reference for educational purposes and to give an update on the state of the art. 
We wish to help reduce the reluctance in performing an LP by demonstrating an 
LP method based on recently published consensus guidelines by Engelborghs et al. 
[1] aiming to minimize the risk of complications. Moreover, we aim to demonstrate 
the utility of the LP as an aid in the diagnosis of neurodegenerative diseases, 
notably Alzheimer’s disease. These are the first steps toward standardizing the 
LP procedure, which will help to implement cerebrospinal fluid (CSF) biomarkers 
in clinical practice [2]. Target audience: Our target audience includes trainees 
in neurology and other clinicians who perform an LP for diagnostic or scientific 
reasons. Moreover, the Video is informative for scientists who use CSF material 
and want to increase their awareness of the procedure. We do wish to emphasize 
that this Video can serve as a basis for practical supervised training. This Video 
shows the recommendations based on consensus guidelines by Engelborghs et al. 
[1]; every professional can choose to deviate from these recommendations when 
deemed necessary. The following section describes the LP procedure as routinely 




Various studies have shown that one of the risk factors for experiencing post-LP 
complications is the actual fear of the LP procedure and post-LP complications 
by the patient [1]. This fear may be reduced by giving adequate information to 
the patient before and during the procedure. Providing visual support, such as 
showing a model of the lower back, is recommended. The importance of flexing the 
back and relaxation during the procedure should be emphasized. This creates more 
intervertebral space while inserting the needle, thereby increasing the chances of 
a successful procedure. The patient should also be informed of the most prevalent 
possible complications, which consist of post-LP back pain (17%), typical post-LP 
headache (PLPH) (9%), and atypical headache (19%) [1,3].
Allergies and contraindications
The physician should check for allergies to bandages, latex, alcohol, or iodine as 




include an intracranial space occupying lesion with mass effect or abnormal 
intracranial pressure, the use of oral anticoagulant medication, coagulopathies 
and uncorrected bleeding diathesis, and a local skin infection at the puncture site. 
For more information on contraindications and allergies we refer to the consensus 
guidelines by Engelborghs et al. [1].
Materials
Before performing the LP, it is essential to prepare all equipment. To reduce the 
risk of infection an aseptic technique is applied using the following materials:
(1) A 25-gauge needle with a stylet
(2) Polypropylene collection tubes
(3) Sterile gloves and sterile field
(4) Sterile and nonsterile gauzes
(5) Iodine or alcohol
(6) Bandage
(7) Protective mat
For (1) a needle with a small diameter, higher than 24 gauge, has proven to reduce 
the risk of post-LP complaints [1]. An atraumatic needle is recommended by 
authors of most studies because that will result in a lower incidence of PLPH, but 
it is not used in the Video, because it results in more attempts and failures of the 
LP procedure, when performed by less experienced clinicians [1]. It is important 
to keep in mind that when intracranial pressure measurement is necessary 
needles smaller than 22 gauge are not suitable [1]. A syringe may be convenient 
for collection of large volumes (10 mL), but the use of a syringe is associated with 
an increased risk of post-LP complaints and is an additional step that leads to 
absorption of proteins [1,4].
LP procedure
Positioning
The LP can be performed in both the sitting and the lateral recumbent position. 
The position depends on the physician’s preferences and the patient’s clinical 
condition. In the sitting position the patient is positioned with his back toward the 
physician, leaning forward as far as possible, thus maximizing the space between 
spinal processes. The spinal processes should be perpendicular to the floor, to 
ensure that the needle is inserted in the midline. The lateral recumbent position, 
however, is recommended because of a lower risk of severe headache [1]. If needed, 
this position is the only way to perform intracranial pressure measurement [1]. In 
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the lateral recumbent position, the patient is asked to lie down on the side and to 
flex the back by pulling the knees to the chest. The knees and shoulders are placed 
in the same plane to make sure the spinal processes are aligned. In both the sitting 
and the lateral recumbent position the back should be flexed as far as possible to 
generate more space between the lumbar spinal processes so the needle can be 
inserted more easily. The physician should verify with the patient that this position 
can be maintained for a sufficient period of time before starting the procedure.
CSF withdrawal
When the patient is positioned properly the physician locates the site of needle 
insertion by palpating the posterior superior iliac crest and follow it in a straight 
line to the lumbar spinal processes. This line indicates the position of the fourth 
lumbar vertebral body. The needle can be safely inserted into the subarachnoid 
space at the L3-4, L4-5, or L5-S1 interspace, because this is well below the 
lower end of the spinal cord. The space between two lumbar spinal processes is 
palpated. This is followed by disinfection of the area with alcohol in a circular 
motion. The physician puts on sterile gloves and checks the position of the patient 
again because the patient may have slightly changed position. Then the area is 
disinfected again with a sterile gauze, after which the needle is inserted in midline 
aiming at the umbilicus of the patient. When the subarachnoidal space is reached, 
a loss of resistance is typically felt. The needle is positioned properly when CSF 
starts dripping after removal of the stylet. CSF is collected in a polypropylene 
tube. When no fluid is detected or bone is encountered the needle will be redrawn 
until the subcutaneous level and inserted again at a different angle, or the needle 
is completely removed and a new attempt is made at an interspace at a different 
level. A maximum of four attempts is advised; however, this depends on the clinical 
need [1]. When the suitable amount of CSF is collected, the stylet is positioned 
back before the needle is removed as this has shown to reduce post-LP complaints 
[1]. A bandage is placed at the site of insertion when the needle is removed. The 
physician should stay in contact with the patient during the entire procedure to 
describe the following steps of the procedure and to give reassurance.
Concluding the procedure
After the LP the patient remains lying for a few moments and gets up slowly 
when feeling well. Studies have shown that bed rest is not associated with a lower 
prevalence of PLPH or post-LP back pain [1]. The patient is provided with printed 





Our efforts resulted in the animation video (see QR code).
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Daily clinical practice has shown that patients are often hesitant to undergo a 
lumbar puncture (LP) because of unfamiliarity with the awaiting procedure 
and/or unrealistic ideas concerning post-LP complications. In light of increased 
number of LPs in diagnostic and research settings, our institute has developed an 
educational video for patients and caregivers in which we inform them about and 
prepare them for the LP procedure. This video was based on the latest literature 
and was developed with the help of communication experts, medical doctors, and 
two separate patient panels.
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INTRODUCTION
Cerebrospinal fluid (CSF) biomarkers such as amyloidb1–42 (Ab42), total tau (Tau), 
and tau phosphorylated at threonine 181 (pTau) have proven to be a valid proxy of 
the underlying neuropathology of Alzheimer’s disease and are of increasing value 
in Alzheimer’s disease diagnosis and research [1–5]. As such, these CSF biomarkers, 
which are obtained through lumbar puncture (LP), are increasingly applied in 
daily clinical practice resulting in an increased number of LPs. In daily practice, 
patients are often anxious to undergo the LP procedure because of unfamiliarity 
with the procedure and/or unrealistic ideas concerning post-LP complications. In 
fact, a large multicenter memory clinic study has shown that patients’ fear of the LP 
procedure and specifically their fear of post-LP complications actually increase the 
risk of post-LP complications and complaints [6]. Adequate preparation through 
education and the provision of accurate information may be beneficial for those 
patients [7–9]. Specifically, the provision of audio-visual information about the 
LP procedure and the risk of complications, in addition to the spoken information 
from the physician, may address unrealistic expectations and help patients better 
understand and prepare for the LP procedure [10]. Therefore, we aimed to develop 
an animation video in which we audio-visually pre-sent information about the LP 
procedure and (the risk of) complications.
METHODS
The content for the video was drafted by the core team consisting of a medical 
doctor, the head of the neurochemistry laboratory, and several communication 
researchers.
Prerequisite requirements
The core team established a few predetermined requirements for the video: (1) the 
content of the video was to be based on insights from the latest literature; (2) the 
duration of the video should not be longer than 2 to 3 minutes to ensure viewers’ 
attention, and (3) an animation video seemed more appropriate than a live video 
of the procedure [6,11,12].
Iterative developmental process
The animation video was developed through an extensive and iterative process 
in co-creation with stakeholders (i.e., doctors, patients, and caregivers). The 




1.  A script was drafted by the core team and reviewed by a panel of medical 
doctors (n=4) who perform LPs on a routine basis in a tertiary memory clinic. 
The panel of medical doctors was not involved in the development of the script. 
In addition, the script was reviewed by a patient and caregiver panel (n=5). 
Based on feedback from both panels, changes were made to the script by the 
core team.
2.  A storyboard for the video (i.e., graphics were added to the script) was 
developed in collaboration with a company specialized in developing animation 
videos for the medical domain. This storyboard was reviewed by the core team 
and revised accordingly.
3.  The first version of the video was reviewed and revised on several occasions. 
The core team as well as a second larger patient and caregiver panel visiting 
the memory clinic of the Alzheimer Center Amsterdam UMC (n=60) took part 
in this reviewing process. The patient and caregiver panel gave feedback by 
making use of a questionnaire. The questionnaire assessed the content and 
the esthetics of the video(e.g., understandability, duration, and the voice-over). 
Moreover, the video was presented during an ABIDE (Alzheimer’s Biomarkers 
In Daily practicE)-project [13] team meeting in which several communication 
experts, medical doctors, neuropsychologists, and neurochemistry laboratory 
members openly exchanged thoughts on the video and pro-vided feedback. 
Finally, the video was presented in a meeting by the Alzheimer’s Association 
Global Biomarker Standardization Consortium, a consortium aimed at the 
standardization and implementation of fluid biomarker tests for use in clinical 
practices around the world, who also provided feedback [9].
Revisions
Feedback obtained during each step of the developmental process was discussed 
within the core team to make decisions on revisions. Feedback was deemed 
relevant when it suited the aim of the video, that is, providing understandable 
preparatory information about the LP procedure and (the risk of) complications, 
or when the same remark was given repeatedly. For an overview of the iterative 
developmental process, see Fig.1.
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Figure 1. Schematic overview of the iterative developmental process of the educational 
video for patients and caregivers. Abbreviations: MD, Medical Doctor; ABIDE, Alzheimer’s 
Biomarkers In Daily practicE; GBSC, Global Biomarker Standardization Consortium.
RESULTS
Our efforts resulted in the animation video (see QR code).
DISCUSSION
Future steps include investigating improvement of patients’ knowledge and 
psychological outcomes, for example, reduction of anxiety regarding the LP 





[1] Coart E, Barrado LG, Duits FH, 
Scheltens P, van der Flier WM, 
Teunissen CE, et al. Correcting for the 
Absence of a Gold Standard Improves 
Diagnostic Accuracy of Biomarkers in 
Alzheimer’s Disease. J Alzheimers Dis 
2015;46:889–99.
[2] Beach TG, Monsell SE, Phillips LE, 
Kukull W. Accuracy of the clinical 
diagnosis of Alzheimer disease at 
National Institute on Aging Alzheimer 
Disease Centers, 2005-2010. J 
Neuropathol Exp Neurol 2012;71:266–
73.
[3] Duits FH, Teunissen CE, Bouwman FH, 
Visser PJ, Mattsson N, Zetterberg H, et 
al. The cerebrospinal fluid “Alzheimer 
profile”: Easily said, but what 
does it mean? Alzheimer’s Dement 
2014;10:713–23.
[4] Jack CR, Bennett DA, Blennow K, 
Carrillo MC, Dunn B, Haeberlein SB, 
et al. NIA-AA Research Framework: 
Toward a biological definition of 
Alzheimer’s disease. Alzheimer’s 
Dement [online serial] 2018;14:535–
62.
[5] Blennow K, Mattsson N, Sch€oll M, 
Hansson O, Zetterberg H. Amyloid 
biomarkers in Alzheimer’s disease. 
Trends Pharmacol Sci 2015; 36:297–
309.
[6] Duits FH, Martinez-Lage P, Paquet C, 
Engelborghs S, Lleo A, Hausner L, et 
al. Performance and complications 
of lumbar puncture in memory 
clinics: Results of the multicenter 
lumbar puncture feasibility study. 
Alzheimer’s Dement 2016;12:154–63
[7]  Waller A, Forshaw K, Bryant J, Mair S. 
Interventions for preparing patients 
for chemotherapy and radiotherapy: 
a systematic review. Support Care 
Cancer [online serial] 2014; 22:2297–
308.
[8]  Schofield MJ, Sanson-Fisher R. 
How to prepare cancer patients for 
potentially threatening medical 
procedures: consensus guidelines. 
NSW Cancer Council Cancer Education 
Research Program. J Cancer Educ 
[online Serial] 1996;11:153–8.
[9]  Kunneman M, Pel-Littel R, Bouwman 
FH, Gillissen F, Schoonenboom NSM, 
Claus JJ, et al. Patients’ and caregivers’ 
views on conversations and shared 
decision making in diagnostic 
testing for Alzheimer’s disease: The 
ABIDE project. Alzheimer’s Dement 
Transl Res Clin Interv [online Serial] 
2017;3:314–22.
[10]  Carey M, Schofield P, Jefford M, 
Krishnasamy M, Aranda S. The 
development of audio-visual materials 
to prepare patients for medical 
procedures: an oncology application. 
Eur J Cancer Care (Engl) [online 
Serial] 2007;16:417–23.
[11]  Engelborghs S, Niemantsverdriet 
E, Struyfs H, Blennow K, Brouns 
R, Comabella M, et al. Consensus 
guidelines for lumbar puncture in 
patients with neurological diseases. 
Alzheimer’s Dement Diagnosis, Assess 
Dis Monit 2017; 8:111–26.
[12]  Babapour Mofrad R, Bouwman FH, Slot 
RER, Timmers T, van der Flier WM, 
Scheltens P, et al. Lumbar puncture in 
patients with neurologic conditions. 
Alzheimer’s Dement Diagnosis, Assess 
Dis Monit 2017;8:108–10.
[13]  de Wilde A, van Maurik IS, Kunneman 
M, Bouwman F, Zwan M, Willemse 
EA, et al. Alzheimer’s biomarkers 
in daily practice (ABIDE) project: 
Rationale and design. Alzheimer’s 






Lumbar puncture patient video 
increases knowledge and reduces 
uncertainty: an RCT
R Babapour Mofrad*, A D Fruijtier*, L N C Visser, N 
Hoogland , M van Dijk, F van Rossum, F H Bouwman, E 
M A Smets, C E Teunissen, W M van der Flier
*Authors contributed equally to this work





Background: Patients often perceive a lumbar puncture (LP) as an invasive 
procedure. We aimed to evaluate the impact of a 3-minute educational animation-
video explaining the LP procedure, on patients’ knowledge, uncertainty, anxiety, 
and post-LP complications.
Methods: We included 203 newly-referred memory clinic patients, who were 
randomly assigned to one of three conditions: 1) home-viewing of the video, 2) 
clinic-viewing of the video, or 3) control-condition (care as usual). Participants 
completed questionnaires measuring knowledge as information recall, uncertainty, 
anxiety, and post-LP complications, the latter when patients underwent an LP-
procedure (n=145).
Results: Viewing the video increased information recall for both home- (P<.001), 
and clinic-viewers (P<.001) compared to controls. Levels of uncertainty decreased 
after viewing (Pfor interaction=.044), particularly for clinic-viewers. Viewing the video 
or not did not affect anxiety and post-LP complications.
Discussion: Preparing individuals for an LP by means of an educational video can 
help to increase knowledge about the procedure and reduce feelings of uncertainty.
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BACKGROUND
Cerebrospinal fluid (CSF) analysis is an important diagnostic tool in many 
neurological diseases, including Alzheimer’s disease (AD). Biomarkers that 
are analyzed in CSF obtained via lumbar puncture (LP) play a crucial role in 
diagnosis of AD with very high sensitivity and specificity [1-3], and will likely 
play an important role in the future of disease modifying treatments. Despite 
the diagnostic relevance of CSF analysis, it is still underutilized. On the one 
hand, physicians are often reluctant to use CSF biomarkers in daily practice, due 
to the invasive nature of the LP. On the other hand, patients can be reluctant to 
undergo an LP. This may be due to uncertainty and/or anxiety regarding the LP 
procedure itself, concerns about possible complications afterwards, or due to a 
lack of knowledge – e.g. they are not sufficiently aware of what the procedure 
entails, or the reasons to perform an LP [4, 5]. In reality, severe complications 
associated with LP’s are rare (i.e. requiring hospitalization = 0.9%) [6, 7]. We 
previously found that feelings of anxiety concerning the LP increase the actual 
risk for complications, such as atypical post-LP headache and local back pain [6]. 
A lack of (accurate) information prior to the LP may negatively affect patients’ 
anxiety and expectations regarding the LP procedure, which in turn increase the 
risk of complications [7].
Results obtained in different settings, such as prior to a colonoscopy, or during 
genetic counseling, showed that information about a medical procedure or 
health risk can reduce uncertainty and anxiety [8-13]. Audiovisual materials, 
like educational patient videos, are an effective method to inform patients [14, 
15]. Informing patients through audiovisual materials has been found to be more 
effective than by verbal or written methods as video’s can better satisfy a patient’s 
needs, and aid in information uptake and recall [16, 17].
In co-creation with stakeholders, we recently developed an animation-video to 
inform and prepare patients and caregivers for the LP procedure in the context of 
AD diagnosis [18] (supplemental figure A.1). In the current randomized controlled 
trial, we evaluated the effectiveness of the video for improving knowledge of the 
LP procedure, decreasing feelings of uncertainty and anxiety, and reducing the 






This study entails a randomized controlled trial for which we consecutively 
invited all newly-referred patients visiting the memory clinic of the Alzheimer 
Center Amsterdam for standardized dementia screening [19], between April 2019 
and March 2020. Participants were recruited by telephone by the researchers 
prior to their visit to the out-patient clinic. Participants were excluded when they 
had audiovisual impairments, did not master the Dutch language or if an e-mail 
address was unavailable. Of the 203 consenting participants, 145 received a lumbar 
puncture and were available for follow-up on post-LP complications (figure 1).
All participants gave informed consent prior to participation. The study was 
reviewed and the need for formal approval was waived by the local medical ethical 
committee. The RCT was registered prior to the start at trialregister.nl, the Dutch 
Trial Registry (Trial NL7725).
Questionnaires were issued at four time-points (figure 2). Upon consent, 
participants received the baseline questionnaire (time-point 1; T1), approximately 
one week prior to their visit. After completion of the T1 questionnaire, participants 
were randomly assigned to one of three conditions, by means of simple 
randomization: 1) Home-viewing, 2) Clinic-viewing, and 3) Control-condition. 
The study was embedded in the extensive routine work-up in the out-patient 
clinic, and all participants received care as usual (i.e. verbal information and an 
informational folder on the LP procedure) regardless of the study condition. The 
information provided in the video closely resembled the standard verbal and 
written information, which included information regarding the LP procedure and 
the most common complications [18]. Once a condition was assigned, condition 
1 (home-viewing) received a link to the video via e-mail up to one week prior to 
their visit, allowing participants to watch the video as often as desired. Condition 
2 (Clinic-viewing) viewed the video in the waiting room using headphones at the 
start of their visit to the out-patient clinic, prior to medical consultations. All 
participants received the second questionnaire at the start of their visit to the 
out-patient clinic at time-point 2 (T2; clinic viewing first watched the video). In 
addition, participants received the third questionnaire at the end of the screening 
day (T3). Finally, participants were contacted by phone within 2 weeks after the 
















































































We assessed four main outcomes; patients’ recall of information, feelings of 
uncertainty and anxiety, and post-LP complications. Additional outcomes of 
interest included patients’ satisfaction with the information and with the LP 
procedure.
Knowledge
Based on the information provided through standard care, we developed a 
questionnaire measuring knowledge as information recall. This questionnaire 
was pilot tested among six individuals to test clarity of questions and variation 
in responses. Participants were provided with eight multiple-choice questions 
and were instructed to select the correct answer out of four. Sum scores for 
information recall were calculated after assigning one point for each correct 
answer. Information recall was assessed at T2 and T3.
Uncertainty and anxiety
Uncertainty levels were reported by participants at T1 and T2 using a selection 
of five relevant items from the Mishel Uncertainty in Illness Scale (MUIS) [20], 
answered on a five-point Likert scale (1 = strongly disagree and 5 = strongly agree; 
Cronbach α T1= .71; Cronbach α T2 = .65). An example of a question was: ‘the goal 
of the lumbar puncture is clear to me’.
State anxiety levels were assessed using a Dutch six-item version of the State-Trait 
Anxiety Inventory (S-STAI-S) at T1, and T2 [21]. The items could be answered on a 
four-point Likert scale ranging from 1= not at all to 4=very much so [21, 22].
Higher scores indicated greater uncertainty and anxiety respectively. Primary 
outcome measures were change over time as indicated by a comparison of 
uncertainty and anxiety levels reported at T1 and T2.
Post-LP complications
Approximately two weeks after their visit (T4), participants were asked by 
telephone in a structured interview about the occurrence of post-LP complications, 
previously described in Duits et al. (2016). In brief, participants reported; 1) 
headache ( yes/no), which in case of a positive answer was next specified as 
typical post-LP headache or atypical headache, 2) local back pain ( yes/no), 
or 3) severe complications ( yes/no). Typical post LP headache was defined 




Severe complications were defined as complications serious enough to require 
hospitalization or an epidural blood patch.
Additional items
At baseline (T1), questions addressed patient demographics (e.g. age, level of 
education). Additionally, baseline medical knowledge and knowledge about an LP 
procedure were both measured using a Visual Analog Scale (VAS; e.g. “How much 
knowledge do you think you have about an LP procedure?”) ranging from zero (no 
knowledge at all) to ten (a lot of knowledge). Further, all participants were asked 
whether they had already seen an educational LP video prior to their visit to the 
out-patient clinic. At T2, home-viewers were asked how often they had watched the 
video, and both home- and clinic-viewers were asked with whom they had watched 
the video. Moreover, at T3, all participants could indicate their satisfaction with 
the provision of information about the LP, and the LP procedure itself on VAS scales 
ranging from 1 = not at all to 10 = very much so.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics 24 (IBM Corp., 
Armonk, NY). Demographic characteristics were compared between condition 
using chi-squared tests, analysis of variance (ANOVA), or Kruskal-Wallis test where 
appropriate; based on continuous, categorical, or ordinal scale of the variable. 
Intention to treat analysis included all 203 participants who were randomized, 
irrespective of whether they eventually underwent an LP. Changes in mean scores 
of self-reported uncertainty and anxiety between conditions over time (T1 vs T2) 
were analyzed using repeated measures ANOVAs with Bonferroni post hoc tests. 
Information recall sum scores and patients’ information- and LP-satisfaction scores 
were compared between conditions using univariate ANOVAs with Bonferroni 
post hoc test. Reported post-LP complications were compared between conditions 
using chi-squared tests. All analyses were corrected for sex and age, based on 
the study population of cognitively impaired individuals with a broad age-range, 
and differences between conditions on demographic characteristics. Analyses for 
information recall were additionally corrected for prior LP knowledge. Next, we 
performed a per-protocol analysis by repeating all analyses in participants who 
underwent an LP (n=145). Finally, for exploratory reasons, we calculated Spearman 
correlations between the different outcome variables (uncertainty, anxiety, 
information recall, information satisfaction and LP procedure satisfaction), and 
between patient-related factors (i.e. age, MMSE, years of education and prior LP 




We included 203 participants, with an average age of 63±9 years, 72 (36%) were 
female, and the average MMSE was 25±4. Sixty-six (33%) participants received 
a dementia diagnosis, of which 48 (24%) AD. Participants with a non-dementia 
diagnosis included; SCD 52 (26%), MCI 14 (7%), and other diagnoses, such as other 
neurological disorders, 71 (34%). Participant characteristics are listed in Table 
1. Participant distribution across conditions resulted in 62 in the home-viewing 
condition, 67 in the clinic-viewing condition, and 74 in the control-condition. 
No differences were found across conditions in age, MMSE, years of education, 
diagnosis, prior medical- and LP knowledge. There was a trend towards more 
females in condition 1 (home-viewing; table 1).
Information recall
We found differences in information recall between conditions at T2 (F(2, 170)= 
23.16, P value < .001) and T3 (F(2, 170)= 14.18, P value < .001). At T2, both home- 
and clinic-viewing recalled more information, compared to the control-condition (P 
value <.001). This difference remained until the end of the day (T3), (P value < .001). 
There was no difference in information recall between home-, and clinic-viewing 
at either T2 or T3. When restricting analyses to participants who underwent an LP 
(i.e. per-protocol analyses), results were similar (supplemental table A.2. Likewise, 
results for uncorrected analyses are comparable (supplemental table A.3).
Uncertainty and anxiety
ANOVA for repeated measures showed an effect of the intervention on the decrease 
in uncertainty (F(2, 183)= 5.02, Pfor interaction = .008). Here, clinic-viewing showed the 
strongest decline in uncertainty over time, compared to both home-viewing, and 
the control-condition (figure 3), though post-hoc analyses did not yield significant 
differences between conditions. Results were largely comparable for uncorrected 
analyses (supplemental table A.3), and after restricting analyses to participants 
who underwent an LP (i.e. per-protocol analyses; supplemental table A.2).
With respect to anxiety, ANOVA for repeated measures did not show an effect of the 
intervention on anxiety over time (F(2, 185)= .44, Pfor interaction = .64). Next, analyses 
were repeated in participants who underwent an LP (n=145). These per-protocol 
analyses, revealed similar results (supplemental table A.2), as did uncorrected 







































































































































































































































































































































































































































































































































































































































































































































































All reported post-LP complications for participants who underwent an LP are 
listed in Table 2. Of all participants who underwent an LP, none reported a severe 
complication. Minor complications were quite common, as 67 (46%) reported 
one or two. We did not find any differences between conditions in the reported 
occurrence of non-specific headache, typical post-LP headache or back pain.
Exploratory analyses
Next, we compared information satisfaction and LP procedure satisfaction across 
conditions. Both the home- (8.9 ± 0.19), and clinic-viewing conditions (8.8 ± 
0.18) were slightly more satisfied with the information received regarding the 
LP compared to control-condition (8.4 ± 0.17), although this effect did not reach 
significance (F(2, 176)= 2.24, P value = .11). There was no difference in satisfaction 
with the LP procedure across conditions (F(2, 147)= .41, P value = .66).
Subsequently, we explored associations between patient-related factors and 
outcome measures. A decrease in uncertainty was associated with a decrease in 
anxiety (ρ=0.25, P value =.001). Further, patients who had greater LP information 
recall, experienced a stronger decrease in uncertainty (ρ=0.23, P value =.002), and 
anxiety over time (ρ=0.16, P value =.037). Finally, patients who had experienced 
a stronger decrease in uncertainty over time, were more satisfied with the 
information received about the LP procedure (ρ=0.28, P value <.000), and with 
the LP procedure itself (ρ=0.25, P value =.003).
Table 2. Reported post-LP complications.








n=145 n=43 n=44 n=57
Typical post-LP headache 13 (9%) 4 (9%) 3 (7%) 6 (11%)
Atypical post-LP headache 32 (22%) 8 (19%) 9 (21%) 15 (26%)
Local back pain 38 (26%) 14 (33%) 10 (23%) 14 (25%)
Severe complications 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Table shows frequencies of post-LP complications per condition, and in total, as reported by 
participants; 1) in case of reported headache (yes/no) this was specified as typical post-LP 
headache or atypical headache, 2) local back pain (yes/no), or 3) severe complications (yes/
no). Post-LP complications were asked by telephone in a structured interview, previously 




In addition, we found an association between age and change in uncertainty over 
time (ρ=-0.28, P value <.001), as younger patients level of uncertainty decreased more 
over time (figure 4). Further, we found that patients with higher MMSE had better 
information recall scores (ρ=0.29, P value <.001; figure 4), and a larger decrease in 
uncertainty over time (ρ=0.31, P value <.001; figure 4). In addition, patients with 
more years of education experienced a greater reduction in uncertainty over time 
(ρ=0.21, P value=.004; figure 4). Additionally, patients who reported to have more 
knowledge regarding the LP procedure at baseline, experienced a greater decrease 
in uncertainty over time (ρ=0.32, P value <.001; figure 4).
Figure 3. Estimated marginal means for uncertainty (MUIS; figure A) and anxiety (STAI; 
figure B) at T1 and T2, with 95% confidence intervals. ANOVA for repeated measures 
showed an effect of the intervention on the decrease in uncertainty (F(2, 183)= 5.02, Pfor 
interaction = .008). Here, clinic-viewing showed the strongest decline in uncertainty over time, 
compared to both home-viewing, and the control-condition, though post-hoc analyses did 
not yield significant differences between conditions. ANOVA for repeated measures for 
anxiety did not show an effect of the intervention on anxiety over time (F(2, 185)= .44, Pfor 
interaction = .64). Green dotted line = C1: home-viewing, orange line = C2: clinic-viewing, and 



























































































































The main finding of this randomized controlled trial on the effectiveness of an 
educational video as an adjunct to standard information, was an improvement in 
knowledge, and a reduction in level of uncertainty. Hence, our study suggests that a 
simple video is an effective tool for preparing individuals for a lumbar puncture in 
the context of AD diagnostics. Importantly, such a video is equally effective when 
offered at home or in the clinic.
As expected, the video increased patients’ knowledge about the LP procedure, 
compared to care as usual. This increase in patients’ procedural knowledge may 
be a result of repeating the information. Nevertheless, previous literature showed 
that the use of audiovisual information was associated with increased procedural 
knowledge, compared to solely verbal and written information [11, 14, 16, 24-27]. 
Therefore, our finding may also be explained by having provided the information in 
an audio-visual format. Accurate knowledge about the diagnostic procedure may 
benefit patients and clinicians in several ways. First, in a former study, we found 
that memory clinic patients highly value procedural information about diagnostic 
tests [28]. Second, information fosters realistic patient expectations regarding 
the procedure and post-LP complications. Third, procedural information allows 
patients to consider the relevance for their personal situation and preferences, and 
thus, empowers them to address such issues during patient-clinician interactions. 
Finally, using a video as a vehicle for patient education has the advantage of 
providing the same information to each patient, thus reducing unwarranted 
practice variation. This standardized information provision might also result in 
a reduction of consultation time [26]. Future work could assess potential benefits 
of the video regarding patient expectations and participation in patient-clinician 
interactions.
Watching the video also contributed to a reduction in uncertainty in patients who 
viewed the video at the day of the LP procedure (condition 2: clinic-viewing). These 
findings are in line with two former studies, which reported reduced procedural 
uncertainty after audiovisual information provision on bariatric surgery 
and cardiac catheterization [12, 13]. In addition, our explorative association 
analyses showed that the video appeared to reduce uncertainty most in younger 
participants, those with a higher MMSE, more years of education, or more prior 
self-reported LP knowledge. It should be noted that self-reported LP-knowledge 
might not represent factual knowledge, but LP-knowledge based on hearsay. This 
might explain why uncertainty could decrease strongly in patients with more 
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prior LP-knowledge. Contrary to our expectation, we did not detect any effects 
of the intervention on patients’ level of anxiety. Former studies in other fields, 
such as ophthalmology or anesthesia, have reported a decrease in anxiety after 
audiovisual information aids [9, 11, 15, 29-32]. However, our results showed 
that patients experienced a relatively low level of anxiety, leaving little room for 
improvement. Therefore, a reduction in anxiety over time might have been too 
small to detect. In addition, physicians in our center are well educated and highly 
experienced in performing an LP. This has led us to develop an educational video 
on performing an LP procedure for professionals [33]. Because the LP is part of 
the routine diagnostic work-up and performed on a daily basis, patients might feel 
more at ease as a result. Alternatively, while the STAI-S is an extensively validated 
questionnaire [21, 22], it might not be sensitive enough to detect subtle changes in 
anxiety in a population including cognitively impaired individuals, as this has not 
been tested in this population. The video did not result in an increase in anxiety 
prior to the procedure, or an increase in post-LP complications, and thus did not 
have any harmful effects.
Watching the educational video had no effect on post-LP complications, whereas 
previously , we found a higher risk for post-LP complications in patients who 
were anxious for post-LP complications [6]. According to our hypothesis, the 
video would reduce anxiety, and as a result post-LP complications. It is likely that 
compared to Duits et al. the sample size was too small to detect small differences 
in post-LP complications (3868 vs 145 participants respectively). To effectively 
draw conclusions about the effect of information provision on the occurrence of 
post-LP complications, this should be assessed using a larger sample. Therefore, 
even without an effect on post-LP complications, the video effectively contributes 
to patient-preparation.
Based on our findings, we recommend to embed the video in clinical practice in 
addition to routine care, as our results show that clinic-viewers appear to benefit 
most from the video. Embedding the video in routine care facilitates healthcare 
providers as it is more efficient than sending it to each patient individually. 
Moreover, it ensures all patients see the video, and that any questions can be 
answered immediately. In addition, providing the video in routine clinical care 
makes it more accessible for every patient. For example, not all patients are able 
to view a video at home due to technological-, or cognitive disadvantages, such as 
cognitive impairment or illiteracy. Nevertheless, home-viewers also benefit from 
the video in terms of increasing their knowledge which may help them prepare 




to the visitation-day and in the clinic, for example by placing the video on the 
website or showing it in the waiting-area. If it’s not feasible to embed the video in 
routine clinical practice, providing the video solely prior to the visitation-day is a 
good alternative. Moreover, the video was developed specifically for cognitively 
impaired individuals [18]. Therefore, the information is presented in an easily 
understandable way. This might make the video as a medium of information 
provision especially suitable for individuals with low health literacy, as this 
concerns 12% of the European population [34].
This study has some limitations. First, the baseline questionnaire had to be filled 
in online, which may be more difficult for individuals with cognitive impairment. 
However, partners were allowed to assist the patient with filling in patients’ 
answers to the questionnaire. In addition, this was a single-center study in 
a tertiary memory clinic, resulting in a relatively highly educated and young 
population. Of note, particularly the young and highly educated patients were 
most likely to benefit from the intervention. Second, inclusion was terminated 
prematurely due to SARS-CoV-2, the coronavirus that caused the COVID-19 
pandemic [35]. This resulted in a somewhat smaller sample size than envisioned, 
and may have led to loss of power, particularly with respect to the post LP 
complications analysis. Nevertheless, for this type of study, we were able to achieve 
a relatively large sample size.
A major strength of this study is the randomized controlled trial design, which 
allowed us to establish the effectiveness of the video compared to standard 
information provision. In addition, this study was embedded into daily clinical 
routine, and therefore, it was designed to mimic the use of the video in a real 
clinical setting. Thus, our results translate directly to clinical practice, and show 
that it is feasible to implement the video in daily routine.
CONCLUSIONS
In conclusion, this RCT shows that a brief, educational video increased patients’ 
knowledge, and decreased uncertainty in a large memory clinic cohort. This 
suggests that the video is of value for individuals undergoing an LP procedure, 
by helping them to prepare for the procedure in daily clinical practice. These 
results support the development of similar videos for other diagnostic modalities, 
such as a PET- or MRI-scan. This type empirical research can also be applied to 
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Decision tree supports the 
interpretation of CSF biomarkers in 
Alzheimer’s disease
R Babapour Mofrad, N S M Schoonenboom, B M Tijms, P 
Scheltens, P J Visser, W M van der Flier, C E Teunissen





Introduction: We developed and validated a clinically applicable decision tree for 
the use of cerebrospinal fluid biomarkers in the diagnosis of Alzheimer’s disease 
(AD).
Methods: Subjects with probable AD (n = 1004) and controls (n = 442) were 
included. A decision tree was modeled using Classification And Regression Tree 
analysis in a training cohort (AD n = 221; controls n = 221) and validated in an 
independent cohort (AD n = 783; controls n = 221). Diagnostic performance was 
compared to previously defined cutoffs (amyloid β 1-42 < 813 pg/ml; tau>375 
pg/ml).
Results: Two cerebrospinal fluid AD biomarker profiles were revealed: the 
“classical” AD biomarker profile (amyloid β 1-42: 647-803 pg/ml; tau >374 pg/
ml) and an “atypical” AD biomarker profile with strongly decreased amyloid β 
1-42 (<647 pg/ml) and normal tau concentrations (<374 pg/ml). Compared to 
previous cutoffs, the decision tree performed better on diagnostic accuracy (86% 
[84-88] vs 80% [78-83]).
Discussion: Two cerebrospinal fluid AD biomarker profiles were identified and 




Cerebrospinal fluid (CSF) biomarkers amyloid β 1-42 (Aβ42), total tau (tau), and 
phosphorylated tau (Ptau) can aid in the diagnosis of Alzheimer’s disease (AD) [1]. 
According to the recent National Institute on Aging and Alzheimer’s Association 
(NIA-AA) criteria and International Working Group (IWG)-2 criteria, an abnormal 
CSF Aβ42 in combination with an abnormal CSF tau or Ptau is considered to be an 
“AD-like” pathological profile [2], [3]. In daily practice, however, not all AD patients 
have a clear abnormal pattern of all three biomarkers. As previously shown, 8% of 
clinically diagnosed AD patients can have abnormal CSF Aβ42 alone without tau 
pathology [4]. Similarly, another study reported five AD subgroups with different 
CSF biomarker profiles with regard to Aβ42, tau, and ubiquitin [5]. The diversity of 
possible CSF biomarker profiles that can accompany AD dementia can be confusing 
for clinicians, contributing to the challenge of implementing CSF markers in daily 
clinical practice. Another complication is the requirement of current criteria for 
AD dementia to have both amyloid and tau pathologies present, with equal weight 
ascribed to each biomarker [2], [3].
The aim of the present study was to determine whether a statistical decision tree 
approach may aid in interpreting combinations of CSF biomarkers. An advantage of 
this approach is that it can identify and visually represent multiple CSF biomarker 
combinations in a decision tree, which can be readily used by the clinician, thereby 
facilitating decision-making in clinical practice. We further assessed the diagnostic 
and predictive performance of the decision tree.
METHODS
Subjects
We selected 1809 subjects with a diagnosis of AD (n = 1004), mild cognitive 
impairment (MCI) (n = 363), or subjective cognitive decline (SCD; n = 442) from 
the Amsterdam Dementia Cohort, who visited our outpatient clinic for diagnosis 
in the period from October 2000 until July 2015, and of whom CSF biomarker 
values were available. All subjects underwent standardized dementia screening 
at the baseline, including physical and neurological examinations, cognitive 
screening, an electroencephalogram, magnetic resonance imaging, and laboratory 
tests. Cognitive screening included at least a Mini-Mental State Examination, and 
often a comprehensive neuropsychological test battery (previously described 
elsewhere) [6], [7]. Diagnoses were made by consensus according to internationally 




[8]. All probable AD dementia patients met the core clinical NIA-AA criteria [9]. MCI 
was determined according to the criteria by Petersen et al. [10] and NIA-AA core 
clinical criteria [11]. All subjects with MCI received follow-up consultations with 
repeated medical and neuropsychological testing. The average follow-up period 
was (mean ± SD) 2.5 ± 1.6 years during which 143 MCI subjects progressed to AD-
type dementia and 220 MCI subjects did not. MCI subjects who had progressed to 
a non-AD type dementia, that is, vascular dementia, Lewy body disease, possible 
AD, “other dementias” (e.g. due to Parkinson’s disease) or were given a postponed 
diagnosis, were labeled as not having AD dementia at the follow-up. All controls 
consisted of SCD subjects who were labeled as such when results of all clinical 
examinations and test results were normal, that is, when the criteria for MCI or 
AD were not fulfilled, and there was no psychiatric diagnosis. Level of education 
was classified according to the Verhage system, ranging from 1 to 7 points (low 
to high education level) [12].
Standard protocol approvals, registrations, and patient consents
All subjects gave written informed consent for the use of clinical data for research 
purposes, and the use of clinical data was approved by the local ethical review 
board [8].
CSF biochemical analysis
CSF was obtained by lumbar puncture, using a 25-gauge needle, and collected 
in 10 mL polypropylene tubes (Sarstedt, Nümbrecht, Germany), which is in line 
with international consensus protocols [13]. Within two hours, CSF samples were 
centrifuged at 1800g for 10 minutes at 4° C. The CSF supernatant was transferred 
to new polypropylene tubes and stored at −20° C until further analysis (within 
two months). Baseline Aβ42, tau, and Ptau-181 were measured with commercially 
available ELISAs (INNOTEST β-AMYLOID(1-42), INNOTEST hTAU-Ag, and 
INNOTEST Phospho tau(181P) Fujirebio, Ghent, Belgium) on a routine basis as 
described before with intra-assay and interassay variations for all analysis of 
<3.2% and 10.9%, respectively [14]. The team performing the CSF analysis was 
not aware of the clinical diagnosis. Previous analysis has shown that there is a drift 
in Aβ42 results over the analysis years [15], [16]. We therefore applied a correction 
to the values to control for this drift, as previously described [17]. No such drift 
was observed for the tau and Ptau values.
Apolipoprotein E genotyping
DNA was isolated from 10 ml vacutainer tubes containing EDTA using the QIAamp 
DNA blood isolation kit from Qiagen (Venlo, The Netherlands). For genotype 
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determination, the LightCycler ApoE mutation Detection Kit (Roche Diagnostics, 
GmbH, Mannheim, Germany) was used.
CART analysis
Classification And Regression Tree (CART) analysis is a nonparametric, supervised 
statistical learning technique that combines variable values, here CSF Aβ42, tau, 
and Ptau, such that these best discriminate between classes, in our case AD 
dementia and controls. The optimal combination of variables and possible cutoff 
values used for classification is determined through an exhaustive search of all 
possibilities by the CART algorithm [18]. The results are presented in a decision 
tree with several splits based on the selected variables and cutoffs, ending with 
the class labels. The Gini criterion was applied to minimize node impurity after 
splitting, and cross-validation was performed to prune the tree based on the 
minimum deviance, that is, the minimum (proportion) deviance improvement 
for proceeding with a new split [19]. We split our data set (controls n = 442; AD n 
= 1004) into a randomly selected training and validation set. The training data set 
included 50% of control subjects (n = 221) and was balanced with an equal amount 
of AD subjects (n = 221). The remaining subjects constituted the validation data 
set (controls n = 221; AD n = 783).
Validation
The decision tree was validated three-fold. First, internal validation applying cross-
validation was used to build the tree. Second, the resulting tree was externally 
validated using an unseen validation data set. For the validation data set, accuracy 
(ACC), sensitivity (SE), and specificity (SP) were compared to the “typical” AD-like 
CSF biomarker profile consisting of decreased Aβ42 (<813 pg/ml) and increased 
tau concentrations (>375 pg/ml), for which cutoffs were previously defined [2], 
[17], [20](see Table 2 for overview). Third, we further validated the performance 
of the tree to discriminate between MCI subjects who showed progression to AD 
dementia and MCI subjects who remained stable or had progressed to a non-AD–
type dementia. We compared the ACC, SE, and SP with the previously defined 
cutoffs. CART analysis was performed using the R package “tree” in R (version 
3.3.1, 2016-05-03). The predictor variables entered into the CART analysis included 
Aβ42, tau, and Ptau levels; Apolipoprotein E (APOE) genotype; sex; and age.
Statistical analysis
Test characteristics consisting of ACC, SE, and SP, together with 95% confidence 
intervals were calculated with the epi.tests function, part of the “epiR” package in 




95% confidence intervals. For the calculations of subject characteristics, and the 
subgroup comparisons, independent t-test, Kruskal-Wallis test, and chi-square 
test were applied. A P-value < .05 was considered significant.
RESULTS
Subject characteristics
Subject characteristics according to diagnostic group are shown in Table 1. In brief, 
the training and validation cohorts used to build and validate the decision tree did 
not differ in subject characteristics. In both training and validation data sets, the 
controls were somewhat younger than AD patients, more often female, and had a 
higher level of education. As expected, Mini-Mental State Examination scores, and 
CSF Aβ42, tau, and Ptau levels were abnormal in AD patients compared to controls 
in both data sets. Furthermore, AD patients more often carried an APOE e4 allele 
compared to controls in both data sets.
CART analysis
Fig. 1 shows the decision tree generated by the CART analysis on the training 
set. The decision tree identified two cutoff values for Aβ42 and one cutoff for tau. 
The first variable selected for decision-making was CSF Aβ42: subjects with Aβ42 
higher than 801 pg/ml are classified as controls (group 1; Aβ42 ≥ 801). When 
Aβ42 levels were lower than 801 pg/ml, tau provided the most significant split at 
a cutoff level of 374 pg/ml. If tau concentrations were equal or higher than 374 pg/
ml, no further splits were made and subjects were assigned the AD label (group 2; 
Aβ42 < 801 and tau ≥374). When tau concentrations were lower than 374 pg/ml, 
a second Aβ42 cutoff at 647 pg/ml provided the best split. This split separated a 
second group of controls with Aβ42 concentrations between 647 and 801 pg/ml 
(group 3; 647 < Aβ42 < 801 and tau <374) and a second group of AD patients with 
Aβ42 concentrations lower than 647 pg/ml (group 4; Aβ42 < 647 and tau <374). 
Group 1 contained most observed controls (n = 182; 82%) and group 2 contained 
most observed AD patients (n = 167; 76%). Additional variables, such as APOE, Ptau, 
sex, and age, did not add to the discriminative power of the decision tree and were 


















































































































































































































































































































































































































































































































































































































Figure 1. Decision tree. Decision tree calculated by Classification And Regression Tree 
(CART) analysis. The tree was built in the training cohort and is validated in the validation 
cohort. Numbers in the boxes indicate the percentage of correctly classified subjects out 
of the total number of subjects in that group for the training cohort in which the tree was 
built. Groups are numbered from 1 to 4. Aβ42 and tau concentrations are shown in pg/ml. 
Abbreviations: SCD, subjective cognitive decline; AD, Alzheimer’s disease; Aβ42, amyloid 
β 1-42; tau, total tau.
Validation: diagnostic performance AD vs controls
As shown in Table 2, the decision tree had an overall SE of 93% [89-96] and SP of 
88% [83-92] to detect AD dementia in the training cohort, and a SE of 86% [83-88] 
and SP of 87% [82-91] to detect AD dementia in the validation cohort. The overall 
diagnostic ACC was: 90% [87-93] and 86% [84-88] in the training and validation 
cohorts, respectively.
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Table 2. Comparison of test characteristics
Aβ42 (pg/ml) tau 
(pg/ml)
Accuracy,% SE, % SP, %
AD vs controls
 Previous cutoff∗ 813 375 80 [78-83] 78 [75-81] 89 [84-93]
 Tree training 801 and 647 374 90 [87-93] 93 [89-96] 88 [83-92]
 Tree validation 801 and 647 374 86 [84-88] 86 [83-88] 87 [82-91]
MCI stable vs progression to AD
 Previous cutoff∗ 813 375 76 [71-80] 77 [69-84] 75 [69-81]
 Tree 801 and 647 374 76 [71-80] 84 [77-90] 70 [63-76]
Comparison of decision tree with typical AD biomarker–like profile using previously 
defined cutoff values for Aβ42 (813 pg/ml) and tau (375 pg/ml).The decision tree has 
two cutoffs for Aβ42. Accuracy, SP, and SE calculations with 95% CI. Abbreviations: AD, 
Alzheimer’s disease; MCI, mild cognitive impairment; SE, sensitivity; SP, specificity; CI, 
confidence interval; Aβ42, amyloid β1-42.∗Cutoff for Aβ42 is based on drift corrected 
data.
The number of correctly labeled subjects per group differed from the training cohort 
in which the tree was built compared to the validation cohort (see Supplementary 
Table 1). Especially, the control group with lower Aβ42 concentrations and normal 
tau concentrations (group 3; 647 < Aβ42 < 801 and tau <374) contained only 29% 
(n = 12/41) correctly classified subjects in the validation cohort, indicating that 
this control group mostly consisted of clinical AD subjects. In contrast, in the 
training cohort, 76% (n = 16/21) were correctly classified as controls.
We next compared the SE and SP levels obtained by the decision tree to those 
obtained with the previous binary cutoffs in the validation cohort. The decision 
tree with multiple cutoffs for Aβ42 had a significantly higher diagnostic ACC (86% 
[84-88]) in discriminating controls from AD compared to the previously defined 
single cutoff’s for Aβ42 and tau together (80% [78-83]). Moreover, the SE of the 
decision tree was also higher than the previously defined cutoffs (86% [83-88] 




Table 3. Subject characteristics MCI cohort
MCI Stable Progression to AD
n, (%) 220 (61%) 143 (39%)
Age, years (SD) 67.3 (6.5) 69.3 (7.4)*
Females, n (%) 144 (65) 73 (51)*
Level of education, mean (SD)† 5.1 (1.4) 5.0 (1.4)
APOE ε4 allele carriers, n (%) 93 (42%) 87 (61%)
MMSE score, mean (SD) 27 (2.3) 26 (2.8)
CSF Aβ1-42 (SD), pg/ml 934 (299) 679 (122)*
CSF tau (SD), pg/ml 375 (227) 668 (350)*
CSF Ptau (SD), pg/ml 58 (29) 70 (34)*
Follow-up duration, years (SD) 2.5 (1.6) 2.4 (1.3)
Abbreviations: MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; 
APOE, apolipoprotein E; Aβ42, amyloid β 1-42; Ptau, tau phosphorylated at threonine 181; 
SD, standard deviation; CSF, cerebrospinal fluid.
Data are mean (SD), unless otherwise specified. Independent T-test, Kruskal-Wallis test, or 
chi square test was used when applicable. *P < .05.†According to the Verhage system.
Validation: predictive performance for progression to AD
Our next step was to evaluate the predictive performance of the decision tree. 
Therefore, we used a cohort of MCI subjects with the follow-up available (average 
follow-up time: 2.5 ± 1.5 years). Subject characteristics are shown in Table 3. In 
brief, MCI subjects who progressed to AD were slightly older and were less often 
female than MCI subjects who did not progress to AD dementia. They also had 
lower CSF Aβ42 levels and higher tau and Ptau levels compared to the MCI subjects 
who did not progress to AD dementia.
The tree correctly identified 70% (n = 154 of 220) of MCI subjects who did not 
develop AD and predicted progression correctly in 84% (n = 120 of 143) of MCI 
subjects who clinically progressed to AD. Most incorrectly classified subjects (n = 
50 of 89, 56%) had clinically not progressed to AD dementia but were classified as 
progressors by the decision tree, and vice versa, the remaining 44% had clinically 
progressed to AD but were classified as nonprogressors by the tree. The overall 




We further compared the four subgroups with different CSF profiles that were 
identified by the CART analysis. Groups 1 and 3 were labeled as control groups 
and had either high Aβ42 levels irrespective of tau (group 1: Aβ42 ≥ 801) or 
intermediate Aβ42 and low tau levels (group 3: 647 < Aβ42 < 801 and tau <374). 
Groups 2 and 4 were labeled as AD, and had low Aβ42 and high tau levels (group 
2:Aβ42 < 801 and tau ≥374), or strongly decreased Aβ42 and low tau levels (group 
4: Aβ42 < 647 and tau<374).
Across the total cohort (Table 4), Mini-Mental State Examination scores were 
highest in control group 1, followed by control group 3, AD group 2, and AD group 
4. Control group 3, showed a similar proportion of APOE e4 carriers compared 
to AD groups 2 and 4. Groups 2 and 4 showed more atrophy for all magnetic 
resonance imaging parameters than control group 1. Control group 3 showed 
similar temporal lobe atrophy as AD groups 2 and 4, and parietal cortical atrophy 
and global cortical atrophy appeared to be in-between control group 1 and AD 
group 2.
Within the MCI cohort (Table 5), group 2 labeled as progressors contained more 
females than group 1 (nonprogressors). Moreover, control group 1, labeled as 
nonprogressors, contained the least APOE e4 carriers, whereas group 3 contained 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The main finding of this study is that a decision tree, consisting of two Aβ42 
cutoff values at 801 pg/ml and 647 pg/ml and one tau cutoff at 374 pg/ml, best 
distinguished between controls and AD dementia. As a result, two AD and two 
control subgroups were identified who showed distinct CSF biomarker profiles. 
Age, Ptau, sex, and APOE status did not contribute to classification. Compared to 
the classical AD-like biomarker profile with previously defined cutoffs (813 pg/
ml for Aβ42 and 375 pg/ml for Tau [17], [20]), the decision tree performed better 
in terms of diagnostic characteristics (diagnostic ACC 86% [84-88]; SE 86% [83-
88]; SP 87% [82-91]). The predictive ACC of the decision tree in MCI subjects was 
similar to that of the previously defined cutoffs (76% [71-80] and 76% [71-80], 
respectively). Using CART analysis, we derived a robust decision tree that is readily 
applicable in the clinic.
Previous attempts to make a decision tree to distinguish AD from controls were 
made by Galasko et al. (1998) using Classification tree analysis [21]. Like in our 
present study, they also identified two cutoff values for CSF Aβ42. However, their 
cohort was relatively small. Here, we reproduce and further extend these findings 
showing strong external validation supporting the robustness of the approach, 
which is a prerequisite for implementation [21].
Others have suggested the use of regression formulas or the tau/Aβ42 ratio to 
combine multiple biomarkers for AD classification [20], [22], [23], [24]. Although 
such approaches can also provide a cut point, a benefit of the decision tree approach 
is that it allows clinicians to combine information from multiple biomarkers, 
providing intuitive interpretation of all markers involved, in contrast to, for 
example, a ratio when an abnormal value may be caused by either the numerator 
and/or denominator of the ratio. This could lead to false positive results, for 
example, an increase in tau can also occur in patients with other neurological 
conditions, such as minor stroke or Creutzfeldt-Jakob Disease, resulting in a high, 
abnormal ratio value, despite normal Aβ42 concentrations [14].
A decision tree does not suffer from those issues and is in better alignment with 
clinical decision paths, logically clustering signs and symptoms [25]. Furthermore, 
logistic regression models can be used to test whether a variable can separate a 
case from a control, provided that these labels are present a priori. A benefit of the 
CART analysis is that it allows for the existence of subgroups, even when these are 
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not known a priori. In our case, we discovered subgroups 3 and 4, which would 
not have been identified in by a logistic regression model [18].
Ptau, age, sex and APOE status were not selected as part of the decision tree, 
suggesting that these variables did not add to the discriminative value of the tree. 
Previous studies showed that CSF levels of Aβ42 are lower in APOE carriers, and 
thus, we expected that APOE allele status would become part of the model [26]. 
A possible explanation for APOE not being included may be that the influence of 
APOE is mediated via Aβ42 levels, such that subgrouping based on APOE is of no 
further value [27]. A recent study of our group in which a data-driven cutoff is 
defined with Gaussian mixed modeling similarly found the cutoff to be independent 
of APOE allele status [16]. Nevertheless, this same study found a higher of Aβ42 
cutoff when age increases [16], whereas in our study, age was not selected by the 
CART algorithm. A possible explanation could be that our cohort was considerably 
young and did not reflect a range of relatively young to old ages. The absence of 
Ptau in the model is in agreement with previous studies and is probably due to its 
high correlation with tau [14].
An additional finding of this study was the identification of two AD subgroups 
that showed distinct CSF biomarker profiles. The first AD subtype had a typical 
AD-like biomarker profile (low Aβ42 and high tau or Ptau; Aβ42 < 801 and tau 
≥374) (group 2). The second AD subtype contained subjects with an “atypical” 
CSF profile with strongly decreased Aβ42 concentrations and normal CSF tau 
levels (group 4; Aβ42 < 647 and tau <374). Despite the different CSF biomarkers 
profiles, the subgroup analysis showed that both AD groups did not differ in 
clinical characteristics or magnetic resonance imaging measures. In view of the 
pathological heterogeneity often seen in AD patients, it might be that group 4, with 
the atypical CSF profile, is a subgroup of AD with a different underlying pathology 
leading to the disease [28]. For example, in a previous study, a subgroup similar 
to our atypical AD subtype (group 4) was identified, with strongly decreased CSF 
Aβ42 concentrations (513 pg/ml) and close to normal CSF tau concentrations (392 
pg/ml) [5]. Interestingly, 15% of this AD subgroup had AD pathology with Lewy 
bodyinclusions at postmortem pathological examinations. Whether this explains 
our atypical group can only be defined after postmortem analysis.
Within controls, we also detected two subgroups: group 1 (n = 182) with normal 
Aβ42 levels (≥801 pg/ml) irrespective of tau levels, and group 3, with slightly 
reduced Aβ42 concentrations (801- 640pg/ml), and normal tau concentrations 




both subgroups with CSF AD profiles (groups 2 and 4). According to the recent 
NIA-AA criteria, the controls in group 3 with already lowered Aβ42, but normal tau 
concentrations have Alzheimer’s pathologic change, and are at the beginning of the 
Alzheimer’s continuum, meaning that these controls could have preclinical AD and 
might develop tau pathology over time [2], [29], [30]. Previous research has shown 
that Aβ42 can be present twenty years before the onset of clinical AD [31], [32]. 
So far, insufficient amount of follow-up information was available to determine 
whether this group was at risk to show clinical progression to MCI or dementia. 
Moreover, group 3 mainly consisted of observed controls in the training cohort, 
whereas it mostly consisted of observed AD patients in the validation cohort. With 
this group (group 3), the decision tree might have identified a “gray” area for Aβ42 
values that fall within the two cutoffs, where the discriminatory performance 
of the biomarker is not sufficient enough to state whether the disease is present 
or absent. We studied the prognostic ACC of the decision tree in MCI patients, 
which was comparable with the prognostic ACC of the previously defined cutoffs. 
However, the decision tree had a lower SP (70%), mostly due to misidentifying 
MCI subjects who remained stable. These MCI subjects had abnormal CSF Aβ42 
concentrations according to the decision tree and did not progress to AD dementia 
within the time they were followed. Thus, it cannot be excluded that if they were 
followed for a longer period, they may have still showed progression.
Limitations of our study are the use of clinical diagnosis as a gold standard to 
derive the decision tree. Because clinical diagnoses are not always correct, even 
in an expert center, this can result in a bias of the diagnostic performance and 
suboptimal cutoff values of the decision tree [33]. The use of SCD subjects over 
healthy subjects as controls could be seen as a limitation. However, we believe SCD 
subjects fit our study design better than healthy controls because they represent 
the population that present themselves to the doctor with memory complaints 
more so than healthy controls. A strength of our study is the availability of a large 
data set that enabled us to validate the decision tree in two independent cohorts.
In conclusion, the CART analysis identified several CSF biomarker profiles to 
classify AD based on two Aβ42 cutoff values and one tau cutoff. This led to an 
improved diagnostic ACC when compared to the regularly used AD-like biomarker 
profile based on single cutoffs. The results incorporated into a decision tree 
facilitate interpretation of CSF biomarker results in clinical practice.
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Part III
Development of novel biomarkers

Chapter 9
Blood-based protein biomarkers in 
definite frontotemporal dementia
R Babapour Mofrad, M del Campo Milan, C F W 
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G B Ramakers, H A M Middelkoop, P P De Deyn, J A H R 
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Background: Frontotemporal dementia (FTD) is caused by frontotemporal lobar 
degeneration (FTLD), characterized mainly by inclusions of Tau (FTLD-Tau) or TAR 
DNA binding43 (FTLD-TDP) proteins. Plasma biomarkers are strongly needed for 
specific diagnosis and potential treatment monitoring of FTD. We aimed to identify 
specific FTD plasma biomarker profiles discriminating FTD from AD and controls, 
and between FTD pathological subtypes. In addition, we compared plasma 
results with results in post-mortem frontal cortex of FTD cases to understand 
the underlying process.
Methods: Plasma proteins (n=1303) from pathologically and/or genetically 
confirmed FTD patients (FTLD-Tau n=16; age= 58.2±6.2; 44% female, FTLD-TDP 
n= 40; age= 59.8±7.9; 45% female), AD patients (n=57; age= 65.5±8.0; 39% female), 
and non-demented controls (n=148; 61.3±7.9; 41% female) were measured using 
an aptamer-based proteomic technology (Somascan). In addition, tissue proteins 
of post-mortem frontal brain cortex of FTD (FTLD-Tau n=5; age= 56.2±6.9, 60% 
female, and FTLD-TDP n= 5; age= 64.0±7.7, 60% female) and non-demented controls 
(n=5; age= 61.3±8.1; 75% female) were measured. Differentially regulated plasma 
and tissue proteins were identified by global testing adjusting for demographic 
variables and multiple testing. Logistic lasso regression was used to identify 
plasma protein panels discriminating FTD from non-demented controls and AD, 
or FTLD-Tau from FTLD-TDP. Performance of the discriminatory plasma protein 
panels was based on predictions obtained from 10-fold cross-validation.
Results: Overall plasma protein expression profiles differed between FTD, AD and 
controls (p=0.005). The overall tissue protein expression profile differed between 
FTD and controls (p=0.003). There was no difference in overall plasma or tissue 
expression profile between FTD subtypes. Regression analysis revealed two 
distinct plasma protein panels that, combined with age and sex, could discriminate 
FTD patients from non-demented controls with modest accuracy (AUC: 0.71, 
8-markers), and FTD from AD with high accuracy (AUC: 0.99, 22-markers). No 
plasma protein panel discriminating FTD pathological subtypes was identified.
Conclusions: We identified promising plasma protein panels as a minimally-
invasive tool to aid in the differential diagnosis of FTD. In addition, the plasma 
proteomes were essentially similar between FTLD-Tau and FTLD-TDP, suggesting 
a similar pathology in both subtypes.
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BACKGROUND
Frontotemporal Dementia (FTD) is one of the most prevalent forms of young onset 
dementia (<65 years) [1]. The underlying pathological process is Frontotemporal 
Lobar Degeneration (FTLD), which can be mainly classified into two different 
pathological subtypes based on the typical protein aggregates present in brain 
tissue: the microtubule associated protein Tau (FTLD-Tau) or TAR DNA-binding 
protein 43 (FTLD-TDP) [2,3]. Each pathological subtype will likely require distinct 
targeted drugs, and therefore, it is necessary to discriminate both subtypes in 
living patients. The poor correlation between the clinical presentation and 
underlying pathology [4] makes it hard to discriminate these pathological subtypes 
in sporadic FTD. However, in familial FTD cases (i.e. approximately 10-25% of 
cases [5]), the underlying genetic mutation is directly linked to these specific Tau 
or TDP pathologies. Genetic mutations in the microtubule-associated protein tau 
(MAPT) lead to FTLD-Tau pathology; while mutations in the progranulin (GRN), 
or chromosome 9 open reading frame 72 (C9ORF72) genes, lead to FTLD-TDP 
pathology [6].
Currently, there is no biomarker for the diagnosis and potential treatment 
response monitoring of FTD and its pathological subtypes. In addition, it is of 
particular importance to differentiate FTD from other dementia disorders, 
such as Alzheimer’s Disease (AD), or non-dementia disorders such as primary 
psychiatric disorders (PPD). Both PPD and AD can sometimes show similar clinical 
features as FTD, including language and executive function impairments [7,8] or 
behavioral changes [3,4]. Previous studies have shown promising CSF or blood 
biomarker alterations in FTD compared to controls, in particular neurofilament 
light (NfL) levels or the CSF p/tTau ratio for the discrimination of FTD pathological 
subtypes [9–12]. However, changes in these markers were either not specific for 
FTD as they were also changed in other types of dementia [9,10], or did not reach 
sufficiently high diagnostic accuracy [11,12]. This warrants the identification of 
novel biomarker candidates for diagnosis and treatment monitoring of FTD and 
its pathological subtypes.
Most FTD biomarker studies performed to date have used CSF as the main source 
for biomarker discovery, due to its close proximity to the brain [9]. However, as 
a lumbar puncture is often perceived as invasive, biomarkers in a more easily 
accessible body fluid such as blood is essential. The new high-throughput multiplex 
aptamer-based multiplex proteomic technology (SomaScan) [13–15], able to 




of novel blood-based biomarkers, and has been used to identify novel candidate 
biomarkers for AD pathology [16–18]. The multiplex feature of the aptamer-
based proteomics technology is of importance as it is expected that a specific 
combination of proteins rather than a single biomarker will probably provide a 
more accurate profile of each specific dementia type, due to the complexity and 
heterogeneity of dementia pathologies [10].
In this study, we aimed to identify novel plasma protein profiles for the specific 
discrimination of FTD from AD and controls, as well as FTLD pathological subtypes 
using this innovative aptamer-based proteomic approach. To understand the 
possible relation of the different markers with the central nervous system, the 
plasma proteome differences were compared to those observed in post-mortem 




Human plasma samples from FTD subjects (n=56) were obtained from two 
specialized memory centers in the Netherlands: Alzheimer Center Amsterdam 
(n=96), and Erasmus Medical Center Rotterdam (n=51) [19–21]. All 56 FTD subjects 
had a definite diagnosis of FTD based on known FTD-causing mutations (i.e. GRN, 
MAPT or C9orf72) and/or autopsy-confirmation. Underlying FTLD-TDP pathology 
was present in 40 subjects (18 autopsy confirmed cases, 13 GRN [of whom 1 was 
autopsy confirmed], 9 C9orf72 [of whom 1 was autopsy confirmed]), and FTLD-
Tau pathology in 16 subjects (3 autopsy-confirmed cases, 13 MAPT [of whom 2 
were also autopsy confirmed]). AD plasma samples (n=57) were selected from 
the Parelsnoer Initiative biobank, the neurodegeneration Parel, which collected 
samples from the eight Academic medical centers in the Netherlands [22]. AD 
subjects were selected based on clinical diagnosis using NINCDS-ADRDA criteria 
[22,23]. Control plasma samples were (n=148) were obtained from Alzheimer 
Center Amsterdam (n=69), Erasmus Medical Center Rotterdam (n=22), and 
the Parelsnoer Initiative biobank (n=57). All samples were collected through 
venipuncture using Ethylenediaminetetraacetic acid (EDTA) collection tubes. 
Blood collection was followed by centrifugation at 1,800g. Plasma supernatant 
was collected, aliquoted and stored in 0.5ml polypropylene tubes at -80°C within 
4 hours in each local biobank. All subjects gave informed consent according to 
the declaration of Helsinki (1991), and protocols were approved by local ethical 
committees at each site.
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Post-mortem brain tissue
Post-mortem brain material was obtained from the Netherlands Brain Bank 
(Amsterdam, the Netherlands). We selected snap frozen medial frontal gyrus from 
FTD cases (FTLD-Tau n=5; FTLD-TDP n=5) and non-demented controls (n=4). Four 
FTLD-TDP cases were familial (GRN n=2, C9orf72 n=2) and one was a sporadic case. 
Of the FTLD-Tau cases, all were familial and had an underlying MAPT mutation. 
Neuropathological evaluation and processing were performed as previously 
described [24]. The distribution and the density of tau aggregates and TDP-43 
inclusions were evaluated according to the criteria described by Lee, Cairns and 
MacKenzie [25–27]. Post-mortem frontal cortex was homogenized using Tissue 
Protein Extraction Reagent (T-Per, 0.1g/ml, Thermo Scientific, Waltham, USA) 
containing EDTA-free Protease Inhibitor Cocktail (1:25, Roche, Basel, Germany), 
and left for 15 min at 4°C. Homogenates were subsequently centrifuged at 10,000g 
for 15 min at 4°C. Protein concentration was measured using Bio-Rad Protein Assay 
(Bio-Rad, Hercules, USA) and bovine serum albumin (BSA) (Thermo Scientific, 
Waltham, USA) following manufacturer’s recommendations. Samples were stored 
at -80ºC until further analysis. All donors (or their next of kin) provided written 
informed consent for brain autopsy and use of tissue and medical records for 
research purposes.
Protein measures
Protein concentrations of 1303 human proteins in plasma of AD and FTD patients 
or controls, and brain tissue homogenates of FTD patients and controls were 
measured at the Neurochemistry Laboratory of Amsterdam UMC using SomaScan 
(SomaLogic, Inc. Boulder, Colorado, USA). Samples were diluted into three 
concentrations (i.e. 40%, 1%, and 0.005%) to enable the appropriate measurement 
range for all Somamers within one sample. The least concentrated sample is 
designed to detect the most abundant proteins, and the most concentrated sample 
is designed to detect the least abundant proteins. The precise SomaScan principle 
has been described in detail previously [13,16]. Samples were randomly divided 
over the plates to ensure an even mix of diagnostic groups. Plasma samples 
were measured in 5 (AD vs CN) and 7 (FTD vs CN) runs, and tissue samples in 
1 (FTD vs CN) run. Technicians trained and certified by SomaLogic conducted 
all analyses in a blinded manner. Both plasma datasets (i.e. FTD vs CN and AD vs 
CN) were run in two batches using different SOMAmer reagent master mixes and 
were standardized to a common reference using common calibrator control lots 
(supplemental text 1). In addition, all SomaScan data were normalized following 
a standard three step procedure (1. hybridization normalization, 2. plate scaling, 




data. The standard normalization procedure and quality acceptance criteria are 
described in detail in the supplemental material.
Statistical analysis
All statistical analyses were performed using R version 3.5.2. Demographics were 
compared between groups using analysis of variance (ANOVA) and Kruskal-Wallis 
tests where appropriate. First, we used the global test [28], which tests if the 
overall protein abundance profile is notably different between diagnoses. This test 
is suitable when there may be insufficient power to detect individual proteomic 
markers. We applied global testing corrected for age and sex to identify an overall 
difference in plasma and post-mortem protein expression profile between i) FTD, 
AD and controls, and ii) FTD pathological subtypes (FTLD-Tau vs FTLD-TDP). We 
also applied the global test in tissue to measure overall differences in protein 
expression profiles between FTD and controls. Multiplicity correction using the 
false discovery rate (FDR) was applied within each global test to the significant 
subtree that identifies those features to which the test result is attributable. Next, 
logistic lasso regression (LLR) with correction for age and sex was performed to 
select a panel of proteins that could discriminate between FTD vs controls, FTD vs 
AD and FTLD-Tau vs FTLD-TDP. Predictive performance was assessed by receiver 
operating characteristic (ROC) curves and the area under the ROC curves (AUCs). 
ROC curves and AUCs were produced by 10-fold cross-validation.
RESULTS
Demographics
FTD patients and controls included in the plasma analyses were both younger 
than AD patients, and had higher MMSE scores (p<0.05, Table 1). FTLD-Tau and 
FTLD-TDP subtypes did not differ in age, sex or MMSE scores. In patients selected 
for the tissue analysis, no differences were observed in age and sex.
Plasma protein profile differs between FTD, AD and controls, but not  
between pathological subtypes
The overall plasma protein expression profile consisting of 1303 proteins was 
different between FTD, AD patients and controls (p=0.005). We identified six 
proteins that attributed to this difference in expression profile (Table 2), which 
were all upregulated in AD compared to both FTD patients and controls (Figure 
1). There was no difference in overall plasma protein profiles between FTD–Tau 
and FTLD-TDP subtypes (p>0.05).
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Table 1. Demographics







FTD 56 (22%) 59.4 (7.4) 25 (45%) 24 (5.2) b
FTLD-TDPd 40 (71%) 59.8 (7.9) 18 (45%) 24 (5.7)
FTLD-Taue 16 (29%) 58.2 (6.2) 7 (44%) 25 (3.6)
AD 57 (22%) 65.5 (8.0)c 22 (39%) 23 (2.3)
Controls 148 (57%) 61.3 (7.9) 60 (41%) 29 (1.4)
Post-mortem frontal cortex
FTD 10 (67%) 60.1 (8.0) 6 (60%) NA
 FTLD-TDP 5 (50%) 64.0 (7.7) 3 (60%) NA
FTLD-Tau 5 (50%) 56.2 (6.9) 3 (60%) NA
Controls 5 (33%) 61.3 (8.1) 3 (75%) NA
Analysis of variance (ANOVA) or Kruskal-Wallis test were used as appropriate. p<0.05 
was considered significant. a age at inclusion in plasma samples and age at death in post-
mortem tissue, b significant difference between FTD-controls, c FTD patients and controls 
were significantly younger than AD patients. d FTLD-TDP pathology was present in 40 
subjects (18 autopsy confirmed cases, 13 GRN [of whom 1 was autopsy confirmed], 9 
C9orf72 [of whom 1 was autopsy confirmed]), and FTLD-Tau pathology in 16 subjects (3 
autopsy-confirmed cases, 13 MAPT [of whom 2 were also autopsy confirmed]). e FTLD-TDP 
was present in 5 subjects (4 cases were familial [GRN n=2 and C9orf72 n=2] and 1 was 
a sporadic case), and FTLD-Tau was present in 5 cases (all 5 cases were familial [MAPT 
n=5]). Abbreviations: AD; Alzheimer’s Disease, TDP; TAR DNA Binding protein 43; FTD, 
Frontotemporal Lobar Degeneration; MMSE, Mini Mental State Examination. NA; Not 
Available.
Plasma protein profiles can discriminate FTD from controls and FTD from AD
Next, we set out to identify panels of plasma proteins to discriminate between 
FTD vs Controls, FTD vs AD and FTD-Tau vs FTLD-TDP. Out of 1303 proteins, eight 
proteins were selected that combined with age and sex discriminated FTD from 
controls in plasma (Figure 2; Table 3) with an area under the curve (AUC) of 0.71 
(Figure 3). We also identified a panel of 22 plasma proteins that discriminated FTD 
from AD with very high accuracy (AUC: 0.99) (Figure 3; Table 4). For FTD subtypes 




Table 2. Plasma proteins from global test
Name Associated with status Statistic Std. Dev p-value
FN1.3 AD 8.72 0.406 2.26e-10
Fibronectin AD 7.39 0.405 5.07e-09
FN1.4 AD 7.18 0.406 2.04e-08
VWF AD 7.01 0.407 3.65e-08
ECM1 AD 4.23 0.398 1.94e-05
ApoE AD 5.68 0.406 9.79e-07
Plasma proteins that attributed to a difference in expression profile between FTD, AD 
and controls after correction for multiple testing. All proteins were upregulated in AD 
compared to FTD and controls. Abbreviations: FN 1.3, Fibronectin Fragment 3; FN 1.4, 
Fibronectin Fragment 4; VWF, Von Willebrand Factor; ECM1, Extracellular matrix protein 
1; ApoE, Apolipoprotein Epsilon. AD, Alzheimer’s Disease.
Tissue proteins levels differ between FTD subjects and controls, but not 
between pathological subtypes
Next, we analyzed post-mortem brain tissue of FTD cases versus controls, and 
FTD subtypes. The overall tissue protein expression profile was different between 
FTD and controls (p=0.003). We identified seven proteins that attributed to this 
difference in expression profile, of which four were upregulated and three were 
downregulated in FTD (Table 5). Similar to plasma results, no differences in overall 
brain protein profile was detected between FTD–Tau and FTD-TDP subtypes 
(p>0.05).










Plasma proteins for the discrimination of FTD vs CN. a Reference is FTD. Abbreviations: 
FTD, Frontotemporal dementia; CN, controls; IL 16, Interleukin 16; CSK 21, Casein kinase II 
subunit alpha; EP15R, Epidermal growth factor receptor substrate 15-like 1; GRN, Granulin; 






































































































































































































































Plasma proteins for the discrimination of FTD vs AD. a Reference is FTD. Abbreviations: FTD, 
Frontotemporal dementia; AD, Alzheimer’s Disease; ICOS, Inducible T-cell costimulator; 
VWF, Von Willebrand Factor; RGMC, Hemojuvelin; TCPTP, Tyrosine-protein phosphatase 
non-receptor type 2; FN 1.3, Fibronectin Fragment 3; FN 1.4, Fibronectin Fragment 4; 
IFNaA, Interferon alpha-2; CLC7A, C-type lectin domain family 7 member A; SLAF5 , SLAM 
family member 5; HSP40, Heat Shock Protein 40; ING1, Inhibitor of growth protein 1; 
AN32B, Acidic leucine-rich nuclear phosphoprotein 32 family member B; GOT1 , cytoplasmic 
aspartate aminotransferase; hnRNPK, Heterogeneous nuclear ribonucleoprotein K; JAG1, 
Protein jagged-1.
147
Table 5. Tissue proteins from global test
Name Associated with status Statistic Std. Dev p-value
C4 FTD 85.4 10.5 2.30e-06
WIF 1 Control cortex 80.6 10.5 1.30e-05
Discoidin domain receptor 1 FTD 80.4 10.5 1.42e-05
LRRT3 Control cortex 78.0 10.5 2.84e-05
HO 2 Control cortex 71.9 10.5 1.29e-04
Annexin I FTD 61.7 10.5 8.67e-04
Alpha-1-antichymotrypsin 
complex FTD 65.7 10.5 4.39e-04
Tissue proteins that attributed to a difference in expression profile between FTD and 
control tissue after correction for multiple testing. Proteins were associated with either 
FTLD or control cortex. Abbreviations: C4; Complement C4, WIF-1; Wnt inhibitory factor 
1, LRRT3; Leucine-rich repeat transmembrane neuronal protein 3, HO-2; Heme oxygenase 











































































































































































Figure 3. Receiver operating characteristic (ROC) curves discriminating FTD from controls 
or AD based on plasma protein sets. Green= plasma protein set, age and sex; blue = age 
and sex. Abbreviations: FTD; Frontotemporal Dementia, AD; Alzheimer’s Disease, TDP43; 
(TAR) DNA-binding protein of 43 kDa.
DISCUSSION
In this plasma proteomics study, we measured 1303 proteins in over 260 human 
plasma samples to identify protein profiles for the specific diagnosis of FTD and 
its pathological subtypes. We found a difference in overall protein profile between 
FTD, AD and controls. Importantly, we identified two plasma protein panels: 1) 
to discriminate FTD from controls and 2) to discriminate FTD from AD patients. 
No plasma or tissue protein changes were detected between FTD pathological 
subtypes.
To our knowledge, we were the first to apply proteomics in blood plasma of 
genetically or pathologically confirmed FTLD patients [29]. We found a difference 
in overall plasma protein profiles between FTD, AD patients and controls, which 




compared to FTD patients and controls, which suggests that these protein 
differences are most likely reflecting AD pathophysiology. A possible explanation 
for these proteins reflecting AD pathology could be that AD pathophysiology 
is perhaps more homogeneous compared to FTD pathophysiology. Of these six 
proteins, fibronectin fragments 3 and 4 and Von Willebrand Factor (VWF), which 
will be discussed in detail below, were also selected in our discriminatory AD vs 
FTD plasma protein panel. Our findings are supported by a previous AD aptamer-
based study, where fibronectin fragment 4 and fibronectin were also selected in a 
panel of plasma proteins to discriminate AD patients from controls [16].
We next studied the overlap in proteins that were differentially expressed in both 
plasma and tissue, to provide neuropathological support for the plasma findings. 
We did not observe an overlap between tissue and plasma differentially expressed 
proteins which suggests that most of the identified plasma protein changes may not 
reflect the pathological changes occurring in the brain, and may have a peripheral 
origin. This could be explained by the redundancy of plasma proteins from the 
periphery, which may mask low concentration and subtle changes of CNS-derived 
proteins in plasma. Another reason why the protein changes identified in plasma 
are not reflected in post-mortem brain tissue might be the different time point of 
collection (i.e. ante-mortem for plasma vs. post-mortem for tissue), and thus the 
different disease stage. Proteomics in body fluids such as blood plasma or CSF can 
provide valuable mechanistic information as to whether post-mortem pathological 
changes are also seen in earlier ante-mortem disease stages, or whether there are 
also systemic responses involved in CNS diseases.
We identified a distinct plasma protein panel that, combined with age and sex, 
could discriminate between FTD patients and non-demented controls with modest 
accuracy (AUC: 0.71). This protein panel consisted of eight proteins, including the 
usual suspect granulin. Granulin is known to be deficient in FTD patients with 
GRN mutation carriers, and was also decreased in our FTD patients compared 
to controls, probably reflecting the relatively large number of GRN cases in our 
cohort. Another protein included in our protein panel discriminating FTD patients 
from controls is Casein kinase II subunit alpha (CSK21), which is a regulator of 
protein phosphorylation and has previously been reported to interact with Fused 
in Sarcoma (FUS) protein [30], a rare pathology seen in FTD [31]. Since we here 
identify that this protein is part of the panel to discriminate a mixed FTLD-Tau and 
FTLD-TDP population from controls, our results tentatively suggest that CSK21 
might be associated with the phosphorylation of Tau or TDP pathology as well. 
Our protein panel further included Beta-Ala-His dipeptidase (CNDP1), an enzyme 
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that is strongly expressed in human brain, which has also been previously selected 
in a CSF protein model to discriminate FTD from non-FTD subjects [32]. The 
remaining five proteins in this panel (i.e. Interleukin 16, Aminoacylase1, Cadherin 
6, Epidermal growth factor receptor substrate 15-like 1, Beta-Ala-His dipeptidase, 
Histone-lysine N-methyltransferase) have not previously been associated with 
FTD and could be potential novel biomarker candidates. In the current form, this 
blood-based biomarker panel does not have sufficient diagnostic accuracy (AUC 
0.71) to be applied in clinical settings. Therefore, for future work it could beneficial 
to include neurofilament light (NfL) to this panel, which is more strongly elevated 
in FTD than in AD compared to controls, to further increase the accuracy of blood-
based biomarker panels [33,34].
We identified a second panel of 22 blood-based proteins discriminating FTD from 
AD with very high accuracy (AUC: 0.99). This high diagnostic accuracy supports 
potential use of this blood-based biomarker panel for the differential dementia 
diagnosis. However, as an AUC of 0.99 is near to perfect, replication of these 
findings, preferably through external validation is needed. The three proteins 
that contributed most to the discriminatory panel, based on the largest beta’s, 
will be discussed in more detail. Von Willebrand Factor (VWF), a glycoprotein 
with critical functions in hemostasis [35], was identified by both the global test 
and was also part of the discriminatory protein panel between AD and FTD. 
It has frequently been studied in AD since vascular damage plays a role in the 
pathogenesis of AD dementia. However, results of VWF levels in AD patients have 
been conflicting. One CSF proteomics study that aimed to discriminate AD from 
non-AD patients based, has shown discrepant results in CSF VWF levels between 
three independent cohorts [36]. Other studies reported no difference in VWF levels 
in blood plasma, CSF or brain cells between AD and controls [37,38], and one large 
population study reported higher levels of VWF in blood plasma of AD patients 
[39]. A possible speculative explanation for these discrepant findings could be 
that the cohorts that reported an increase in VWF levels, including ours, had more 
patients with mixed vascular and AD pathology, whereas other cohorts mostly 
included patients with pure AD pathology. The protein with the second strongest 
beta was Fibronectin (FN), a glycoprotein that plays a role in tissue repair, and 
regulating cell attachment, motility, hemostasis and embryogenesis [40]. Several 
studies reported higher amounts of high molecular FN forms in plasma, CSF and 
frontal and temporal cortex of AD patients compared to vascular dementia and 
controls [36,41,42], corroborating our results showing higher levels of fibronectin 
fragments 3 and 4 in AD patients compared to FTD patients and controls. 




model [43]. Thus, our results together with previous literature suggest an increase 
of fibronectin fragments in AD which might potentially convey a neuroprotective 
effect. The last protein with a strong beta was interferon alpha-2 protein (IFNaA), 
a cytokine produced by peripheral blood leukocytes or lymphoblastoid cells[44]. 
In addition to its antiviral activity, IFNaA inhibits the proliferation of cells and 
regulates the activation of the immune system. IFNaA has not previously been 
associated with either AD or FTD. The lowered plasma levels of IFNaA in AD 
patients compared to FTD patients and controls is in line with reports showing a 
peripheral dysregulation of the immune system in AD patients [17].
We could not find differentially regulated proteins between Tau and TDP 
pathological subtypes in tissue or plasma, nor could we identify discriminatory 
plasma protein signatures between these subtypes. Throughout literature, it 
has been challenging to identify and validate protein alterations between both 
pathological subtypes. For CSF, two previous proteomic studies reported several 
differentially regulated CSF proteins [45] or a biomarker panel in CSF which 
enabled sensitive differentiation between TDP and Tau pathology [46], although 
independent multicenter validation and replication on different platforms is 
still needed. The lack of a biomarker (panel) for FTD subtypes with feasibility in 
clinical practice thus far, could have several possible explanations. First, a potential 
explanation is the heterogeneity within Tau and TDP pathological subtypes, such 
as the different isoforms of TDP and Tau pathology, which have not been accounted 
for in fluid biomarker studies so far [47,48]. For instance, patients with the TDP-A 
isoform might have a different protein signature than patients with the TDP-C 
isoform. This heterogeneity will complicate the search for a single discriminatory 
protein panel for TDP vs Tau, and will require larger and more homogeneous 
sample sizes, which are scarce. An alternative explanation could be that both 
pathological subtypes might have similar downstream pathological pathways 
leading to FTD. For instance, local TDP and Tau pathology could potentially be 
initiating the same prominent cascades, represented in similar proteomic changes 
in body fluids, ultimately leading to the neurodegenerative changes seen in FTD. 
This could also explain why both pathological subtypes are seen across the clinical 
FTD spectrum [10]. Lastly, in most FTD biomarker studies familial and sporadic 
cases are often grouped to achieve a large sample size. However, the question 
remains whether the familial form of FTD with GRN, C9orf72 or MAPT mutations 
is biologically similar to sporadic FTD patients with TDP or Tau proteins. Future 
studies where (plasma) protein profiles of familial and sporadic FTD subtypes are 
independently studied could provide more clarity.
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Among the limitations of our study is that despite the large number of plasma 
proteins analyzed, the aptamer-based proteomic platform is still a targeted 
analysis dependent on the protein library. Thus, we cannot exclude that the other 
relevant or powerful brain-disease related biomarkers are not present within the 
aptamer library (i.e. Somamer library [49]). Nevertheless, the hypothesis free 
approach allowed us to identify novel proteins, not yet associated with FTD or 
AD, in addition to previously described proteins. Another limitation is the lack 
of replication of our findings in an independent validation cohort, especially 
considering the high accuracy of our FTD vs AD discriminatory panel.
The strengths of our study are that all our FTD cases had confirmed diagnosis 
based on genetic and/or pathological confirmation. Because FTD is clinically 
heterogeneous and does not correlate strongly to its pathologic subtypes, cohorts 
with known pathologic subtypes are important to provide relevant insights into 
underlying disease mechanisms. Of note, some of the AD plasma samples analyzed 
in this study came from non-specialized memory clinics, and were diagnosed using 
clinical criteria without AD CSF biomarker confirmation.
CONCLUSIONS
In summary, we analyzed an unprecedented large number of proteins (1303) in 
plasma of FTD confirmed cases with confirmed underlying neuropathology. We 
observed that the plasma or tissue proteome were essentially similar between 
FTLD-Tau and FTLD-TDP. In addition, we identified novel differentially regulated 
plasma proteins between AD, FTD, and controls, which could be hypothesis-
generating in terms of underlying mechanistic pathways. Moreover, we were able 
to identify two discriminatory plasma protein panels for FTD diagnosis. Although 
validation is still needed, these minimally invasive blood-based protein panels 
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Proteomic platform, data standardization and quality control
The SomaScan® Platform for proteomic profiling reports SOMAmer® reagents, 
single-stranded DNA aptamers, to 1303 unique Human Protein Targets. A complete 
list of the proteins is included in the Supplemental Table 1. The modified aptamer 
binding reagents2, SomaScan assay3, its performance characteristics5, 6, and 
specificity7,8,9 to human targets have been previously described. The assay used 
standard controls including 12 hybridization normalization control sequences 
used to control for variability in the Agilent readout process as well as 5 human 
calibrator controls and 2 quality controls per run used to mitigate batch effects 
and verify the quality of the assay run using standard acceptance criteria. Samples 
run in two batches (early and late 2016) used different SOMAmer® reagent master 
mixes and were standardized to a common reference using common calibrator 
control lots. Overall precision metrics for quality control replicates across 
batches were slightly elevated compared to within batch metrics but well within 
expectation.
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The SomaScan® Assay is run using 96 well plates in a 32 sample format; 8 sample 
locations are allocated for control samples used to control for batch effects and to 
estimate the precision of the Assay across runs. Five pooled Calibrator replicates, 
two pooled Quality Control (QC) replicates, and one buffer replicate are run on 
every plate. The readout is performed using Agilent hybridization, scan, and 
feature extraction technology. Twelve Hybridization Control SOMAmers are added 
alongside SOMAmers to be measured from the biological samples and controls 
of each well during the SOMAmer elution step to control for readout variability. 
Normalization of control replicates and Samples is performed using median 
signal normalization within plate for independent groups of Calibrator Control 
replicates, Quality Control replicates, and Samples. The control samples are run 
repeatedly during assay qualification and robust point estimates are generated 
and stored as references for each SOMAmer result for the Calibrator samples. The 
results are used as references for each calibrator lot and master mix of SOMAmer® 
reagents. Plate Calibration is performed by calculating the ratio of the Calibrator 
Reference RFU value to the plate-specific Calibrator replicate median RFU value 
for each SOMAmer. The resulting ratio distribution is decomposed into a Plate 
Scale factor defined by the median of the distribution and a vector of SOMAmer-
specific Calibration Scale Factors. Post calibration precision is estimated using 
quality control replicates run on each plate, the distribution of %CVs is indicative 
of the overall performance of data standardization methods.
For bridging across assay parameter changes, precision of the QC sample within 
and across batches can be an indicator of quality, where the lower percent CV 
is typically associated with higher reproducibility. For Batch 1 and Batch 2, QC 
Control Lot SL18268 was run on each plate. Quantiles for the distribution of QC 
CVs within and across batches are shown in Table 1. 50% of SOMAmer reagents 
have CVs less than 7% for Batch 1 and Batch 2, and 95% should have CVs of 
approximately 21%. After combining data across batches there is a slight increase 
in the %CVs over single batch expectation (median 7%, 90th percentile 21%) the 
results are near expectation and greatly improved by calibration.
For this study, plates from Batch 1 and Batch 2 were processed using the same 
calibrator reference (SL16486), but different master mixes. Batch 1 used 
“Plasma_4.0_20150812_1.5k”, while Batch 2 used “Plasma_4.1_20160229_1.5k”. In 
order to directly compare the two batches, Batch 2 was normalized using the same 
global calibrator reference as Batch 1. This means that Batch 2 was normalized 
against a global calibration reference that did not match its same master mix lot. 




across 4 plates) than Batch 1 (average 4.78% across 8 plates). PCA suggests that 
the normalization method minimized bias between the lot differences of Batch 1 
and Batch 2 (Figure 1).
For bridging across assay parameter changes, precision of the QC sample 
(independent plasma replicates) between batches may be a better indicator of 
quality than calibration scale magnitude. Post calibration accuracy is estimated 
using the ratio of the QC reference RFU value to the plate-specific QC replicate 
median RFU value for each SOMAmer reagent. The resulting QC ratio distribution 
provides a robust estimate of accuracy for each SOMAmer sequence on every 
plate. Plate-specific Acceptance Criteria: Hybridization Control and Median Signal 
Normalization scale factors are expected to be in the range of 0.4-2.5. The median 
of the calibration scale factors is expected to be within 0.8-1.2 and a minimum of 
95% of the individual SOMAmer reagents in the total array must be within +0.4 
from the median. Of 275 samples, only 2 did not pass the quality criteria and were 
flagged as outliers.
Figure 1: Assessment of PC1 and PC2 suggests that the normalization method minimized 
bias between the lot differences of Batch 1 and Batch 2.
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Table 1: Quantiles for the distribution of QC CVs within and across batches indicates that 
50% of SOMAmer reagents have CVs less than 7% for Batch 1 and Batch 2, and 95% should 
have CVs of approximately 21%. Combining data across batches results in a slight increase 
in the %CVs over single batch expectation (median 7%, 90th percentile 21%).
Batch QC 5% 50% 95%
1 SL18268 3.8% 6.9% 21.0%
2 SL18268 3.5% 6.4% 21.6%
Combined without calibration SL18268 5.6% 10.9% 32.4%




















10365-132_3 IL-23 P29460, Q9NPF7
10366-11_3 PDGFRA P16234













11103-24_3 HSP 27 P04792
11104-13_3 YKL-40 P36222
11105-171_3 Alpha enolase P06733
11510-31_3 Apo L1 O14791
11513-92_3 CD38 P28907
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14158-17_3 Annexin V P08758
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2182-54_1 C4b P0C0L4 P0C0L5















2358-19_2 VEGF sR3 P35916
2359-65_4 HCE004152 HCE004152
2381-52_4 C5 P01031




2431-17_3 Cathepsin G P08311









Supplementary Table 1: Continued.
SeqId Target UniProt
2474-54_5 SAP P02743
2475-1_3 SCF sR P10721
2480-58_3 TIMP-3 P35625
2500-2_3 Angiopoietin-4 Q9Y264





















2607-54_2 CLF-1/CLC Complex O75462 Q9UBD9








Supplementary Table 1: Continued.
SeqId Target UniProt
2618-10_2 ERBB4 Q15303
2619-72_2 GA733-1 protein P09758
2620-4_2 gp130, soluble P40189
2622-18_1 HO-2 P30519
2623-54_4 HPV E7 Type 16 P03129
2624-31_2 HPV E7 Type18 P06788
2625-53_4 HSP 90a/b P07900 P08238
2630-12_2 IL-1 R AcP Q9NPH3
2631-50_2 IL-10 Rb Q08334
2632-5_2 IL-12 Rb1 P42701
2633-52_2 IL-13 Ra1 P78552
2634-2_2 IL-2 sRg P31785
2635-61_2 Layilin Q6UX15




2638-12_2 M-CSF R P07333
2640-3_2 MSP R Q04912









2654-19_1 TNF sR-I P19438
2658-27_1 TrkC Q16288
2665-26_2 BCMA Q02223
2666-53_2 Bone proteoglycan II P07585







Supplementary Table 1: Continued.
SeqId Target UniProt
































2743-5_2 Sonic Hedgehog Q15465
2744-57_2 IgG P01857
2746-56_1 TSLP R Q9HC73
2747-3_2 ULBP-3 Q9BZM4
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Supplementary Table 1: Continued.
SeqId Target UniProt
2748-3_2 Activin A P08476
2750-3_2 Apo A-I P02647
2751-16_2 Azurocidin P20160
2752-62_2 BMP-14 P43026








2765-4_3 GDF-11/8 O95390 O14793
2768-56_2 Hemopexin P02790















2796-62_2 Fibrinogen P02671 P02675 P02679
2797-56_2 Apo B P04114
2805-6_2 ACE2 Q9BYF1
















2829-19_2 IL-27 Q8NEV9 Q14213
2831-29_1 Kallikrein 11 Q9UBX7
2833-20_1 Kallikrein 4 Q9Y5K2
2834-54_1 kallikrein 8 O60259
2835-1_4 Ku70 P12956
2836-68_2 Lipocalin 2 P80188
2837-3_2 Met P08581
2838-53_1 MMP-17 Q9ULZ9








































2937-10_2 Apo E3 P02649
2938-55_2 Apo E4 P02649
2939-10_2 Artemin Q5T4W7
2942-50_2 Cytochrome c P99999
2943-5_2 Cytochrome P450 3A4 P08684
2944-66_2 DAN P41271
2945-25_1 ER P03372











Supplementary Table 1: Continued.
SeqId Target UniProt
2960-66_2 Properdin P27918

















2986-49_2 Gro-b/g P19876 P19875
2987-37_3 Histone H1.2 P16403
2988-57_2 ICOS Q9Y6W8
2991-9_2 IL-1 sRI P14778
2992-59_2 IL-17 sR Q96F46











Supplementary Table 1: Continued.
SeqId Target UniProt
























3052-8_2 Fas ligand, soluble P48023





















3073-51_2 IL-18 BPa O95998
3074-6_2 LBP P18428











3151-6_1 IL-2 sRa P01589












3177-49_2 Carbonic Anhydrase IV P22748
3178-5_2 CATC P53634
3179-51_2 Cathepsin A P10619
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Supplementary Table 1: Continued.
SeqId Target UniProt
3181-50_2 Cathepsin S P25774
3182-38_2 CD39 P49961













3199-54_2 kallikrein 12 Q9UKR0
3200-49_2 kallikrein 13 Q9UKR3










3217-74_2 Protease nexin I P07093
3220-40_2 RET P07949
3221-54_1 SARP-2 Q8N474









































3326-58_2 Nectin-like protein 2 Q9BY67
3327-27_1 NET4 Q9HB63
177




















3357-67_2 CDK2/cyclin A P24941 P20248
3358-51_2 CDK5/p35 Q00535 Q15078









3373-5_2 Granzyme H P20718
3374-49_2 HCK P08631
3376-49_2 IL-17 RD Q8NFM7











3390-72_2 PIK3CA/PIK3R1 P42336 P27986
3391-10_2 PK3CG P48736




















3421-54_2 CD30 Ligand P32971










Supplementary Table 1: Continued.
SeqId Target UniProt
3440-7_2 granzyme A P12544
3441-64_2 GSK-3 alpha/beta P49840 P49841
3443-61_2 HIPK3 Q9H422
3445-53_2 IL-15 Ra Q13261






































3503-4_2 Integrin a1b1 P56199, P05556
3504-58_2 LEAP-1 P81172
3505-6_2 Lymphotoxin a1/b2 P01374, Q06643












3534-14_2 CD40 ligand, soluble P29965
3535-84_1 DKK1 O94907















































3647-49_4 TLR4:MD-2 complex O00206 Q9Y6Y9
3651-50_5 VEGF sR2 P35968
3654-27_5 BMPER Q8N8U9
3656-9_1 Cadherin-12 P55289







Supplementary Table 1: Continued.
SeqId Target UniProt
3676-15_3 IGF-II receptor P11717




















3795-6_2 ADAM 9 Q13443
3796-79_2 ANGL4 Q9BY76
3797-1_1 Cadherin-2 P19022
3798-71_1 Carbonic anhydrase 9 Q16790











Supplementary Table 1: Continued.
SeqId Target UniProt
3813-3_2 FYN P06241














3844-2_1 Cyclophilin A P62937
3845-51_2 DLRB1 Q9NP97
3847-56_2 ETHE1 O95571
3848-14_2 GAPDH, liver P04406




















































































4159-130_1 Factor H P08603
4160-49_1 MMP-2 P08253
4162-54_2 Transferrin P02787
4163-5_2 Histone H2A.z P0C0S5
4165-2_1 Thyroglobulin P01266
4179-57_3 14-3-3
P31946, P62258, P61981, 









Supplementary Table 1: Continued.
SeqId Target UniProt
4188-1_2











4232-19_2 IGF-I sR P08069

























Supplementary Table 1: Continued.
SeqId Target UniProt
4294-16_2 Sphingosine kinase 1 Q9NYA1
4297-62_3 Spondin-1 Q9HCB6
4301-58_2 Thymidine kinase P04183
4304-18_2
transcription factor 





















4396-54_1 IFN-lambda 1 Q8IU54





4423-77_2 BCL2-like 1 protein Q07817
4428-1_2 CHST2 Q9Y4C5
4429-51_2 CHST6 Q9GZX3






















4472-5_2 Tropomyosin 2 P07951
4474-19_2 Ubiquitin P62979
4476-22_2 ZAP70 P43403
4479-14_2 C1-Esterase Inhibitor P05155
4480-59_2 C3b P01024
4481-34_2 C4 P0C0L4, P0C0L5
4482-66_2 C5b, 6 Complex P01031,P13671
4487-1_1 FGF7 P21781
4490-65_2 IL-3 Ra P26951
4491-4_2 IL-5 Ra Q01344
4493-92_1 IL-11 P20809
















4545-53_3 DnaJ homolog Q96DA6
4546-27_3 EMR2 Q9UHX3
4547-59_2 FLRT1 Q9NZU1





















4708-3_2 17-beta-HSD 1 P14061


















4786-58_3 Cytidylate kinase P30085
4792-51_2








4832-75_2 TRAIL R1 O00220
4834-61_2 Epithelial cell kinase P29317
4840-73_1 G-CSF P09919
4842-62_2 Glypican 3 P51654
4851-25_1 IL-1a P01583
4859-6_1 BMPR1A P36894




4876-32_1 Coagulation Factor IX P00740











4903-72_1 Calcineurin Q08209 P63098
4904-7_1 Caspase-2 P42575
4905-63_1 Coactosin-like protein Q14019
4906-35_1 Coagulation Factor V P12259










4915-64_2 Hemoglobin P69905, P68871
4916-2_1 IgD P01880











40S ribosomal protein 
SA P08865
4959-2_1 AGR2 O95994




Supplementary Table 1: Continued.
SeqId Target UniProt









4969-2_1 Carbonic anhydrase I P00915



























Supplementary Table 1: Continued.
SeqId Target UniProt
5000-52_1 LG3BP Q08380






5008-51_1 Mn SOD P04179
5009-11_1 Moesin P26038
5011-11_1 PBEF P43490





















Tropomyosin 1 alpha 
chain P09493





















5082-51_3 IL-1 sR9 Q9NP60
5084-154_3 IL-17B R Q9NRM6
5085-18_3 IL-20 Ra Q9UHF4
5087-5_3 IL-22BP Q969J5
5088-175_3 IL-23 R Q5VWK5
















Supplementary Table 1: Continued.
SeqId Target UniProt
5105-2_3 Nogo Receptor Q9BZR6
5106-52_3 NOTC2 Q04721


































Supplementary Table 1: Continued.
SeqId Target UniProt
5223-59_3 GCKR Q14397
5225-50_3 CK2-A1:B P68400 P67870










5245-40_5 AMPK a2b2g1 P54646 O43741 P54619
5246-64_3 cGMP-stimulated PDE O00408





























5312-49_3 Apo E2 P02649
5315-22_3 Troponin T P45379
5316-54_3 Prothrombin P00734
5328-33_37 EGFRvIII P00533
5335-73_3 annexin VI P08133
5337-64_3 B7-2 P42081





5347-59_3 Cyclin B1 P14635
5349-69_3 DLL1 O00548
5350-14_2 GPC6 Q9Y625
5351-52_3 hnRNP A2/B1 P22626
5352-11_3 HVEM Q92956
5353-89_2 IL-1Ra P18510






5360-9_2 PKB beta P31751
5363-51_3 Semaphorin 3E O15041
5364-7_3 SET Q01105
5383-14_3 BAFF Receptor Q96RJ3
5384-67_3 BRF-1 Q92994
5392-73_2 Fas, soluble P25445













Troponin I, skeletal, 
fast twitch P48788







5460-60_3 DEAD-box protein 19B Q9UMR2
5462-62_3 Ficolin-3 O75636
5463-22_3 GAS1 P54826
5464-52_3 GRB2 adapter protein P62993
5465-32_3 H6ST1 O60243
5467-15_3 HSP 90b P08238





































5825-49_3 IFN-g R1 P15260
5834-18_3 IL-9 P15248









5864-10_3 aldolase A P04075
5867-60_3 ARGI1 P05089
5870-23_2 BAD Q92934













5903-91_2 HSP70 protein 8 P11142
5909-51_3
Nucleoside 













6641-60_3 PolyUbiquitin K48 P0CG47











7655-11_3 N-terminal pro-BNP P16860
7660-21_3 Tropomyosin 4 P67936
8446-4_3 PACAP-27 P18509
201









8465-52_3 Cathepsin H P09668
8467-9_3 Activin AB P08476 P09529
8468-19_3 PSA P07288
8469-41_3 IGFBP-2 P18065

















































Plasma amyloid-β oligomerization 
assay as a pre-screening test for 
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Background: We assessed the performance of plasma amyloid oligomerization 
tendency (OAβ) as a marker for abnormal amyloid status. Additionally, we 
examined long-term storage effects on plasma OAβ.
Methods: We included 399 subjects regardless of clinical diagnosis from the 
Amsterdam Dementia Cohort and European Medical Information Framework for 
AD project (age:63.8±6.6; 44% female). Amyloid status was determined by visual 
read on Positron Emission Tomography (PET; n abnormal= 206). Plasma OAβ was 
measured using the Multimer Detection System (MDS). Long-term storage effects 
on MDS-OAβ were assessed using General Linear Models. Associations between 
plasma MDS-OAβ and Aβ-PET status were assessed using logistic regression and 
receiver operating characteristics analyses. Correlations between plasma MDS-
OAβ and CSF biomarker levels were evaluated using Pearson correlation analyses
Results: MDS-OAβ was higher in in individuals with abnormal amyloid, and it 
identified abnormal Aβ-PET with an Area Under the Curve (AUC) of 0.74 (95%CI: 
0.67-0.81), especially in samples with short-term storage duration. Combining 
APOEe4 and age with plasma MDS-OAβ revealed an AUC of 81% for abnormal 
amyloid PET status (95%CI:74%-87%). Plasma MDS-OAβ correlated negatively 
with MMSE (r=-0.29,p<.01), and CSF Aβ42 (r=-0.20,p<0.05), and positively with 
CSF t-Tau (r=0.20,p=0.01).
Conclusions: Plasma MDS-OAβ combined with APOEe4 and age, accurately 
identifies brain amyloidosis in a large Aβ-confirmed population. Using plasma 
MDS-OAβ as a screener reduced the costs and number of PET scans needed to 
screen for amyloidosis, which is relevant for clinical trials. Additionally, plasma 
MDS-OAβ levels appeared affected by long-term storage duration, which could be 
of interest for others measuring plasma Aβ biomarkers.
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BACKGROUND
Accumulating evidence shows that small soluble Amyloid-β oligomers (AβOs), are 
the most toxic and pathogenic form of Aβ species in Alzheimer’s Disease (AD) 
[1,2]. Many toxicities have been ascribed to AβOs including synaptic dysfunction, 
induction of tau pathology, neuroinflammation, impaired axonal transport, and 
neuronal death [3]. In addition, AβOs have shown a better correlation with the 
presence and degree of cognitive symptoms than Aβ plaque counts [4], suggesting 
that AβOs might provide a more accurate reflection of clinical presentation than 
Aβ plaque load.
Currently, proxies of Aβ plaques are measured with high sensitivity and 
specificity with Positron Emission Tomography (PET) imaging or measurement 
of Cerebrospinal fluid (CSF) Aβ42 concentrations. However, these methods are not 
available in routine laboratory settings, and often come with high costs or burden 
for the patient. Therefore, blood-based biomarkers are considered as low-cost and 
minimally invasive alternatives.
Plasma AβO concentrations or misfolded Aβ oligomeric assemblies have previously 
shown good diagnostic accuracies in identifying AD from controls (Area Under 
the Curve (AUC): 0.71-0.80) [5,6]. Using the Multimer Detection System (MDS) 
to measure plasma AβO levels has resulted in even higher diagnostic accuracies 
(AUC: 0.85-0.87) in discriminating AD from controls [7]. However, the ability of 
plasma MDS-OAβ to identify individuals with abnormal amyloid status has not yet 
been studied. This is relevant, because the definition of AD in-vivo is shifting to a 
biological construct and increasingly based on amyloid status [8]. Therefore, we 




We included 399 subjects from the Amsterdam Dementia Cohort (ADC) and the 
European Information Framework for AD (EMIF-AD) Preclinical AD project, 
regardless of clinical diagnosis. Inclusion criteria were met when amyloid PET 
results were available and the time between plasma sampling and PET scan did 
not exceed one year. During their visit, all subjects underwent comprehensive 
dementia screening including neurologic examination, laboratory tests, 




Clinical diagnosis was established by consensus according to international 
consensus criteria [8,11–14], and included: Mild Cognitive Impairment (MCI; n= 
42), AD (n= 164), non-AD dementia (n=58) and other disorders (n=61) including 
neuropsychiatric disorders, neurological disorders, or individuals with postponed 
diagnosis. Controls consisted of participants with subjective cognitive decline 
(SCD; n=14), and normal controls (NC; n=60). Normal controls in this study were 
included from the Preclinical AD study [15].
Amyloid status
Amyloid PET status was available in all subjects (n=399). [18F]Florbetaben (n 
=138), [18F]Florbetapir (n =1), [18F]Flutemetamol (n =138), or [11C]Pittsburgh 
compound B (PiB; n =122) were used as radioactive amyloid tracers. A Medrad 
(Warrendale, PA) infusion system was used for tracer infusion. [18F]Florbetapir 
and [11C]PIB scans were acquired through 90-minute dynamic scanning using a 
PET/CT Ingenuity TF or Gemini TF [Philips Medical Systems, Best, the Netherlands] 
([18F]Florbetapir), and ECAT EXACT HR + scanner [Siemens/CTI, Knoxville, TN]) 
([11C]PiB). Scanning started simultaneously with tracer infusion at approximately 
370MBq [18F]florbetapir, and 351MBq [11C]PiB. [18F]Florbetaben and [18F]
flutemetamol scans were acquired through 20-minute static PET scanning using a 
PET/MR and Gemini TF-64 PET/CT scanner, Philips Medical Systems, respectively. 
Scanning started 90 minutes after tracer injection at approximately 250MBq 
[18F]florbetaben, and 180MBq [18F]flutemetamol. Amyloid status was defined 
as either abnormal or normal after visual assessment by either one (ADC) or three 
experienced nuclear medicine physicians (preclinical AD project) where majority 
vote ruled.
Cerebrospinal fluid analysis
CSF Aβ42 was measured using two analytical methods: Innotest and Euroimmun 
ELISAs. Innotest ELISAs were used to measure levels of CSF amyloid beta 1-42, 
total Tau (t-Tau) and Tau phosphorylated at threonine 181 (p-Tau) for 268 subjects 
(Fuijirebio, Ghent, Belgium). CSF Aβ levels were corrected for the drift seen 
throughout CSF analysis years [16]. Euroimmun beta-amyloid ELISAs (Euroimmun, 
Lübeck, Germany/ADx Neurosciences, Ghent, Belgium) were used to measure levels 
of CSF Aβ1-40 and 1-42 of normal controls (n=60). All CSF samples were measured 
centrally at the Neurochemistry Laboratory of Amsterdam UMC.
Apolipoprotein E status
Apolipoprotein E (APOE) genotyping was performed using LightCycler ApoE 
mutation Detection Kit (Roche Diagnostics, GmbH, Mannheim, Germany), after 
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isolation of genomic DNA from Ethylenediaminetetraacetic acid (EDTA) plasma 
(Qiagen, Venlo, the Netherlands). APOEe4 status was dichotomized into APOEe4 
allele carriers (i.e. at least one APOEe4 allele), and non-carriers (i.e. no APOEe4 
allele).
Plasma sampling and analysis
Blood plasma was collected in an EDTA vacutainer tube through venipuncture 
using standardized in-house protocols. EDTA plasma was centrifuged at 1,800×g 
for 10 minutes at room temperature and stored in 0.5ml polypropylene tubes at 
-80°C in the Amsterdam UMC biobank. Prior to analysis, plasma aliquots were 
thawed at 37 °C for 15 minutes. Peoplebio inc. measured MDS-OAβ levels in all 
plasma samples centrally using the Multimer Detection System. All samples were 
analyzed twice in singlet, on two consecutive days. Intra-assay variations were 
below 10%, and 2% of the samples (n=8) showed interassay variations higher than 
20% CV. All samples were above the lower limit of quantification (LLOQ; 0.239 
ng/ml). Hemolytic samples (n=15) were excluded, as hemoglobin might interfere 
with the MDS-OAβ signal [17]. The exact MDS method was described in detail 
previously [18].
Statistical analyses
SPSS version 24 (IBM, Armonk, NY) was used for all statistical analyses, and data 
were visualized using R version 3.5.2 (“eggshell igloo”). Subject characteristics 
were compared between amyloid normal and abnormal subjects, using students 
t-test, chi-squared test, and Man-Whitney U tests where appropriate. Plasma MDS-
OAβ was normalized using a 2-step transformation [19]. Upon visual inspection we 
recently observed a possible effect of long-term storage on plasma MDS-OAβ levels 
(data not published). As plasma samples which are used for research purposes 
might have a long storage period after biobank retrieval, we additionally assessed 
the effect of long-term storage on plasma MDS-OAβ levels by using General Linear 
Models (GLM) with factors sample storage period, PET amyloid status, and their 
2-way interactions (full model shown in table e-1). In case of a significant 2-way 
interaction between storage period in years and PET amyloid status, we performed 
GLM for plasma MDS-OAβ stratified for storage period based on the median storage 
period (4 years). Differential expression of plasma MDS-OAβ levels between normal 
amyloid and abnormal amyloid subjects was evaluated using GLM with plasma 
MDS-OAβ as outcome measure, amyloid status as factor, and age, sex, APOEe4 
status and cohort as covariates. Syndrome diagnosis was not a confounder, and 
therefore not included as a covariate. Pearson correlation analyses were used 




of global cognition, or levels of CSF Aβ42, t-Tau and p-Tau measured by Innotest 
ELISA. The potential of the plasma Aβ oligomer assay to identify PET abnormal 
amyloid status was assessed by receiver operating characteristic (ROC) analysis 
using predicted values of binary logistic regression models. The Area Under the 
Curve (AUC), and corresponding sensitivities and specificities were calculated at 
an optimal cut-off for each model using Youden J’s index (sensitivity + specificity 
- 1). The models contained 1) plasma MDS-OAβ, 2) age and APOEe4 status, or 3) 
plasma MDS-OAβ combined with age and APOEe4 status. AUC’s between models 
were compared using DeLong analysis [20]. Additionally, to assess the performance 
of the plasma MDS-OAβ assay in early AD stages, analyses were repeated in a 
subgroup of pre-dementia subjects including controls and MCI subjects. Lastly, 
we investigated how the use of the plasma MDS-OAβ marker can reduce the costs 
and number of PET scans needed to screen individuals for a hypothetical clinical 
trial which needs 100 abnormal amyloid individuals. For this analysis we used the 
sensitivity and specificity levels that corresponded with the highest Youden cut-
off. Analyses were stratified for SCD, MCI and AD diagnosis as the prevalence of 
abnormal amyloid individuals differs per diagnosis [21]. We assumed an average 
cost of 5000 USD [22] per amyloid PET scan, and estimated 100 USD per plasma 
MDS-OAβ sample. A p-value <0.05 was considered statistically significant.
RESULTS
Patient characteristics
The average age of the total population was, 63.8 ± 6.6 years old, 44% was 
female, and the average MMSE was 24 ± 5. Abnormal amyloid status was found 
in 206 (52%) subjects which included more often AD dementia subjects, whereas 
normal amyloid subjects included more often controls. Individuals with abnormal 
amyloid had lower MMSE scores and were more often APOEe4 carrier compared 
to individuals with normal amyloid status (table 1). An interaction with storage 
period was found (p<0.01; figure 1, table 2), after which the cohort was stratified 
based on the median storage period (4 years). The groups with storage period ≤4 
years and >4 years did not differ from each other in patient characteristics. Both 
had more abnormal amyloid subjects who had lower MMSE scores, and were more 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2. Full model for storage period and amyloid PET status for plasma MDS-OAβ
β (se) b p-value
Storage period, yrs .03 (.01) .02
Amyloid PET status a .38 (.08) <.001
Amyloid PET status*Storage period, yrs -.04 (.01) .003
We used General Linear Models (GLM) with factors storage period and PET amyloid 
status, and their 2-way interactions. a Reference is normal amyloid PET status. p <0.05 is 
considered significant. b plasma MDS-OAβ was normalized using two-step transformation. 
Abbreviations: MDS-OAβ, Aβ oligomeric tendency; yrs, years; PET, Positron Emission 
Tomography.
Figure 1. Scatterplot presents the correlation between plasma MDS-OAβ and storage 
period in years. Blue dots represent normal amyloid PET individuals, and red dots repre-
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Figure 3. Receiver Operating Characteristic (ROC) curves discriminate abnormal amyloid 
from normal  amyloid subjects as  defined by amyloid PET scan based on plasma Aβ oligo-
mer levels (blue line), age and APOEe4 genotype (purple line), and a multivariate model 
including APOEe4 genotype, age and plasma Aβ oligomer levels (yellow line).
Plasma MDS-OAβ performance in samples with a short-term storage duration
For samples with a storage period ≤4 years (n=207), plasma MDS-OAβ levels 
corrected for age, sex, APOEe4 status and cohort, were higher in abnormal amyloid 
subjects compared to normal amyloid subjects (β ±se: 0.17±0.05; p=0.001; figure 
1). Plasma MDS-OAβ was negatively correlated with CSF Aβ42 levels (r=-0.20, 
p=0.035) and MMSE scores (r= -0.29, p<0.01), and positively correlated with CSF 
t-Tau (r=0.20, p=0.01) (figure 2). There was no correlation with CSF p-Tau levels 
(r=0.12, p>0.05). ROC analyses (figure 3) revealed that plasma MDS-OAβ could 
accurately identify individuals with abnormal amyloid PET (AUC= 0.74, 95% CI= 
0.67 -0.81), with a sensitivity of 76% and specificity of 67%. When combined with 
age and APOEe4 status the AUC increased to 0.81 (95% CI= 0.74-0.87), with a 
sensitivity and specificity of 58% and 89%, which performed better than age and 
APOEe4 genotype alone (AUC= 0.70, 95% CI= 0.63-0.78, p=0.01).
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Plasma MDS-OAβ performance in samples with a long-term storage duration
We repeated our analyses in samples (n=192) that had been stored for a longer 
period (>4 years), and observed no difference in plasma MDS-OAβ levels between 
abnormal and normal amyloid individuals (β±se: 0.04±0.06, p>0.05, figure 2), nor 
could it discriminate between abnormal and normal amyloid status (AUC: 0.50, 
p>0.05).
Plasma MDS-OAβ as an early predictor of amyloid status
Next, analyses were repeated in a pre-dementia subgroup including CN and 
MCI subjects (storage period ≤4 years; n=78). Plasma MDS-OAβ could identify 
individuals with abnormal amyloid PET with an AUC of 0.77 (95% CI = 0.60-0.93), 
and a sensitivity and specificity of 67% and 83%, respectively. When combined 
with age and APOEe4 status the AUC increased to 0.86 (95% CI= 0.75-0.96), with a 
sensitivity and specificity of 75% and 83%, which performed better than age and 
APOEe4 genotype on a trend level (AUC: 0.76, 95% CI: 0.62-0.89, p=0.10).
Plasma MDS-OAβ as a pre-screener
Lastly, we investigated how the use of plasma oligomers as a pre-screen could 
reduce costs to find 100 individuals with amyloid pathology on a PET scan among 
individuals with normal cognition, MCI, or AD dementia. Given an expected 
prevalence of amyloid pathology of 30% in CN, 50% in MCI and 70% in AD subjects 
[21], the number of amyloid PET scans to find 100 amyloid positives within each 
group without pre-screening would be 333 (CN), 200 (MCI), and 143 (dementia). 
Assuming the sensitivity of 76% and specificity of 69% of the plasma MDS-OAβ test 
(highest Youden cut-off: 0.45), MDS-OAβ needed to be determined in 439 CN, 263 
MCI and 188 AD subjects to identify 195 CN, 141 MCI and 118 AD subjects with an 
abnormal MDS-OAβ test in order to find 100 abnormal amyloid PET cases within 
each clinical group. The plasma MDS-OAβ assay as a pre-screener would reduce 
the number of PET scans with 138 (40%) in CN, 59 (30%) in MCI, and 25 (18%) in 
AD subjects. When considering plasma MDS-OAβ costs, this would result in a cost 
reduction of 40% in CN, 30% in MCI, and 15% in AD compared to when the plasma 
MDS-OAβ assay was not used.
DISCUSSION
We showed that plasma MDS-OAβ has good accuracy to pre-screen for brain 
amyloidosis in a memory clinic population, particularly when combined with 
APOEe4 and age (AUC > 0.80). In addition, plasma MDS-OAβ showed a negative 




Using plasma MDS-OAβ as a pre-screener resulted in reduced number of PET scans 
and lowered costs for amyloid screening up to 40%, which is highly beneficial for 
clinical trials. Of note, these results are only valid for relatively fresh samples, as a 
negative effect of long-term storage was found for plasma MDS-OAβ concentrations.
To date, few studies have measured Aβ oligomers levels in blood plasma, as detecting 
crude oligomeric Aβ in plasma is challenging owing to its low concentration in 
blood. Using the MDS platform, we successfully measured increased plasma MDS-
OAβ levels in abnormal amyloid-PET individuals compared to individuals with 
normal amyloid-PET levels. This finding is in line with previous studies reporting 
increased levels of Aβ oligomers in brain tissue, CSF, and plasma of AD patients. 
[5,23–25] This increase in Aβ oligomer levels is in contrast to monomeric Aβ 
levels, which show an evident decrease rather than increase in blood plasma. 
[26–30] This upregulation of Aβ oligomers could be explained by oligomerization 
of Aβ monomers, resulting in higher plasma Aβ oligomer levels and decreased 
monomeric Aβ levels. Our results also showed a correlation between plasma MDS-
OAβ and CSF Aβ42, t-Tau or MMSE scores, which is in line with previous plasma Aβ 
monomer studies. [7,26,27,30] However, these correlations were not strong, and an 
explanation for this could be the peripheral production of plasma Aβ, by platelets, 
skeletal muscle cells and other cell types [31] that contribute to circulating Aβ 
levels resulting in a dilution of the relation with CNS processes.
This is the first study to report on plasma AβOs as a marker for brain amyloidosis 
in a large amyloid PET confirmed cohort. As the definition of AD is shifting from 
a syndrome to a biological construct, it is relevant to evaluate the performance 
of biomarkers in discriminating amyloid status [8]. One small-scale study did 
evaluate oligomeric assemblies of misfolded Aβ protein as a plasma marker for 
amyloid status between prodromal PET-positive individuals (n=36) and healthy 
elderly PET-negative individuals (n=37) [6]. Using an immune-infrared sensor 
method they achieved an AUC of 0.78 (95% CI 0.68–0.88) [6]. We showed a similar 
good accuracy of plasma MDS-OAβ to screen for amyloid status (AUC: 0.81) in a 
large amyloid PET confirmed cohort when combined with APOEe4 and age. When 
restricting the analyses to individuals in pre-dementia stages (i.e. CN and MCI), the 
accuracy of plasma MDS-OAβ combined with APOEe4 and age increased further 
to 0.86.
One of the suggested applications of a plasma Aβ biomarker is a screening test 
for brain amyloidosis in specialized memory clinics or for clinical trial inclusion 
[32]. Previous studies have been successful in identifying amyloid status with high 
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accuracies (AUC: 0.79-0.97) using various types of plasma Aβ markers [26–30]. 
The plasma MDS-OAβ assay had similar or somewhat lower accuracies compared 
to these other plasma Aβ biomarker tests. However, the techniques used in some 
studies, such as immunoprecipitation mass spectrometry [28,29], are labor-
intensive and time-consuming, thus preventing the high-throughput analysis 
required for screening purposes. In contrast, the MDS method highly resembles 
an ELISA in simplicity [7,18,33], and as such, allows broad implementation. Another 
added value of our study is that we have tested the plasma MDS-OAβ assay in 
a heterogeneous cohort including other neurodegenerative or neuropsychiatric 
disorders besides the clinical AD spectrum, while previous plasma Aβ included 
primarily cohorts which contained the clinical AD spectrum (i.e. healthy controls, 
MCI or AD dementia). The heterogeneity of the cohort used in this current study 
better resembles a memory clinic population, the setting where plasma biomarkers 
will likely be applied in the future to pre-screen for brain amyloidosis. Additionally, 
using plasma MDS-OAβ as a pre-screener in a hypothetical clinical trial scenario 
lowered the number of PET scans up to 40% and reduced total costs up to 40% 
depending on clinical diagnosis. Therefore, plasma MDS-OAβ could be beneficial 
for pre-screening in clinical trial settings, as it could greatly reduce costs.
It is well known that preanalytical factors concerning sample handling and 
processing can influence the measured concentration of (plasma) biomarkers, 
therefore leading to variability in results, preventing establishment of a universal 
cutoffs and between-laboratory comparisons [34,35]. We previously observed 
a negative effect of long-term storage on plasma MDS-OAβ levels upon visual 
inspection (data not published), and therefore, decided to evaluate this in the 
current study. We found that with longer shelf-life plasma MDS-OAβ levels no 
longer differed between normal and abnormal amyloid individuals. Our finding 
is not fully in line with one recent study that investigated the long term storage 
effect on plasma monomeric Aβ, and found stable plasma Aβ levels after long-
term storage up to 5 years at -80°C [36]. This discrepancy might be caused by 
the difference in storage length between the previous study (up to 5 years) and 
the current study (up to 19 years). It might also be caused by the difference in 
analytical methods (MDS vs. IMR) or the different Aβ species (MDS-OAβ vs (in 
principle) monomeric Aβ42). It could be the case that plasma MDS-OAβ levels of 
normal amyloid increase over time and reach similar levels as plasma MDS-OAβ 
levels of abnormal amyloid individuals, whereas in monomeric Aβ42 this does not 
happen. It could be hypothesized that long-term storage might induce stress on 
the oligomeric Aβ42 protein which results in perturbation of the protein and an 




occur in abnormal amyloid individuals as they have already reached maximum 
oligomerization. A similar increase in protein aggregation induced by protein-
stress has previously been reported after freeze-thawing [37]. The effect of 
long-term storage time implies that the plasma MDS-OAβ assay cannot be used 
to perform research projects with samples that have been stored in biobanks 
for a long period. This novel finding could be of interest to other research 
groups interested in measuring plasma biomarkers of amyloid. Additional pre-
analytical testing is needed to determine the precise maximum storage period, 
and to compare the effect of long-term storage with other types of blood based Aβ 
biomarkers. Nonetheless, as in daily clinical routine fresh blood samples are used 
we do not expect this will present a problem for daily clinical practice.
Strengths and limitations
Our study has several strengths including our large well-defined amyloid PET 
confirmed memory clinic population. In addition, CSF and plasma collection follows 
a highly standardized protocol in our center, thus minimizing confounding effects 
in pre-analytical processing. Moreover, the oligomerization assay technique 
developed for this plasma MDS-OAβ assay can potentially be employed for other 
proteinopathies as well, such as α-synuclein which is often seen in dementia with 
Lewy bodies. This might result in a screening panel of plasma biomarkers for 
different types of neurodegenerative disease. Among the limitations of our study 
is that the plasma MDS-OAβ assay is not yet available on an automatic platform, 
thus enhancing the risk for analytical variation. However, automation is currently 
under development, further facilitating broad implementation and minimizing 
analytical variation. In addition, plasma MDS assays for other AD biomarkers, 
such as phosphorylated Tau, are currently under development to further capture 
the full pathological profile of AD [8]. Lastly, it would be interesting to study the 
association between plasma MDS-OAβ with specific cognitive domains, through 
elaborate neuropsychological testing, to get an in-depth understanding of the 
association between plasma MDS-OAβ and cognitive impairment.
CONCLUSIONS
In conclusion, plasma MDS-OAβ has the potential to be used as a pre-screener 
for brain amyloidosis in large heterogeneous memory clinic populations. The 
advantages of the low-cost MDS-OAβ blood test include the ease of blood collection 
over a lumbar puncture or a costly PET scan. Additionally, using plasma MDS-OAβ 
as a pre-screener based on the results of this current study, reduced the number 
of amyloid PET scans needed and lowered total costs up to 40%, highlighting a 
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potential use for clinical trials settings. In addition, the novel finding of long-term 
storage duration on plasma MDS-OAβ levels could be of interest to other research 
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This thesis provides insight in the influence of sex on in-vivo DLB neuropathology 
and AD neuropathological trajectories and contributes to the limited literature 
on sex differences in dementia. In addition, this thesis adds to the identification, 
development and implementation of biofluid biomarkers in the diagnosis of 
dementia subtypes. In this chapter, we summarize the findings from the studies 
in this thesis (figure 1) and place them into context of existing literature.
In the first part of this thesis we utilized CSF biomarkers to deepen our knowledge 
regarding neuropathological differences between women and men in dementia. 
In chapter 2 we aimed to evaluate in-vivo sex differences in CSF biomarkers 
throughout the clinical Alzheimer’s Disease (AD) spectrum (i.e. Subjective 
Cognitive Decline (SCD), Mild Cognitive Impairment (MCI) and AD dementia), 
taking the potentially modifying role of Apolipoprotein (APOE) ε4 genotype into 
account. We showed that female APOE ε4 carriers have higher CSF total Tau (t-Tau) 
and phosphorylated Tau (p-Tau) concentrations than male APOE ε4 carriers in 
early disease stages (i.e. SCD and MCI). In contrast, female APOE ε4 noncarriers 
had higher CSF (p)Tau concentrations than male noncarriers in advanced disease 
stages (i.e. MCI and AD dementia). These findings suggest that APOE differentially 
affects sex differences in CSF biomarkers throughout the clinical AD spectrum.
Previous studies have also described sex differences in dementia with Lewy Bodies 
(DLB). For instance, DLB is more prevalent in men than in women and post-mortem 
studies have found sex differences in underlying DLB pathology. In chapter 3, 
we assessed whether these differences were also present in ante-mortem in-
vivo CSF biomarkers, and whether sex differences translated to variability in 
clinical manifestation. We showed that women had lower α-synuclein (α-syn) and 
amyloid-β 1-42 (Aβ42) levels than men, alongside a shorter duration of complaints, 
suggesting more alpha-synucleinopathy and amyloid pathology in-vivo. Moreover, 
at time of diagnosis, women had lower cognitive test scores and more frequent 
hallucinations. Our findings suggest that in DLB, women have a more aggressive 
disease course compared to men. In chapter 4, we discuss the nature and burden 
of AD pathology in a broader context in response to a study that has identified key 
differences between women and men in post-mortem AD patients.
Biofluid biomarkers, in particular CSF biomarkers, have led to a better diagnostic 
accuracy compared to the use of AD clinical criteria. Promoting the implementation 
of current biomarkers in secondary or tertiary care is, therefore, paramount. 
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In the second part of this thesis, we aimed to facilitate the implementation of 
current AD CSF biomarkers in clinical practice, a critical step for the bench-to-
bedside translation of scientific findings. Chapter 5 presents an educational video 
for professionals in which we illustrate the Lumbar Puncture (LP) procedure as 
defined in recently developed consensus guidelines [1]. In chapter 6 we developed 
an educational animation-video for patients and caregivers in which we inform 
them about and prepare them for the LP procedure. Both videos were based 
on the latest literature [1] and were developed together with communication 
experts, medical doctors, and patient panels. As patients’ LP-related anxiety 
has previously been associated with a higher risk for post-LP complications [2], 
we evaluated whether a better understanding of the LP procedure through the 
patient video, might reduce patients’ feelings of uncertainty and anxiety and 
post-LP complications (chapter 7). We showed an increase in patient’s LP related 
knowledge and a decrease in feelings of uncertainty, but not anxiety, for individuals 
who had watched the video compared to those who received standard explanation 
of the LP procedure. Therefore, we recommend the educational video as an support 
tool to prepare patients for the LP procedure.
Another major challenge in the implementation of CSF biomarkers in daily clinical 
practice is the correct use and interpretation of CSF biomarker results. This is 
especially relevant as not each AD patient has a typical AD biomarker profile (i.e. 
decreased Aβ42 and increased t-Tau). Therefore, in chapter 8, we developed and 
validated a clinically applicable decision tree for the use of CSF biomarkers in the 
diagnosis of AD. A decision tree was modeled using Classification And Regression 
Tree (CART) analysis, which we next validated against previously defined cutoffs 
which dictate separate interpretation of each biomarker. We identified two 
cerebrospinal fluid AD biomarker profiles: i) the “typical” AD biomarker profile 
(i.e. decreased Aβ42, and increased t-Tau) and ii) the “atypical” AD biomarker 
profile, with strongly decreased of Aβ42 but normal t-Tau concentrations
In the third part of this thesis, we focused on the discovery and clinical validation 
of novel biomarkers for AD and non-AD dementias in an easily accessible body fluid 
such as blood. In chapter 9, we used an aptamer-based proteomics technology, 
measuring over 1303 proteins, to identify specific plasma biomarker profiles 
discriminating FTD from AD or cognitively unimpaired controls, as well as between 
FTD pathological subtypes. In addition, we compared aptamer-based plasma with 
tissue results from FTD patients to understand the underlying process. We found 
no difference between FTLD-Tau and FTLD-TDP subtypes in both plasma and 




that, combined with age and sex, could discriminate FTD patients from cognitively 
unimpaired controls with modest accuracy, and FTD from AD with high accuracy. 
These plasma protein panels are potentially promising as minimally invasive tools 
to aid in the specific diagnosis of FTD.
The dynamic process of Aβ oligomerization is considered vital for the neurotoxic 
effects of Aβ in AD. Measuring plasma Aβ oligomerization tendency (OAβ) in blood 
would provide a simple and low-cost tool for AD diagnosis. Therefore, in chapter 
10 we assessed the performance of plasma OAβ as a marker for abnormal amyloid 
PET status in our memory clinic cohort. Plasma OAβ was measured using the novel 
Multimer Detection System (MDS). We showed that plasma MDS-OAβ together 
with APOE ε4 and age, had the potential to accurately identify brain amyloidosis. 
Additionally, using plasma MDS-OAβ as a prescreener reduced the costs and 









Understanding sex differences in biofluid biomarker concentrations
The study of sex differences in neurodegenerative diseases is still in its infancy. To 
date, studies have mostly focused on sex differences in the most common form of 
dementia, namely AD. The prevalence of AD is twice as high in women as in men 
[3]. The higher life expectancy of women is often hypothesized to be a reason 
for the higher prevalence of AD dementia among women compared to men. In 
addition, there is an increasing amount of literature reporting sex differences in AD 
neuropathology (chapter 4). Women tend to have a higher neurofibrillary tangle 
(NFT) burden than men, while differences in Aβ plaque load are less apparent 
[4–7]. Moreover, there are indications that the APOE ε4 allele, a major risk factor 
for sporadic AD, modifies sex differences in AD biomarkers [4,7]. In-vivo CSF 
biomarker studies have shown higher CSF total Tau (t-Tau) and phosphorylated 
Tau (p-Tau) concentrations in female APOE ε4 allele carriers than in male APOE 
ε4 carriers [4,7,8]. By contrast, postmortem studies do not show this sex-specific 
association based on APOE ε4 carriership [4,5]. In this thesis, we observed higher 
CSF t-Tau and p-Tau concentrations in female APOE ε4 carriers than in male 
carriers in pre-dementia stages (i.e. SCD and MCI), which were no longer present 
in the AD dementia stage. The findings of this thesis suggest that the apparent 
discrepancy between ante-mortem and post-mortem findings could be explained 
by disease stage (chapter 2). 
Interestingly, we also observed higher t-Tau and p-Tau concentrations in female 
noncarriers compared to male noncarriers in MCI and AD dementia stage, but not 
in the early SCD stage. When following the amyloid cascade hypothesis [9,10], 
which suggests amyloid plaque deposition is followed by NFT aggregation, our 
findings together with existing literature suggest that sex differences in AD occur 
downstream of amyloid deposition. Although based on cross-sectional data, our 
results suggest an APOE ε4 dependent sex difference in AD disease trajectories. 
However, these findings need to be interpreted with caution as previous work has 
shown that cross-sectional CSF findings not always reflect longitudinal changes in 
CSF biomarker levels [11,12]. A previous biomarker study found low concentrations 
of CSF t-Tau and p-Tau in asymptomatic mutation carriers 10-20 years prior to 
their estimated age at symptom onset (EAO), and higher concentrations after 
EAO. However, longitudinal CSF t-Tau and p-Tau observations showed the opposite 
pattern with increased (p)Tau concentrations prior to EAO and decreased 
levels after EAO. These results were later confirmed in a larger study which 
showed similar longitudinal patterns for both total and phosphorylated CSF Tau 
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concentrations [11]. These results emphasize the importance of longitudinal data 
when modeling biomarker trajectories across the course of a disease. Therefore, 
it would be interesting to study whether our cross-sectional data, when taking 
sex and APOE ε4 into account, give an accurate representation of longitudinal 
trajectories of CSF (p)Tau in AD. Establishing longitudinal biomarker research 
will be facilitated by the emergence of novel and improved plasma biomarkers 
for AD pathology [13,14].
Literature on sex differences in other types of dementia, such as DLB, has been 
scarce. For DLB, most studies report a higher prevalence in men than in women 
[4,5,6,7]. In addition, post-mortem examinations showed that men were more likely 
to die with “pure” DLB pathology than women, and women were more likely to 
have mixed DLB and AD pathology [10, 11]. The few in-vivo studies performed 
to date of sex differences in clinical symptoms and CSF biomarker levels in DLB 
showed that visual hallucinations were more common in women than in men, and 
showed lower levels of CSF alpha-synuclein in women compared to men [17,18]. 
We added to existing literature by showing that women had both lower Aβ42 and 
α-syn levels than men, alongside a shorter duration of complaints (chapter 3). 
Moreover, at the time of diagnosis, women had lower cognitive test scores and 
more frequent hallucinations, the latter confirming previous findings. Based on 
our findings, one could hypothesize that women have a more aggressive disease 
course in DLB compared to men.
Interestingly, in AD we did not observe sex differences in CSF Aβ42 concentrations, 
whereas in DLB sex differences in Aβ42 concentrations were present (chapter 2-3). 
A possible explanation for the lower levels of CSF Aβ42 in DLB women compared to 
men, but not between AD women and men could be that α-syn affects the formation 
of Aβ42 and vice versa [15]. Therefore, lower levels of α-syn in DLB women 
compared to men could have led to an increased aggregation and accumulation 
of amyloid pathology, which is represented as low Aβ42 concentrations in CSF [15–
17]. Since α-syn pathology is not a major pathological hallmark of AD as for DLB, 
this could synergistic interaction between amyloid and a-syn would be missing 
in AD.
Thus far, the assumption in both dementia research and clinical practice was 
that the female and male pathophysiology is similar. However, we here show 
that this might not be the case (chapter 2-3). Our findings have several potential 
clinical implications, which could ultimately lead to women and men receiving a 




in underlying dementia pathology and potentially even disease trajectories, 
suggest that women and men could possibly benefit from different therapeutic 
approaches. As DLB women had more AD and DLB pathology in-vivo they would 
perhaps benefit more from a combined AD/DLB therapeutic agent than solely an 
DLB therapeutic agent (chapter 3). Similarly, in AD it might be more relevant for 
women to start anti-Tau therapies sooner than men, as Tau accumulation appears 
to occur in an earlier stage in women compared to men (chapter 2). In addition, 
since sex differences are seen in both autopsy post-mortem and ante-mortem CSF 
data, an effect of sex should be taken into consideration for emerging fluid-based 
biomarkers, including blood biomarkers. Especially since the use of blood-based 
biomarkers for AD pathology are currently being explored for clinical practice. The 
available blood-based biomarker studies so far have not studied or might not have 
reported sex differences [14,18–22], which should be included in future studies.
Implementation of current biomarkers
An accurate and timely diagnosis of AD is relevant for both patient care and 
research purposes. The current CSF biomarkers for AD (i.e. Aβ42, t-Tau and p-Tau) 
have enabled the detection of AD pathology in-vivo, and the current diagnostic 
criteria emphasize the use of these biomarkers in suspected AD. However, despite 
the benefits of CSF AD biomarkers, patients are often hesitant to undergo the LP 
procedure for obtaining CSF AD biomarker results, due to unrealistic expectations 
about the LP procedure and its possible complications. To help patients fully 
understand how CSF biomarker results are obtained, it is essential to properly 
inform them about the LP procedure. Currently, in our memory clinic setting is 
information provision often limited to verbal and written methods only. However, 
information provision through audiovisual materials, such as educational patient 
videos are an effective method to inform patients [23,24], and educational videos 
have been found to satisfy patient’s needs and aid in information uptake and recall 
more than just verbal or written information provision [25,26]. An increased 
attention span together with the multisensory presentation of a video, could 
explain why viewers improve their knowledge compared to when they receive 
only text or verbally provided information. In this thesis we observed that the 
educational patient video leads to increased knowledge about the LP procedure, 
and that it reduced feelings of uncertainty in the studied population (chapter 7). 
Studies from other medical fields support our findings and also showed reduced 
uncertainty levels after receiving information about a medical procedure or health 
risk [27–32]. Taken together, reduced feelings of uncertainty and increased patient 
knowledge prior to patient-clinician interactions could increase a patients sense 
of empowerment, which might encourage patients to address any questions or 
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issues they have during the consultation prior to the LP procedure. Increased 
patient empowerment could ultimately aid in informed decision making about 
whether or not to undergo the LP procedure, which is advocated by health policy 
makers as the preferred model of doctor-patient consultation [33]. In addition, 
meeting patients’ informational needs has shown to be relevant as it can result in 
a better health status, lower levels of distress, improved satisfaction with care, 
and a greater sense of control [34–38]. Future studies will have to show whether 
educational patient video’s indeed result in a more active involvement of patients 
in their informed decision making processes.
Watching the educational video had no effect on post-LP complications. Based on 
a previous study [2] which observed a higher risk for post-LP complications in 
patients who were anxious for post-LP complications, we expected that a reduction 
in uncertainty and anxiety would result in less post-LP complications. A potential 
explanation could also be that our sample size was too small compared to the 
sample from the previous study [2] (145 vs 3868 participants), to detect small 
differences in post-LP complications. To effectively draw conclusions about the 
effect of information provision on the occurrence of post-LP complications, this 
should be assessed using a larger sample.
Educational videos might also effective tools for medical students or healthcare 
professionals to learn more about a medical procedure [39–42]. The dual visual 
and auditory nature of videos and the ability to pause, rewind and repeatedly 
watch the video enhances learning [43]. Especially, in terms of practical knowledge, 
videos are well suited to illustrate abstract or hard-to-visualize practical skills, 
such as an LP procedure, and are clearly superior to written materials. Moreover, 
one previous study showed that an educational video as part of a structured 
training program, can be used to benefit quality of care and patient safety [44]. 
The educational LP video for professionals (chapter 5) is currently being used 
to educate medical students and neurology residents in the LP procedure at 
several European medical centers. Future research should evaluate whether the 
LP educational video for professionals supports previous literature from other 
fields and results in increased knowledge about the LP procedure, and benefits 
patient care due to a higher LP-success rate.
After acquiring CSF, the decision tool developed in chapter 8 could aid physicians 
in interpreting biomarker results. The benefit of CART analyses over conventional 
regression analyses is that the outcome is a decision tree which can be used more 




of three biomarkers separately. More importantly, in chapter 8 the CART 
analysis identified a clinical AD subgroup with a CSF biomarker profile which has 
previously not been recognized. AD patients were identified with very low CSF 
Aβ42 concentrations, but normal total Tau concentrations. Normally, in cases such 
as these where CSF biomarkers give inconclusive results (i.e. isolated abnormal 
aβ42; 26%), an amyloid- PET scan is requested in cases such as these to confirm 
diagnosis [45,46]. However, as this ‘inconclusive’ CSF profile has been identified as 
a second AD biomarker profile by the CART analysis, our data suggest that further 
confirmation with amyloid PET would no longer be necessary in 26% of the cases 
[45]. In daily practice this could result in reduced medical costs and less exposure 
to radioactivity for patients. It should be noted that novel automated platforms 
have been developed and implemented in our clinic for the measurement of CSF 
aβ42, T-Tau and p-Tau since the time this the publication of chapter 8. However, 
as Innotest Aβ42, t-Tau and p-Tau show high correlation with Elecsys Aβ42, t-Tau 
and p-Tau measurements [47–49], we expect similar outcomes using data from 
automatic platforms.
Development and validation of novel biomarkers
The growing interest in developing blood-based biomarkers, together with the 
development of sensitive assays to detect low quantities of biomarkers in biofluids 
has moved the field closer to identifying blood-based biomarkers for AD and 
non-AD neurodegenerative diseases.
Identification of novel blood-based biomarkers for specific diagnosis of FTD
Several novel biofluid biomarkers have been identified recently for the disease 
pathophysiology in familial and non-familial FTD. Mostly these studies have been 
performed in CSF, as it closely reflects ongoing pathological processes due to its 
close proximity to the brain [50–55]. Although CSF has many advantages, such 
as it being a matrix where neuronally derived molecules are present at relatively 
high concentrations, a more easily accessible matrix such as blood plasma is often 
preferred for repeated measurements in clinical practice or in trials. In chapter 
9, we identified a plasma panel which could identify FTD patients from controls. 
However, in the current form, this blood-based biomarker panel does not have an 
optimal diagnostic accuracy to be applied in clinical settings. For future work it 
could be beneficial to include other biomarkers to this panel, such as neurofilament 
light (NfL) which is more strongly elevated in FTD than in many other dementias 
compared to controls, to further increase the accuracy of blood-based biomarker 
panels [56,57]. Alternatively, future studies could focus on biomarker discovery in 
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CSF, after which novel more sensitive methods are used to measure the identified 
CSF biomarker candidates in blood.
We could not find differentially regulated proteins between Tau and TDP43 
pathological subtypes in plasma or tissue, nor could we identify discriminatory 
plasma protein signatures between subtypes. Although some studies were able 
to identify protein alterations between both pathological subtypes [50,58], 
most studies have been unsuccessful in identifying and validating biomarkers 
for the pathological subtypes of FTD in clinical practice. This could have several 
explanations. First, an explanation could be the heterogeneity within Tau and 
TDP pathological subtypes [59,60], for instance patients with the TDP-A isoform 
might have a different protein signature than patients with the TDP-C isoform. 
This heterogeneity will complicate the search for a single discriminatory protein 
panel for TDP vs Tau, and will require larger and more homogeneous sample sizes 
which are scarce. An alternative explanation is that both TDP and Tau pathological 
subtypes might initiate the same downstream pathological pathways, which will 
result in similar proteomic changes. This would also explain why both pathological 
subtypes are seen throughout the clinical FTD spectrum [61]. Lastly, in most FTD 
biomarker studies familial and sporadic cases are often grouped to achieve a large 
sample size. However, future studies must show whether the familial form of FTD is 
similar to the sporadic FTD form in terms of underlying pathological mechanisms 
and plasma protein profiles. Studies, which independently evaluate (plasma) 
protein profiles of familial and sporadic FTD subtypes could provide more clarity.
Clinical validation of an assay for blood-based AD biomarkers
For AD, novel methods to measure Aβ in blood, such as the aβ oligomeric assay 
or plasma Aβ42/Aβ40 using the ultrasensitive (Simoa) approach are easier to 
implement than CSF Aβ42, but do not yet have sufficient diagnostic precision to 
be useful clinically [21]. Recently, the discovery of plasma p-Tau181 and p-Tau 217 
has led to better diagnostic accuracies than Aβ42/Aβ40 or oligomeric plasma aβ 
[13,14]. However, verification of the diagnostic performance of plasma p-Tau181 
and 217 in a larger number of autopsy-confirmed cases and independent studies 
[14] or unselected and diverse populations [13] is still needed. Therefore, for the 
time being plasma biomarkers appear to be most valuable for screening purposes: 
to identify underlying AD pathology in cognitively normal individuals or in people 
with mild cognitive impairment [18], after which CSF analysis or a PET scan can 
provide more diagnostic certainty in those who test positive. Thus, the blood 
test should yield a low number of false negatives, i.e. people with underlying 




biomarkers as a funnel biomarker, has shown to potentially reduce the number 
of CSF [18] and PET scans (chapter 10) that need to be performed. For example, 
the plasma MDS-OAβ assay from chapter 10 shows a potential reduction of the 
number of PET scans up to 40% when the plasma marker is used as a screening 
tool in a hypothetical situation. As PET scans costs considerably more than the 
plasma MDS-OAβ assay this results in lower healthcare or trial costs. An additional 
benefit is that less potential trial candidates will be exposed to radiation during 
a PET scan.
Utility of blood-based biomarker panels in dementia
It has previously been proposed that panels of plasma biomarkers may outperform 
single candidate markers for diagnosing, prognosing and characterizing AD [62,63]. 
For example, it has been shown that plasma p-Tau181 combined with plasma 
Aβ42/Aβ40 led to higher diagnostic accuracy than using plasma Aβ42/Aβ40 alone 
[64]. The development of blood biomarkers for (non-) AD dementias is currently 
occurring so rapidly that we are only a few steps away from a world where a panel 
of all-dementia biomarkers becomes a reality. This panel would ideally include 
pathology specific biomarkers for the most common type of dementias, and it 
would be used by the general practitioner in primary care or via population wide 
screening to identify individuals who are at risk for dementia, and to specify which 
type of dementia this risk concerns. These patients could then be forwarded to 
secondary care, where additional diagnostic tests such as CSF or PET scans are 
performed, to provide patients with precise information and aid in planning their 
future. Moreover, based on these results patients can be (increasingly) offered to 
participate in clinical trials, or would receive disease modifying therapies, when 
these become available. Interestingly, the MDS technology used in chapter 10 can 
be used to identify other disease specific plasma protein oligomers as well, since it 
is based on amplification of the oligomer signal through an incubation step [65,66]. 
This amplification allows for the normally low quantity of plasma oligomers of 
proteins such as Aβ42, Tau, TDP43 or α-syn to be sensitively measured [65,66]. 
Currently, assay development for TDP-43 oligomers has been initiated. Ideally, 
the rapid development of blood biomarkers would result in a robust ‘all-dementia’ 
blood-based biomarker panel with such high diagnostic accuracy, that secondary 
confirmation with CSF or PET is no longer needed.
Methodological considerations
There are several methodological issues that need to be considered when 




A potential limitation of this thesis could be the use of subjective cognitive decline 
(SCD) subjects as controls in all chapters, except chapter 10 where we also used 
healthy volunteers. Some argue that SCD subjects are not suitable as controls 
as a proportion of these individuals is likely to progress to Alzheimer’s disease 
(AD) [67,68]. However, around one third of the general population has underlying 
AD pathology as well [69], therefore, there is still a chance of progression to AD 
when controls are selected from the general population. Moreover, in daily clinical 
practice biofluid biomarkers can be used in SCD subjects, and not in healthy 
controls.
Cohorts
In this thesis we used data from various cohorts, although most studies performed 
in this thesis included participants from the Amsterdam Dementia Cohort (ADC; 
chapters 2-3, 7-8). The ADC is a memory-clinic cohort of Alzheimer Center 
Amsterdam [70,71]. A major strength of the ADC cohort is that all participants 
underwent a standardized work-up which included extensive phenotyping. A 
great advantage is that this extensive phenotyping of ADC participants is paired 
with biological samples (e.g. cerebrospinal fluid, blood plasma) that are processed 
according to a standardized protocol and stored in a large centralized biobank 
[71]. The extensive phenotyping together with biological samples has allowed 
us to couple biomarker findings with clinical data. For example, in chapter 8, 
we studied the clinical phenotype of patient subgroups with different biomarker 
profiles. The ADC is a tertiary memory clinic specialized in young-onset dementia. 
This could make the findings of this thesis less generalizable to older populations. 
However, this could also be a strength as younger dementia patients are thought to 
have less concomitant pathologies than elderly dementia patients, and biomarkers 
may have more added value in this younger population [72–74]. Nonetheless, as 
most chapters in this thesis are based on the Alzheimer Dementia Cohort future 
replication in external populations is needed to allow broad generalization.
Another cohort used in this thesis was the Parelsnoer initiative cohort (chapter 
10): the neurodegenerative Pearl. Samples from this cohort included subjects 
from eight medical centers throughout the Netherlands [75]. However, not all 
medical centers routinely determined CSF biomarker levels in the clinical work-
up. Although patients were diagnosed in secondary and tertiary centers, the lack 
of biomarker data could potentially have resulted in a lower diagnostic accuracy of 
AD subjects in this cohort. Additionally, the use of samples from multiple centers 




variability is also a strength as it supports the robustness of results. This is also 
the case in chapter 10 which is a two-site study, with subjects from the PreclinAD 
[76] study from Manchester University and the Amsterdam Dementia Cohort.
Measurements
During the period in which the studies for this thesis were performed, assay 
platforms, diagnostic criteria, and protocols evolved. Initially, the Innotest enzyme-
linked immunosorbent assay (ELISA) was widely used for routine CSF biomarker 
analysis of aβ42, t-Tau and p-Tau. However, with the manual Innotest ELISA 
there were large interlaboratory variations (>15%), due to preanalytical sample 
handling and analytical variation [77–81]. This hampered the establishment of 
universal biomarker cut-off levels, and therefore between-laboratory comparisons. 
In addition, the Innotest aβ42 ELISA has shown an upward drift of aβ42 values 
throughout the analysis years [81–83]. Therefore, the fully automated Elecsys 
platform for CSF aβ42, t-Tau and p-Tau measurements was introduced, which has 
good intra- and interlaboratory variations of 2% to 5% [84]. An evolution also 
occurred for the diagnostic and research criteria for DLB and AD which were 
updated in 2017 and 2018, respectively, and shifted from a syndrome definition of 
disease to a biological construct. In the novel criteria biomarkers are incorporated 
to establish AD pathology and to support clinical diagnosis in-vivo [85,86]. The 
evolution of biomarker assay platforms, protocols and criteria by which a disease 
is defined might have introduced heterogeneity in the datasets used throughout 
the chapters in this thesis (i.e. chapter 2-3, 8-9).
Future perspective
In dementia, different underlying disease mechanisms are observed in 
individuals with the same clinical dementia diagnosis. The occurrence of 
heterogeneous patient subgroups with specific neurobiology could attribute to 
our limited ability to identify effective drugs in clinical trials. Therefore, using 
an individual’s biomarker expression profile to establish a biological diagnosis 
and to select an appropriate treatment will be of importance for future trials. 
This process is known as personalized or precision medicine and is where the 
future of dementia research and care is heading. To achieve tailored medicine per 
individual, it is necessary to develop panels of inexpensive and minimally invasive 
biomarkers, such as blood-based biomarkers. Chapters 9 and 10 have aided in 
the search for and development of blood-based biomarkers for AD and non-AD 
neurodegenerative disease. These chapters show the feasibility of the approaches 
and are, therefore, important first steps towards the development of panels of 
blood-based biomarkers. Additionally, we have shown that sex has the potential to 
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influence biofluid biomarker concentrations (Chapters 2-4). Therefore, to achieve 
personalized healthcare an individual’s specific biological make-up, including 
sex, should also be taken into account. Lastly, an important aspect of providing 
personalized medicine is the shared decision making process in which patients 
can express their questions or expectations regarding a (diagnostic) procedure 
or treatment. Patient information has been found to be one of the most important 
dimensions of patient-centered care and meeting information needs has shown 
to aid in informed decision making. Chapters 5-7 contain tools to provide in 
patients informational needs. The results from our study support the development 
of similar educational videos for other diagnostic modalities as well, such as a 
PET- scan.
CONCLUSION
The findings of this thesis can be used to facilitate personalized biological 
diagnosis based on a person’s phenotype (e.g. sex) and in-vivo pathological changes 
using biofluid biomarkers. This knowledge can be instrumental to accelerate the 





[1] Engelborghs S, Niemantsverdriet 
E, Struyfs H, Blennow K, Brouns 
R, Comabella M, et al. Consensus 
guidelines for lumbar puncture in 
patients with neurological diseases. 
Alzheimer’s Dement Diagnosis, 
Assess Dis Monit 2017. doi:10.1016/j.
dadm.2017.04.007.
[2] Duits FH, Martinez-Lage P, Paquet C, 
Engelborghs S, Lleó A, Hausner L, et 
al. Performance and complications 
of lumbar puncture in memory 
clinics: Results of the multicenter 
lu mba r pu nc t u re fea sibi l i t y 
study. Alzheimer’s Dement 2016. 
doi:10.1016/j.jalz.2015.08.003.
[3] Gaugler J, James B, Johnson T, Scholz 
K, Weuve J. 2016 Alzheimer’s disease 
facts and figures. Alzheimer’s Dement 
2016;12:459–509. doi:10.1016/j.
jalz.2016.03.001.
[4] Hohman TJ, Dumitrescu L, Barnes LL, 
Thambisetty M, Beecham G, Kunkle 
B, et al. Sex-Specific Association of 
Apolipoprotein E With Cerebrospinal 
Fluid Levels of Tau. JAMA Neurol 
2 0 1 8 ;7 5 : 9 8 9 .  d o i : 10 . 10 0 1 /
jamaneurol.2018.0821.
[5] Oveisgharan S, Arvanitakis Z, Yu L, 
Farfel J, Schneider JA, Bennett DA. Sex 
differences in Alzheimer’s disease and 
common neuropathologies of aging. 
Acta Neuropathol 2018;136:887–900. 
doi:10.1007/s00401-018-1920-1.
[6] Barnes LL, Wilson RS, Bienias JL, 
Schneider JA, Evans DA, Bennett 
DA. Sex Differences in the Clinical 
Manifestations of Alzheimer Disease 
Pathology. Arch Gen Psychiatry 
2 0 0 5 ; 6 2 : 6 8 5 .  d o i :10 . 10 0 1 /
archpsyc.62.6.685.
[7] Altmann A, Tian L, Henderson VW, 
Greicius MD. Sex modifies the APOE 
-related risk of developing Alzheimer 
disease. Ann Neurol 2014;75:563–73. 
doi:10.1002/ana.24135.
[8] Damoiseaux JS, Seeley WW, Zhou 
J, Shirer WR, Coppola G, Karydas 
A, et al. Gender Modulates the 
APOE 4 Effect in Healthy Older 
Adults: Convergent Evidence from 
Functional Brain Connectivity and 
Spinal Fluid Tau Levels. J Neurosci 
2012;32:8254–62. doi:10.1523/
JNEUROSCI.0305-12.2012.
[9] Hardy JA, Higgins GA. Alzheimer’s 
disease: the amyloid cascade 
hy pot hesis .  Sc ience (80 - ) 
1992;256:184–6.
[10] Selkoe DJ, Hardy J. The amyloid 
hypothesis of Alzheimer’s disease at 
25 years. EMBO Mol Med 2016;8:595–
608. doi:10.15252/emmm.201606210.
[11] Sutphen CL, McCue L, Herries EM, 
Xiong C, Ladenson JH, Holtzman DM, et 
al. Longitudinal decreases in multiple 
cerebrospinal f luid biomarkers of 
neuronal injury in symptomatic 
late onset Alzheimer’s disease. 
Alzheimer’s Dement 2018;14:869–79. 
doi:10.1016/j.jalz.2018.01.012.
[12] Fagan AM, Xiong C, Jasielec MS, 
Bateman RJ, Goate AM, Benzinger 
TLS, et al. Longitudinal Change 
in CSF Biomarkers in Autosomal-
Dominant Alzheimer’s Disease. Sci 




[13] Palmqvist S, Janelidze S, Quiroz YT, 
Zetterberg H, Lopera F, Stomrud E, 
et al. Discriminative Accuracy of 
Plasma Phospho-tau217 for Alzheimer 
Disease vs Other Neurodegenerative 
Disorders. JAMA - J Am Med Assoc 
2020;324:772–81. doi:10.1001/
jama.2020.12134.
[14] Thijssen EH, La Joie R, Wolf A, Strom A, 
Wang P, Iaccarino L, et al. Diagnostic 
value of plasma phosphorylated 
tau181 in Alzheimer’s disease and 
frontotemporal lobar degeneration. 
Nat Med 2020. doi:10.1038/s41591-
020-0762-2.
[15] Clinton LK, Blurton-Jones M, 
Myczek K, Trojanowski JQ, LaFerla 
FM. Sy nerg ist ic Interac t ions 
between A , Tau, and -Synuclein: 
Acceleration of Neuropathology 
and Cognitive Decline. J Neurosci 
2010;30:7281–9. doi:10.1523/
JNEUROSCI.0490-10.2010.
[16] Colom-Cadena M, Gelpi E, Charif S, 
Belbin O, Blesa R, Martí� MJ, et al. 
Confluence of α-synuclein, tau, and 
β-amyloid pathologies in dementia 
with Lewy bodies. J Neuropathol 
Exp Neurol 2013. doi:10.1097/
NEN.0000000000000018.
[17] Irwin DJ, Lee VMY, Trojanowski 
JQ. Parkinson’s disease dementia: 
convergence of α-synuclein, tau 
and amyloid-β pathologies. Nat 
Rev Neurosci 2013;14:626–36. 
doi:10.1038/nrn3549.
[18] Verberk IMW, Slot RE, Verfaillie SCJ, 
Heijst H, Prins ND, van Berckel BNM, et 
al. Plasma Amyloid as Prescreener for 
the Earliest Alzheimer Pathological 
Changes. Ann Neurol 2018;84:648–
58. doi:10.1002/ana.25334.
[19] Nabers A, Perna L, Lange J, Mons 
U, Schartner J, Güldenhaupt J, 
et al. Amyloid blood biomarker 
detects Alzheimer’s disease. EMBO 
Mol Med 2018;10. doi:10.15252/
emmm.201708763.
[20] Nakamura A, Kaneko N, Villemagne 
VL, Kato T, Doecke J, Doré V, et al. 
High performance plasma amyloid-β 
bioma rker s for A l z hei mer ’s 
disease. Nature 2018;554:249–54. 
doi:10.1038/nature25456.
[21] Janelidze S, Stomrud E, Palmqvist 
S, Zetterberg H, van Westen D, 
Jeromin A, et al. Plasma β-amyloid 
in Alzheimer’s disease and vascular 
disease. Sci Rep 2016;6:26801. 
doi:10.1038/srep26801.
[22] Palmqvist S, Janelidze S, Stomrud 
E, Zetterberg H, Karl J, Zink K, et al. 
Performance of Fully Automated 
Plasma Assays as Screening Tests for 
Alzheimer Disease–Related β-Amyloid 
Status. JAMA Neurol 2019;76:1060. 
doi:10.1001/jamaneurol.2019.1632.
[23] Soydaş Yeşilyurt D, Yildiz Findik 
U� . Effect of Preoperative Video 
Informat ion on Anxiet y and 
Satisfaction in Patients Undergoing 
Abdominal Surgery. CIN Comput 
Informatics, Nurs 2019;37:430–6. 
doi:10.1097/CIN.0000000000000505.
[24] Snyder-Ramos SA, Seintsch H, 
B??ttiger BW, Motsch J, Martin 
E, Bauer M. Patient Satisfaction 
and Information Gain After the 
Preanesthetic Visit: A Comparison 
of  Fac e -t o -Fac e  I n t er v ie w, 
Brochure, and Video. Anesth Analg 
2005;100:1753–8. doi:10.1213/01.
ANE.0000153010.49776.E5.
[25] Sudore RL, Schillinger D. Interventions 
to Improve Care for Patients with 





[26] Ahlander BM, Engvall J, Maret E, 
Ericsson E. Positive effect on patient 
experience of video information given 
prior to cardiovascular magnetic 
resonance imaging: A clinical trial. 
J Clin Nurs 2018. doi:10.1111/
jocn.14172.
[27] Scott A. Managing anxiety in ICU 
patients: the role of pre-operative 
information provision. Nurs Crit 
Care 2004;9:72–9. doi:10.1111/j.1478-
5153.2004.00053.x.
[28] Freeman-Wang T, Walker P, Linehan 
J, Coffey C, Glasser B, Sherr L. 
Anxiety levels in women attending 
colposcopy clinics for treatment for 
cervical intraepithelial neoplasia: a 
randomised trial of written and video 
information. Br J Obstet Gynaecol 
2001;108:482–4. doi:10.1016/S0306-
5456(00)00121-2.
[29] Lobb EA, Butow PN, Barratt A, 
Meiser B, Gaff C, Young MA, et al. 
Communication and information-
giving in high-risk breast cancer 
consultations: influence on patient 
outcomes. Br J Cancer 2004;90:321–7. 
doi:10.1038/sj.bjc.6601502.
[30] Luck A, Pearson S, Maddem G, Hewett 
P. Effects of video information 
on precolonoscopy anxiety and 
knowledge: a randomised trial. Lancet 
1999;354:2032–5. doi:10.1016/S0140-
6736(98)10495-6.
[31] Arterburn DE, Westbrook EO, 
Bogart TA, Sepucha KR, Bock SN, 
Weppner WG. Randomized Trial 
of a Video-Based Patient Decision 
Aid for Bariatric Surgery. Obesity 
2011;19:1669–75. doi:10.1038/
oby.2011.65.
[32] Chair SY, Chau MY, Sit JWH, 
Wong EML , Chan AWK . The 
psychological effects of a videotape 
educ at iona l inter vent ion on 
cardiac catheterization patients. 
Contemp Nurse 2012. doi:10.5172/
conu.2012.40.2.225.
[33] Zill JM, Scholl I, Härter M, Dirmaier 
J. Which dimensions of patient-
centeredness matter? - Results of a 
web-based expert Delphi survey. PLoS 
One 2015;10. doi:10.1371/journal.
pone.0141978.
[34] Husson O, Mols F, van de Poll-Franse 
LV. The relation between information 
provision and health-related quality 
of life, anxiety and depression among 
cancer survivors: a systematic 
review. Ann Oncol 2011;22:761–72. 
doi:10.1093/annonc/mdq413.
[35] Mallinger JB, Griggs JJ, Shields CG. 
Patient-centered care and breast 
cancer survivors’ satisfaction with 
information. Patient Educ Couns 2005. 
doi:10.1016/j.pec.2004.09.009.
[36] Mesters I, van den Borne B, De Boer M, 
Pruyn J. Measuring information needs 
among cancer patients. Patient Educ 
Couns 2001;43:255–64. doi:10.1016/
S0738-3991(00)00166-X.
[37] Arraras JI, Kuljanic-Vlasic K, Bjordal 
K, Yun YH, Efficace F, Holzner B, et al. 
EORTC QLQ-INFO26: a questionnaire 
to assess information given to cancer 
patients a preliminary analysis in 
eight countries. Psychooncology 
2007;16:249 –54. doi:10.1002/
pon.1047.
[38] Mills ME, Sullivan K. The importance 
of information giving for patients 
newly diagnosed with cancer: a 





[39] Allen Moore W, Russell Smith A. Effects 
of video podcasting on psychomotor 
and cognitive performance, attitudes 
and study behaviour of student 
physical therapists. Innov Educ Teach 
Int 2012;49:401–14. doi:10.1080/1470
3297.2012.728876.
[40] Kay RH. Exploring the use of 
video podcasts in education: A 
comprehensive review of the 
literature. Comput Human Behav 
2012;28:820–31. doi:10.1016/j.chb. 
2012.01.011.
[41] Lloyd SA, Robertson CL. Screencast 
Tutorials Enhance Student Learning of 
Statistics. Teach Psychol 2012;39:67–
71. doi:10.1177/0098628311430640.
[42] Stockwell BR, Stockwell MS, Cennamo 
M, Jiang E. Blended Learning 
Improves Science Education. Cell 
2015;162:933–6. doi:10.1016/j.
cell.2015.08.009.
[43] Schreiber BE, Fukuta J, Gordon F. 
Live lecture versus video podcast in 
undergraduate medical education: A 
randomised controlled trial. BMC Med 
Educ 2010;10:68. doi:10.1186/1472-
6920-10-68.
[44] Barsuk JH, McGaghie WC, Cohen ER, 
Balachandran JS, Wayne DB. Use of 
simulation-based mastery learning 
to improve the quality of central 
venous catheter placement in a 
medical intensive care unit. J Hosp 
Med 2009;4:397–403. doi:10.1002/
jhm.468.
[45] Reimand J, Groot C, Teunissen CE, 
Windhorst AD, Boellaard R, Barkhof F, 
et al. Why Is Amyloid-β PET Requested 
After Performing CSF Biomarkers? 
J Alzheimer’s Dis 2020;73:559–69. 
doi:10.3233/JAD-190836.
[46] Leuzy A, Savitcheva I, Chiotis K, Lilja 
J, Andersen P, Bogdanovic N, et al. 
Clinical impact of [ 18 F]flutemetamol 
PET among memory clinic patients 
with an unclear diagnosis. Eur J Nucl 
Med Mol Imaging 2019;46:1276–86. 
doi:10.1007/s00259-019-04297-5.
[47] Willemse EAJ, Maurik IS, Tijms BM, 
Bouwman FH, Franke A, Hubeek I, et 
al. Diagnostic performance of Elecsys 
immunoassays for cerebrospinal fluid 
Alzheimer’s disease biomarkers in a 
nonacademic, multicenter memory 
clinic cohort: The ABIDE project. 
Alzheimer’s Dement Diagnosis, 
Assess Dis Monit 2018;10:563–72. 
doi:10.1016/j.dadm.2018.08.006.
[48] Lifke V, Kollmorgen G, Manuilova 
E, Oelschlaegel T, Hillringhaus L, 
Widmann M, et al. Elecsys® Total-Tau 
and Phospho-Tau (181P) CSF assays: 
Analytical performance of the novel, 
fully automated immunoassays 
for quantification of tau proteins 
in human cerebrospinal f luid. 
Clin Biochem 2019. doi:10.1016/j.
clinbiochem.2019.05.005.
[49] Shaw LM, Hansson O, Manuilova E, 
Masters CL, Doecke JD, Li QX, et al. 
Method comparison study of the 
Elecsys® β-Amyloid (1–42) CSF 
assay versus comparator assays 
and LC-MS/MS. Clin Biochem 
2019;7 2:7–14 .  doi :10 .1016/j .
clinbiochem.2019.05.006.
[50] Teunissen CE, Elias N, Koel-
Simmelink MJA, Durieux-Lu S, 
Malekzadeh A, Pham T V., et al. 
Novel diagnostic cerebrospinal fluid 
biomarkers for pathologic subtypes 
of frontotemporal dementia identified 
by proteomics. Alzheimer’s Dement 





[51] Hu WT, Watts K, Grossman M, Glass 
J, Lah JJ, Hales C, et al. Reduced 
CSF p-Tau181 to Tau ratio is a 
biomarker for FTLD-TDP. Neurology 
2013;81:1945–52. doi:10.1212/01.
wnl.0000436625.63650.27.
[52] Borroni B, Benussi A, Archetti S, 
Galimberti D, Parnetti L, Nacmias 
B, et al. Csf p-tau 181 /tau ratio as 
biomarker for TDP pathology in 
frontotemporal dementia. Amyotroph 
Lateral Scler Front Degener 
2015;16:86–91. doi:10.3109/216784
21.2014.971812.
[53] Foiani MS, Cicognola C, Ermann N, 
Woollacott IOC, Heller C, Heslegrave 
AJ, et al. Searching for novel 
cerebrospinal f luid biomarkers of 
tau pathology in frontotemporal 
dementia: an elusive quest. J Neurol 
Neurosurg Psychiatry 2019;90:740–6. 
doi:10.1136/jnnp-2018-319266.
[54] Meeter LHH, Vijverberg EG, Del 
Campo M, Rozemuller AJM, Donker 
Kaat L, de Jong FJ, et al. Clinical value 
of neurofilament and phospho-tau/
tau ratio in the frontotemporal 
dementia spectrum. Neurology 
2018;90:e1231–9. doi:10.1212/
WNL.0000000000005261.
[55] Pijnenburg YAL , Ver wey NA, 
van der Flier WM, Scheltens P, 
Teunissen CE . Discr iminat ive 
and prog nost ic potent ia l of 
cerebrospinal f luid phosphoTau/
tau ratio and neurofilaments for 
frontotemporal dementia subtypes. 
Alzheimer’s Dement Diagnosis, 
Assess Dis Monit 2015. doi:10.1016/j.
dadm.2015.11.001.
[56] Meeter LH, Dopper EG, Jiskoot LC, 
Sanchez-Valle R, Graff C, Benussi L, 
et al. Neurofilament light chain: a 
biomarker for genetic frontotemporal 
dementia. Ann Clin Transl Neurol 
2016. doi:10.1002/acn3.325.
[57] Bridel C, Van Wieringen WN, 
Zetterberg H, Tijms BM, Teunissen 
CE, Alvarez-Cermeño JC, et al. 
Diagnostic Value of Cerebrospinal 
Fluid Neurofilament Light Protein 
in Neurology: A Systematic Review 
and Meta-analysis. JAMA Neurol 
2019;76:1035–48. doi:10.1001/
jamaneurol.2019.1534.
[58] Hu  W T,  C h e n -P l o t k i n  A , 
Grossman M, Arnold SE, Clark 
CM, Shaw LM, et al. Novel CSF 
biomarkers for frontotemporal 
lobar degenerations. Neurology 
2010;75:2079–86. doi:10.1212/
WNL.0b013e318200d78d.
[59] Mackenzie IRA, Neumann M, Bigio 
EH, Cairns NJ, Alafuzoff I, Kril J, 
et al. Nomenclature and nosology 
for neuropathologic subtypes of 
frontotemporal lobar degeneration: 
an update. Acta Neuropathol 
2010;119:1–4. doi:10.1007/s00401-
009-0612-2.
[60] Buée L, Bussière T, Buée-Scherrer 
V, Delacourte A, Hof PR. Tau protein 
isoforms, phosphorylation and role in 
neurodegenerative disorders11These 
authors contributed equally to this 
work. Brain Res Rev 2000;33:95–130. 
doi:10.1016/S0165-0173(00)00019-9.
[61] Meeter LH, Kaat LD, Rohrer JD, 
Van Swieten JC. Imaging and fluid 
biomarkers in frontotemporal 
dementia. Nat Rev Neurol 2017. 
doi:10.1038/nrneurol.2017.75.
[62] Zetterberg H, Burnham SC. Blood-
based molecular biomarkers for 
Alzheimer’s disease. Mol Brain 
2019;12:26. doi:10.1186/s13041-019-
0448-1.
[63] Baird AL, Westwood S, Lovestone S. 
Blood-Based Proteomic Biomarkers 
of Alzheimer’s Disease Pathology. 




[64] Janelidze S, Mattsson N, Palmqvist 
S, Smith R, Beach TG, Serrano GE, et 
al. Plasma P-tau181 in Alzheimer’s 
disease: relationship to other 
biomarkers, differential diagnosis, 
neuropathology and longitudinal 
progression to Alzheimer’s dementia. 
Nat Med 2020. doi:10.1038/s41591-
020-0755-1.
[65] An SSA, Lee B, Yu JS, Lim K, Kim GJ, 
Lee R, et al. Dynamic changes of 
oligomeric amyloid β levels in plasma 
induced by spiked synthetic Aβ42. 
Alzheimers Res Ther 2017;9:86. 
doi:10.1186/s13195-017-0310-6.
[66] An SSA, Lim KT, Oh HJ, Lee BS, Zukic 
E, Ju YR, et al. Differentiating blood 
samples from scrapie infected and 
non-infected hamsters by detecting 
disease-associated prion proteins 
using Multimer Detection System. 
Biochem Biophys Res Commun 
2010;392:505–9. doi:10.1016/j.
bbrc.2010.01.053.
[67] Slot RER, Sikkes SAM, Berkhof J, 
Brodaty H, Buckley R, Cavedo E, et al. 
Subjective cognitive decline and rates 
of incident Alzheimer’s disease and 
non–Alzheimer’s disease dementia. 
Alzheimer’s Dement 2019;15:465–76. 
doi:10.1016/j.jalz.2018.10.003.
[68] Rhodius-Meester HFM, Liedes H, 
Koikkalainen J, Wolfsgruber S, 
Coll-Padros N, Kornhuber J, et al. 
Computer-assisted prediction of 
clinical progression in the earliest 
stages of AD. Alzheimer’s Dement 
Diagnosis, Assess Dis Monit 
2018;10:726–36. doi:10.1016/j.
dadm.2018.09.001.
[69] Vos SJB, Xiong C, Visser PJ, Jasielec 
MS, Hassenstab J, Grant EA, et al. 
Preclinical Alzheimer’s disease and 
its outcome: A longitudinal cohort 
study. Lancet Neurol 2013;12:957–65. 
doi:10.1016/S1474-4422(13)70194-7.
[70] Van Der Flier WM, Pijnenburg YAL, 
Prins N, Lemstra AW, Bouwman FH, 
Teunissen CE, et al. Optimizing patient 
care and research: The Amsterdam 
dementia cohort. J Alzheimer’s 
Dis 2014;41:313–27. doi:10.3233/
JAD-132306.
[71] van der Flier WM, Scheltens P. 
Amsterdam Dementia Cohor t: 
Performing Research to Optimize 
Care. J Alzheimer’s Dis 2018;62:1091–
111. doi:10.3233/JAD-170850.
[72] P. Gelber R, J. Launer L, R. White 
L. The Honolulu-Asia Aging Study: 
Epidemiologic and Neuropathologic 
Research on Cognitive Impairment. 
Curr Alzheimer Res 2013;9:664–72. 
doi:10.2174/156720512801322618.
[73] Barker WW, Luis CA, Kashuba A, Luis 
M, Harwood DG, Loewenstein D, et 
al. Relative frequencies of Alzheimer 
disease, Lewy body, vascular and 
frontotemporal dementia, and 
hippocampal sclerosis in the State 
of Florida Brain Bank. Alzheimer 
Dis Assoc Disord 2002;16:203–12. 
doi:10.1097/00002093-200210000-
00001.
[74] Jellinger KA. The enigma of mixed 
dementia. Alzheimer’s Dement 
20 07;3:4 0 –53 .  doi :10 .1016/j .
jalz.2006.09.002.
[75] Aalten P, Ramakers IHGB, Biessels 
GJ, de Deyn PP, Koek HL, OldeRikkert 
MGM, et al. The Dutch Parelsnoer 
Inst itute - Neurodegenerat ive 
diseases; methods, design and 
baseline results. BMC Neurol 2014. 
doi:10.1186/s12883-014-0254-4.
[76] Konijnenberg E, Carter SF, ten Kate 
M, den Braber A, Tomassen J, Amadi 
C, et al. The EMIF-AD PreclinAD 
study: study design and baseline 






[77] Verwey NA, van der Flier WM, Blennow 
K, Clark C, Sokolow S, De Deyn PP, et al. 
A worldwide multicentre comparison 
of assays for cerebrospinal f luid 
biomarkers in Alzheimer’s disease. 
Ann Clin Biochem 2009;46:235–40. 
doi:10.1258/acb.2009.008232.
[78] Vos SJB, Visser PJ, Verhey F, Aalten P, 
Knol D, Ramakers I, et al. Variability of 
CSF alzheimer’s disease biomarkers: 
Implications for clinical practice. 
PLoS One 2014. doi:10.1371/journal.
pone.0100784.
[79] Kang J-H, Korecka M, Toledo JB, 
Trojanowski JQ, Shaw LM. Clinical 
Utility and Analytical Challenges in 
Measurement of Cerebrospinal Fluid 
Amyloid-β1–42 and τ Proteins as 
Alzheimer Disease Biomarkers. Clin 
Chem 2013;59:903–16. doi:10.1373/
clinchem.2013.202937.
[80] Bjerke M, Portelius E, Minthon 
L , Wallin A , Anckarsäter H, 
Anckarsäter R, et al. Confounding 
Factors Influencing Amyloid Beta 
Concentration in Cerebrospinal Fluid. 
Int J Alzheimers Dis 2010;2010:1–11. 
doi:10.4061/2010/986310.
[81] Mattsson N, Andreasson U, Persson 
S, Carrillo MC, Collins S, Chalbot S, 
et al. CSF biomarker variability in 
the Alzheimer’s Association quality 
control program. A lzheimer ’s 
Dement 2013;9:251–61. doi:10.1016/j.
jalz.2013.01.010.
[82] Willemse EAJ, van Uffelen KWJ, van 
der Flier WM, Teunissen CE. Effect 
of long-term storage in biobanks 
on cerebrospinal f luid biomarker 
Aβ1-42, T-tau, and P-tau values. 
Alzheimer’s Dement Diagnosis, Assess 
Dis Monit 2017;8:45–50. doi:10.1016/j.
dadm.2017.03.005.
[83] Tijms BM, Willemse EAJ, Zwan MD, 
Mulder SD, Visser PJ, van Berckel BNM, 
et al. Unbiased Approach to Counteract 
Upward Drift in Cerebrospinal Fluid 
Amyloid-β 1–42 Analysis Results. Clin 
Chem 2018;64:576–85. doi:10.1373/
clinchem.2017.281055.
[84] Mattsson N, Lönneborg A, Boccardi 
M, Blennow K, Hansson O. Clinical 
validity of cerebrospinal fluid Aβ42, 
tau, and phospho-tau as biomarkers 
for Alzheimer’s disease in the context 
of a structured 5-phase development 
f ramework . Neurobiol Ag ing 
2017;52:196–213. doi:10.1016/j.
neurobiolaging.2016.02.034.
[85] Jack CR, Bennett DA, Blennow 
K, Carrillo MC, Dunn B, Budd 
Haeberlein S, et al. NIA-AA Research 
Framework: Toward a biological 
definition of Alzheimer’s disease. 
Alzheimer’s Dement 2018;14:535–62. 
doi:10.1016/j.jalz.2018.02.018.
[86] McKeith IG, Boeve BF, Dickson 
DW, Hall iday G, Taylor J-P, 
Weintraub D, et al. Diagnosis 
and management of dementia 












Dementie is een klinisch syndroom dat zich kenmerkt door progressieve 
achteruitgang in het denkvermogen (de cognitie). Er zijn verschillende vormen 
van dementie, waarvan de ziekte van Alzheimer (engels: Alzheimer’s Dementia, 
AD) in ongeveer 70% van alle gevallen de onderliggende oorzaak is. Andere 
neurodegeneratieve aandoeningen die dementie kunnen veroorzaken zijn 
frontotemporale dementie (FTD) en dementie met Lewy lichaampjes (Engels: 
Dementia with Lewy Bodies, DLB). Momenteel treft dementie wereldwijd 
ongeveer 50 miljoen mensen. Als gevolg van de groeiende en vergrijzende 
bevolking en het huidige gebrek aan preventieve of curatieve behandeling, 
wordt verwacht dat het aantal personen met dementie in 2050 de 150 miljoen 
zal overschrijden. De aanzienlijke fysieke, emotionele en financiële last die 
dementie op patiënten, hun verzorgers en de samenleving legt, heeft ertoe geleid 
dat de Wereldgezondheidsorganisatie dementie heeft erkend als een wereldwijde 
prioriteit voor de volksgezondheid.
Neuropathologische kenmerken van dementie
De neurodegeneratieve aandoeningen die ten grondslag kunnen liggen aan 
dementie worden elk gekenmerkt door karakteristieke neuropathologische 
veranderingen. Deze neuropathologische veranderingen kunnen het beste in beeld 
worden gebracht door de hersenen na overlijden (post mortem) te onderzoeken. 
De ziekte van Alzheimer kenmerkt zich door samenklonteringen en ophopingen 
van de eiwitten amyloid en tau in de hersenen. Bij frontotemporale dementie zijn 
het tau of Tar-DNA bindend (TDP43) eiwit de belangrijkste eiwitneerslagen die 
gezien worden in de hersenen. Tot slot worden er in de hersenen van patiënten met 
DLB voornamelijk ‘Lewy-lichaampjes’ aangetroffen die bestaan uit een afwijkende 
vorm van het α-synucleí�ne eiwit. De aanwezigheid van deze eiwitten zal leiden tot 
hersenschade en het afsterven van hersencellen. Op den duur kan dit leiden tot 
cognitieve problemen.
Biomarkers voor dementie
Een biomarker is een objectief meetbare indicator voor een normaal biologisch 
of ziekte proces, bijvoorbeeld een eiwit. Biomarkers stellen ons in staat om 
neuropathologische kenmerken van dementie gedurende het leven (in-vivo) in kaart 
te brengen, en zo de diagnose in een eerder stadium te stellen. Het hersenvocht 
(engels: Cerebrospinal fluid, CSF) omringt de hersenen en is daarom een ideale bron 
voor biomarkers die (ziekte)processen weerspiegelen in de hersenen. De bekendste 
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CSF biomarkers die we tot op heden kunnen meten zijn de zogenaamde Alzheimer-
eiwitten: amyloid-β 1-42 (Aβ42), totaal tau (t-tau) en een gefosforyleerde vorm 
van tau (p-tau). Een typisch AD-biomarker profiel bestaat uit verlaagde Aβ42 en 
verhoogde t-tau en p-tau concentraties. Uit onderzoek is gebleken dat deze CSF 
AD-biomarkers de onderliggende neuropathologie van AD nauw weerspiegelen. 
Door de neuropathologische achtergrond van patiënten in kaart te brengen boeken 
we vooruitgang met het zoeken naar in-vivo verschillen in ziektemechanismen 
tussen subgroepen van patiënten (bv tussen vrouwen en mannen). Daarnaast is 
bekend dat de CSF AD-biomarkers goede diagnostische markers zijn. Daarom is 
het van belang om de implementatie van deze CSF biomarkers in de dagelijkse 
praktijk te bevorderen door zowel patiënten als artsen hiervoor te stimuleren. 
Ondanks dat we een lange weg hebben afgelegd voor AD-biomarkers blijft de 
zoektocht zich voortzetten naar biomarkers in nieuwe lichaamsvloeistoffen, zoals 
bloedplasma. Daarnaast is er een tekort aan goede diagnostische biomarkers voor 
andere belangrijke vormen van dementie, zoals FTD. Het blijven ontwikkelen van 
nieuwe diagnostische biomarkers is essentieel om toekomstige patiënten zo vroeg 
en nauwkeurig mogelijk te diagnosticeren en goed te vervolgen over de tijd. Zo 
kunnen we patiënten effectieve behandeling en begeleiding bieden.
Sekse verschillen in dementie
Er zijn steeds meer aanwijzingen dat een ziekte zich bij verschillend kan uiten 
tussen vrouwen en mannen. Er is bijvoorbeeld een hogere prevalentie van auto-
immuunziekten bij vrouwen en ischemische hartziekten worden vaak niet herkend 
bij vrouwen omdat zij andere symptomen hebben. Uit recente literatuur blijkt dat 
sekseverschillen ook een rol spelen bij dementie. De prevalentie van AD is hoger bij 
vrouwen, terwijl het omgekeerde geldt voor DLB (hogere prevalentie bij mannen). 
Bovendien wijst steeds meer onderzoek in de richting van sekse verschillen in de 
AD eiwitten in de hersenen. Vrouwen lijken meer van het tau eiwit te hebben in de 
hersenen dan mannen, terwijl de verschillen in het amyloid eiwit minder duidelijk 
zijn. In hersenen van mannen met DLB werd vaker zuiver DLB neuropathologie 
gezien, in tegenstelling tot vrouwen met DLB waar vaker een gemengde DLB- en 
AD-pathologie werd aangetroffen. Hoewel post-mortem studies zeer belangrijk 
zijn, is een groot nadeel dat ze de ziekte in het eindstadium weerspiegelen. CSF 
biomarkers daarentegen kunnen pathologische processen in-vivo weergeven. De 
kennis over sekseverschillen in CSF biomarkers en het effect dat ziektestadium 
of genetische risicofactoren, zoals het Apolipoproteí�ne ε4 (APOE ε4) gen, kunnen 
hebben op deze sekseverschillen is echter nog zeer beperkt.
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Implementatie van de huidige CSF biomarkers
De ontdekking van CSF AD-biomarkers heeft geleid tot een betere diagnostische 
nauwkeurigheid dan het toepassen van alleen klinische criteria voor AD. Zo 
kunnen AD patiënten met een sensitiviteit en specificiteit van 80-90% worden 
onderscheiden van controles. Dit heeft ertoe geleid dat deze CSF biomarkers zijn 
opgenomen in de onderzoekscriteria voor AD. Ondanks de hoge diagnostische 
waarde, zijn er zowel patiënt- als arts gerelateerde factoren die de implementatie 
van deze biomarkers in de dagelijkse praktijk belemmeren.
Een van deze factoren is de houding van zowel patiënten als clinici ten opzichte 
van de lumbaal punctie (LP) procedure, die wordt gebruikt om CSF te verkrijgen. 
In de dagelijkse praktijk blijkt dat patiënten vaak bang zijn om een LP te ondergaan 
vanwege een gebrek aan kennis over de procedure en/of onrealistische ideeën 
over complicaties na de LP. Opmerkelijk was dat de angst voor complicaties een 
risicofactor bleek te zijn voor het daadwerkelijk ervaren van post-LP klachten. We 
veronderstellen dat de samenhang tussen angst en het ervaren van post-LP klachten 
ten minste gedeeltelijk wordt verklaard door onvoldoende informatievoorziening 
over de procedure en eventuele complicaties. Eenvoudige, gemakkelijk verteerbare 
informatie over de LP procedure voor patiënten en naasten ontbreekt echter.
Naast patiënt gerelateerde factoren, varieert de houding van clinici ten opzichte 
van LP sterk. Veel clinici zijn terughoudend met het uitvoeren van een LP, omdat 
dit over het algemeen als een invasieve procedure wordt beschouwd. De procedure 
is echter eenvoudig uit te voeren en het algehele complicatierisico is laag (~ 1% 
). Verouderde kennis en kunde omtrent het uitvoeren van een LP of een gebrek 
aan training zijn andere redenen die die clinici kunnen weerhouden om een LP 
uit te voeren. Het ontwikkelen van instrumenten voor het informeren en trainen 
van clinici, zou een grote bijdrage kunnen leveren aan de implementatie van CSF 
biomarkers in de dagelijkse praktijk. Ten slotte is de interpretatie van CSF AD-
biomarkers niet altijd eenvoudig. In het bijzonder wanneer biomarker resultaten 
tegenstrijdig zijn. Zo is er een kleine groep patiënten die niet het typerende AD 
biomarker profiel hebben in de liquor. Daarom is het nodig hulpmiddelen aan te 
bieden die de interpretatie van deze biomarkers in klinische routine ondersteunen.
Het ontwikkelen van nieuwe biomarkers
Voor grootschalige screening of het uitvoeren van herhaaldelijke metingen bij 
patiënten zijn CSF biomarkers minder geschikt. De LP procedure is namelijk 
voorbehouden aan artsen en kan een tijdrovende procedure zijn. Daarom is het veld 
zich in toenemende mate gaan richten op het ontwikkelen van nieuwe biomarkers 
253
Nederlandse samenvatting
in andere lichaamsvloeistoffen, zoals het bloedplasma. Er is aanzienlijke 
vooruitgang geboekt op het gebied van AD bloedbiomarkers. Enkele jaren geleden 
werden immunoprecipitatie massaspectrometrie (IP-MS) technieken ontwikkeld 
die twee vormen van het amyloid eiwit, Aβ40 en Aβ42, kon meten in het bloed. De 
diagnostische diagnostische nauwkeurigheid bedroeg ongeveer 90%. Ondanks 
de optimistische resultaten zijn deze technieken (IP-MS) vaak arbeidsintensief 
en tijdrovend. Hierdoor zijn ze niet geschikt voor high-throughput analyses. Als 
oplossing werd in 2011 werd de ultragevoelige Single molecule array (Simoa) assay 
geboden. De verhouding Aβ42 tot Aβ40 eiwit bleek verlaagd in patiënten waar 
middels een PET scan het amyloid eiwit in de hersenen werd aangetroffen. Hoewel 
de Simoa assay een veelbelovende techniek is die een belangrijke stap voorwaarts 
betekent, meet deze techniek vermoedelijk monomere vormen van Aβ40 en Aβ42. 
Echter, toont toenemend bewijs aan dat kleine oplosbare Aβ-oligomeren (AβO’s) 
de meest pathogene vorm van het Aβ eiwit zijn. Bovendien hebben AβO’s een 
goede correlatie laten zien met de aanwezigheid en mate van cognitieve klachten. 
Dit suggereert mogelijk dat plasma AβO’s mogelijk ook de ernst van de klinische 
ziekte zouden kunnen weerspiegelen. Er is echter nog weinig bekend over de 
bruikbaarheid van plasma AβO’s om het amyloid eiwit in de hersenen te kunnen 
vaststellen.
Tot dusver hebben nog niet veel biomarkers zich vertaald naar klinisch gebruik 
voor niet-AD neurodegeneratieve ziekten, zoals FTD. Bloedbiomarkers voor 
FTD zoals Neurofilament light (NfL) of progranuline (GRN), waren aanvankelijk 
veelbelovend in het onderscheiden van FTD patiënten van controles. Later 
bleken deze bloedbiomarkers echter niet specifiek te zijn voor FTD, omdat de 
eiwitconcentraties ook veranderd waren in andere vormen van dementie of, omdat 
ze alleen specifiek waren voor genetische varianten van FTD. Het is wellicht wel 
belangrijker om bloedbiomarkers te ontwikkelen die de meest voorkomende 
neuropathologische subtypes van FTD (d.w.z. FTD-Tau en FTD-TDP43) kunnen 
onderscheiden. Volgens de huidige hypothese behoeven de subtypes waarschijnlijk 
verschillende therapieën gericht op de onderliggende neuropathologie. 
Daarom is er een sterke behoefte aan nieuwe bloedbiomarkers voor FTD en de 
neuropathologische subtypes. Het bestuderen van het proteoom in bloedplasma 
zou kunnen leiden tot de identificatie van een eiwit of een combinatie van eiwitten 
die wellicht kunnen worden gebruikt als nieuwe biomarkers voor FTD.
Doel van dit proefschrift
Dit proefschrift heeft drie hoofddoelen:
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1. Het begrijpen van de invloed van sekse op AD liquor biomarkers bij verschillende 
vormen van dementie.
2. De implementatie van huidige liquor biomarkers in de dagelijkse klinische 
praktijk vergemakkelijken.
3. Identificatie en ontwikkeling van nieuwe bloedbiomarker assays voor de 
diagnose van FTD en AD.
Resultaten
In deel 1 van dit proefschrift hebben we CSF biomarkers gebruikt om meer 
kennis te vergaren over neuropathologische verschillen tussen vrouwen en 
mannen met dementie. In hoofdstuk 2 onderzochten we per klinisch stadium 
van de ziekte van Alzheimer naar verschillen tussen vrouwen en mannen in CSF 
AD-biomarkers concentraties. De klinische ziektestadia bestaan uit subjectieve 
cognitieve achteruitgang (Engels: Subjective Cognitive Decline, SCD), gevolgd 
door milde cognitieve stoornissen (Engels: Mild Cognitive impairment, MCI) en 
AD dementie. Daarnaast hebben we onderzocht of dit anders was voor patiënten 
die drager zijn van het APOE ε4 risico gen voor AD. We toonden aan dat vrouwelijke 
APOE ε4 dragers hogere t-tau en p-tau concentraties hebben dan mannelijke APOE 
ε4 dragers in vroegere ziektestadia (SCD en MCI). We zagen in patiënten zonder 
het APOE ε4 risico gen, dat vrouwen hogere t-tau en p-tau concentraties hebben 
dan mannen in gevorderde ziektestadia (MCI en AD-dementie). Deze bevindingen 
zouden kunnen suggereren dat er een ander AD ziektemechanisme is tussen 
vrouwen en mannen, afhankelijk van het APOE ε4 dragerschap.
In hoofdstuk 3 hebben we in DLB patiënten onderzocht of er verschillen waren 
tussen vrouwen en mannen in CSF biomarkers concentraties. Ook hebben we 
bekeken of er sekseverschillen waren in de klinische manifestatie van de ziekte. 
We toonden aan dat vrouwen lagere α-syn en Aβ42 eiwit concentraties hadden 
in vergelijking met mannen. Dit zou kunnen betekenen dat vrouwen ook tijdens 
het leven meer alfa-synucleí�nopathie en amyloid pathologie hebben dan mannen. 
Bovendien hadden vrouwen op het moment van het stellen van de diagnose een 
kortere klachtenduur, lagere cognitieve testscores en vaker hallucinaties. Deze 
bevindingen zouden kunnen suggereren dat vrouwen met DLB een agressiever 
ziektebeloop hebben vergeleken met mannen. In hoofdstuk 4 reageren we op 
een studie die belangrijke post mortem verschillen in AD neuropathologie tussen 
vrouwen en mannen heeft aangetoond.
In deel 2 van dit proefschrift wilden we de implementatie van de huidige CSF AD-
biomarkers in de klinische praktijk vergemakkelijken, een cruciale stap voor de 
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bench-to-bedside vertaling van wetenschappelijke bevindingen. In hoofdstuk 5 
hebben we een educatieve video ontwikkeld voor professionals om hun kennis 
en kunde over de LP procedure te vergroten. De video zou kunnen worden 
toegepast in de training voor de LP procedure. In hoofdstuk 6 hebben we een 
educatieve animatie-video ontwikkeld voor patiënten en hun naasten, waarin 
we hen informeren over en voorbereiden op de LP procedure. Beide video’s zijn 
gebaseerd op de nieuwste literatuur en zijn ontwikkeld in samenwerking met 
communicatiedeskundigen, artsen en patiënten panels.
In hoofdstuk 7 evalueerden we of de educatieve patiëntenvideo uit hoofdstuk 
6 zou kunnen leiden tot een beter begrip van de LP procedure en een afname 
van onzekerheid, angst en de daarmee samenhangende post-LP klachten. We 
vergeleken patiënten die de standaard mondelinge en schriftelijke uitleg kregen 
over de LP procedure met patiënten die daarnaast ook de video hadden bekeken. 
We toonden aan dat patiënten die de video hadden bekeken meer kennis hadden 
over de LP procedure en minder onzeker waren. We zagen geen verschil in angst 
of de frequentie van post-LP klachten na de procedure.
Een andere uitdaging bij de implementatie van liquor biomarkers in de dagelijkse 
klinische praktijk is het juiste gebruik en interpretatie van liquor biomarker 
resultaten. Dit is vooral relevant omdat niet elke AD patiënt een typisch AD-
biomarker profiel heeft (d.w.z. verlaagde Aβ42 en verhoogde t-tau concentraties). 
Daarom hebben we in hoofdstuk 8 een klinisch toepasbare beslisboom ontwikkeld 
en gevalideerd voor de interpretatie van CSF AD-biomarker concentraties. De 
beslisboom werd gemodelleerd met behulp van een Classification And Regression 
Tree (CART) analyse. Vervolgens werd die gevalideerd tegen het gebruik van 
afzonderlijke afkapwaardes per biomarker. We identificeerden twee CSF AD-
biomarker profielen: i) het “typische” AD-biomarkerprofiel (verlaagde Aβ42 en 
verhoogde t-tau) en ii) het “atypische” AD-biomarker profiel, met sterk verlaagde 
Aβ42 maar normale t-tau concentraties. Vergeleken met eerdere afkapwaarden 
presteerde de beslisboom beter op diagnostische nauwkeurigheid.
In deel 3 van dit proefschrift hebben we ons gericht op het identificeren en 
valideren van nieuwe bloed biomarkers voor FTD en AD. In hoofdstuk 9 gebruikten 
we een ‘proteomics’ technologie waarmee we meer dan 1303 eiwitten konden 
meten in het bloed. Protemics is een technologie die het mogelijk maakt om op 
grote schaal eiwitten te onderzoeken. Ons doel was specifieke plasma biomarker 
profielen te identificeren waarmee onderscheid gemaakt kan worden tussen FTD, 
AD en cognitief normale controles, evenals tussen de neuropathologische subtypes 
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van FTD. Daarnaast hebben we dezelfde technologie toegepast in hersenweefsel 
van FTD patiënten en controles, evenals de neuropathologische FTD subtypen. We 
identificeerden twee verschillende plasma biomarker panels die, in combinatie 
met leeftijd en geslacht, met enige nauwkeurigheid FTD patiënten van cognitief 
onaangetaste controles, en met hoge nauwkeurigheid FTD van AD patiënten kon 
onderscheiden. In de huidige vorm hebben beide bloed biomarkerpanels echter 
geen optimale diagnostische nauwkeurigheid om in de dagelijkse praktijk te 
worden toegepast. Voor toekomstig werk kan het nuttig zijn om andere biomarkers 
in dit panel op te nemen, zoals neurofilament light (NfL), om de nauwkeurigheid van 
op bloedbiomarker panels verder te vergroten. Als alternatief zouden toekomstige 
studies zich kunnen concentreren op het ontdekken van biomarkers in CSF, waarna 
nieuwe, meer gevoelige technieken worden gebruikt om de geí�dentificeerde CSF 
biomarker kandidaten in het bloed te meten. We konden geen eiwitten vinden voor 
het onderscheid tussen de Tau- en TDP43-pathologische subtypen in plasma of 
weefsel. Dit kan meerdere verklaringen hebben. Ten eerste kan de heterogeniteit 
binnen de pathologische subtypes van Tau en TDP43 een rol spelen hierin. Een 
alternatieve verklaring is dat zowel TDP- als Tau-pathologische subtypes dezelfde 
pathologische cascade initiëren, wat zal resulteren in vergelijkbare veranderingen 
in het proteoom. Ten slotte worden in de meeste FTD-biomarkerstudies familiale 
en sporadische gevallen vaak gegroepeerd om een  grote steekproefomvang te 
bereiken. Toekomstige studies moeten echter uitwijzen of de familiale vorm van 
FTD vergelijkbaar is met de sporadische FTD-vorm in termen van onderliggende 
pathologische mechanismen en plasma-eiwitprofielen. Studies die onafhankelijk 
(plasma)eiwitprofielen van familiale en sporadische FTD-subtypes evalueren, 
zouden meer duidelijkheid kunnen verschaffen.
In hoofdstuk 10 richtten we ons op het valideren van een reeds ontwikkelde 
biomarker voor AD die de oligomerisatietendens van het amyloid eiwit meet in 
bloedplasma. Het meten van het plasma Aβ-oligomerisatietendens (OAβ) in bloed 
gebeurd met behulp van de nieuwe Multimer Detection System (MDS) techniek 
en zou een eenvoudig en goedkoop hulpmiddel kunnen zijn om de diagnose AD te 
kunnen stellen. Daarom onderzochten we of plasma-OAβ een geschikte marker zou 
kunnen zijn om patiënten te identificeren bij wie het amyloid eiwit middels een PET 
scan is aangetoond in de hersenen. Dit zijn patiënten met een abnormale amyloid 
PET scan. We toonden aan dat abnormale plasma MDS-OAβ concentraties samen 
met APOE ε4 en leeftijd de potentie had om nauwkeurig patiënten te identificeren 
met ophopingen van het amyloid eiwit in de hersenen. Bovendien verminderde het 
gebruik van plasma-MDS-OAβ als een ‘pre-screener’ de kosten en het aantal PET-




Patiënten met dezelfde onderliggende oorzaak van dementie (bv. AD, FTD of DLB) 
hebben niet altijd exact dezelfde onderliggende neuropathologie. Zo is bijvoorbeeld 
aangetoond dat vrouwen met de ziekte van Alzheimer, meer tau eiwit hebben 
dan mannen met de ziekte van Alzheimer. Deze verschillen konden wij ook 
aantonen in-vivo. Het voorkomen van heterogene patiënten subgroepen met elk een 
specifieke neurobiologie zou kunnen verklaren waarom er tot op heden nog weinig 
effectieve geneesmiddelen zijn ontwikkeld tegen de ziekte. Daarom is de toekomst 
van dementieonderzoek en -zorg in toenemende mate gericht op het bieden van 
gepersonaliseerde oftewel precisie geneeskunde. Verwacht wordt dat biomarkers 
hierin een grote rol zullen spelen, doordat ze ons in staat stellen om in de toekomst 
tot een biologische diagnose te komen gebaseerd op de in-vivo neuropathologie 
van een individu. Om maatwerk te kunnen bieden is het noodzakelijk om panels 
van goedkope en minimaal invasieve biomarkers te ontwikkelen, zoals bloed 
biomarkers. In dit proefschrift hebben wij belangrijke eerste stappen gezet in de 
richting van de ontwikkeling van bloed biomarker kandidaten voor panels.
Tot slot, behelst een ander belangrijk aspect van gepersonaliseerde geneeskunde 
de gezamenlijke besluitvorming. Een proces waarin de zorgverlener en de patiënt 
samen beslissingen nemen over diagnostiek, behandelingen of begeleiding, 
op grond van kennis, klinische ervaring en de voorkeuren en waarden van de 
patiënt. Wij toonden aan dat educatieve video’s de kennis vergroten en kunnen 
voorzien in de informatiebehoeften van onze patiëntenpopulatie. De resultaten 
van ons onderzoek ondersteunen de ontwikkeling van vergelijkbare toekomstige 
educatieve video’s voor andere diagnostische modaliteiten, om zo bij te dragen 
aan het gezamenlijke besluitvormingsproces.
Conclusie
Dit proefschrift geeft inzicht in de invloed van sekse op AD en DLB neuropathologie 
in-vivo en draagt bij aan de beperkte literatuur over sekseverschillen in dementie. 
Daarnaast draagt dit proefschrift bij aan de identificatie, ontwikkeling en 
implementatie van huidige CSF en toekomstige bloed biomarkers. Verwacht wordt 
dat biomarkers een grote rol zullen spelen in de precisie geneeskunde, doordat 
het ons mogelijk zal maken een biologische diagnose te stellen gebaseerd op de 
in-vivo neuropathologie van een individu. Deze kennis kan instrumenteel zijn 
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